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Paternally-expressed Dlk1 promotes fetal growth, while maternally-expressed 
Grb10 inhibits fetal growth. The respective growth-regulatory roles are 
consistent with the predominant theory for the evolution of imprinted gene 
expression, the parent-offspring conflict hypothesis. This predicts that in 
mammals imprinting has evolved because of differing parental interests in the 
distribution of maternal resources to her offspring, at least in species where 
females tend to reproduce with more than one mate during their reproductive 
lifespan. Genetic evidence indicates that Dlk1 and Grb10 control embryo size 
and adult body composition, potentially through a common pathway. However, 
the biochemical links between them are still lacking. 
 
Here, I combined biochemical methods, including two sets of TMT quantitative 
proteomics using pMEFs and liver derived from E14.5 WT, Dlk1+/p, Grb10m/+ 
and Grb10m/+/Dlk1+/p mouse embryos. I found that Dlk1 and Grb10 proteins 
oppositely affected the expression of each other in vitro and in vivo. 
Proteomics analyses uncovered that Dlk1+/p embryos were divergent from 
Grb10m/+ and Grb10m/+/Dlk1+/p which were similar at a proteomics level, 
supporting the genetic findings from previous studies. Furthermore, GO-term 
enrichment analysis revealed that RTK related biological processes were 
significantly enriched in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p embryos. 
Several RTKs and their signal partners displayed reduced expression in the 
knockout pMEF and liver proteomes. In particular, cell signalling studies in 
E14.5 pMEFs of the four genotypes suggested that PDGFR signalling may 






Akt    Protein kinase B 
APS   Ammonium persulfate 
ATP   Adenosine-5'-triphosphate 
BAT   Brown adipose tissue 
BCA   Bicinchoninic acid 
BSA   Bovine serum albumin 
CDK1   Cyclin dependent kinase 1 
CDKN1C  Cyclin dependent kinase inhibitor 1C 
C/EBPα  CCAAT/Enhancer binding protein alpha  
CHO    Chinese hamster ovary 
CHX   Cycloheximide 
CNS   Central nervous system 
CREB   cAMP response element binding protein 
DAPI   4', 6'-diamino-2-phenylindole 
Dlk1   Delta-like 1 
Dlk1   Delta-like non-canonical notch ligand 1 
DMEM   Dulbecco's modified Eagle's medium 
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ECL   Enhanced chemiluminescence substrate 
EDTA   Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
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EGTA Ethylene glycol-bis (β-aminoethyl ether)-N,N,N',N'-tetraacetic 
acid 
ELISA   Enzyme-linked immunosorbent assay 
EphR B6  Ephrin receptor B6 
Erbb2   Erb-B2 receptor tyrosine kinase 2 
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H&E staining Haemotoxylin and Eosin staining 
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IF        Immunofluorescence 
IGF1   Insulin-like growth factor 1 
6 
 
IGF1R   Insulin-like growth factor 1 receptor 
IGF2   Insulin-like growth factor 2 
IGF2R   Insulin-like growth factor 2 receptor 
IGF1   Insulin-like growth factor 1 
IGF1R   Insulin-like growth factor 1 receptor 
IGF2   Insulin-like growth factor 2 
IGF2R   Insulin-like growth factor 2 receptor 
IHC   Immunohistochemistry 
Insr   Insulin receptor 
IR    Insulin receptor 
IP    Immunoprecipitation 
IRS1/2   Insulin receptor substrate 1/2 
ITMS   Ion trap mass spectrometry 
kb     Kilobase 
kDa    Kilodaltons 
KO    Knockout 
KRAS    Kirsten rat sarcoma GTPase 
kV    Kilovolts 
LB    Lysogeny broth 
LC    Liquid chromatography 
MAPK    Mitogen-activated protein kinase 
MEF   Mouse embryonic fibroblast 
MEK    MAPK/ERK kinase 
mRNA   Messenger ribonucleic acid 
MS    Mass spectrometry 
MS/MS   Tandem mass spectrometry 
ms    Millisecond 
mTOR   Mammalian target of rapamycin 
mTORC1  Mammalian target of rapamycin complex 1 
m/z    Mass to charge ratio 
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MuSK   Muscle-specific Kinase 
Nedd4 Neural precursor cell expressed developmentally 
down-regulated protein 4  
NGS   Normal goat serum 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PCA   Principle component analysis 
PDGF   Platelet derived growth factor 
PDGFR  Platelet derived growth factor receptor 
PDGFRa  Platelet Derived Growth Factor Receptor alpha 
PDGFRb  Platelet Derived Growth Factor Receptor beta 
PFA   Paraformaldehyde 
PI3K   Phosphoinositide 3-kinase 
PKA    Protein kinase A 
PKC    Protein kinase C 
pMEF   Primary mouse embryonic fibroblast 
ppm   Parts per million  
PTPRF   Protein tyrosine phosphatase, receptor type F 
PVDF   Polyvinylidene fluoride 
Ras    Rat sarcoma GTPase 
RNA    Ribonucleic acid 
RNAi    RNA interference 
rpm    Revolutions per minute 
RTK    Receptor tyrosine kinase 
RT-qPCR   Reverse transcription quantitative polymerase chain reaction 
S    Serine 
SDS    Sodium dodecylsulphate 
SDS-PAGE  Sodium dodecylsulphate polyacrylamide gel electrophoresis 
SEM   Standard error of the mean 
Ser    Serine 
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SH2    Src homology 2 domain 
SH3    Src homology 3 domain 
siRNA    Short interfering RNA 
Src    Sarcoma GTPase 
STAT3   Signal transducer and activator of transcription 3 
T    Threonine 
T25   25 cm2 cell culture flask 
T75   75 cm2 cell culture flask 
TACE   TNF-a converting enzyme 
TBS   Tris-buffered saline 
TBST   Tris-buffered saline with Tween-20 
TEMED  N,N,N',N-tetramethylethylenediamine 
TGFB    Transforming growth factor beta 
Thr    Threonine 
TMB   3,3′,5,5′-Tetramethylbenzidine 
TMT    Tandem mass tag 
TNFα    Tumour necrosis factor alpha 
Tween-20  Polyoxyethylene sorbitan monolaureate 
Tyr    Tyrosine 
UTR   Untranslated region 
VEGFR2  Vascular Endothelial Growth Factor Receptor 2 
VEGFR3  Vascular Endothelial Growth Factor Receptor 3 
WAT   White adipose tissue 
WB    Western blotting 
WT    Wild-type 
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1.1  Genomic Imprinting 
Mammals inherit two gene copies from their parents, and the two parental 
genomes are expressed equally in the offspring based on Mendelian 
inheritance. However, Mendel’s law is not applied to all the mammalian genes. 
A small group of genes called imprinted genes follow a parent-of-origin-specific 
expression pattern (Figure 1.1). In the case of imprinted genes, one gene copy 
from the paternal or maternal allele is suppressed by epigenetic modifications, 
such as DNA methylation and histone modification (Inbar-Feigenberg et al., 
2013). So far, only about 150 imprinted genes have been identified in mouse 
among which less than half have been proved to exist in human (Bartolomei 
and Ferguson-Smith, 2011; Peters, 2014). Imprinted genes are usually found 
in clusters within the genome and controlled by a common imprinting control 
region (ICR). DNA methylation in the ICR plays an essential role in regulating 
the expression or suppression of genes within an imprinted gene locus (Barlow 
and Bartolomei, 2014). Imprinted genes attracted attention because many of 
them are widely expressed in the embryo and placenta (Fowden et al., 2011). 
Many of them are involved in prenatal and postnatal development, energy 
homeostasis, and some are involved in social behaviours (Garfield et al., 2011; 
Dent and Isles, 2014; Peters, 2014; Charalambous et al., 2012; Charalambous 
et al., 2014). Research predicted that more than 1000 gene loci are imprinted 
in mouse brain, but this prediction is currently lacking confirmation by 
biological experiments (Kelsey and Bartolomei, 2012). However, we could 






Figure 1.1 Parent-of-origin-specific expression of the imprinted gene. 
Coloured boxes represent genes and arrows indicated expressed allele. The 
green boxes and arrows represent the majority of mammalian genes, 
expressed from both parental alleles. Delta-like 1 (Dlk1) and growth factor 
receptor–bound protein 10 (Grb10) exemplify genes expressed from the 
paternally-inherited (PAT) and maternally-inherited (MAT) alleles, respectively. 
 
The evolutionary benefits of imprinted gene expression are still under debated. 
For instance, genes with biallelic (non-imprinted) expression could better 
protect the genome from recessive mutations and deletions compared to 
imprinted genes (Holman and Kokko, 2014). So what can an imprinted gene 
benefit from their monoallelic expression? The widely accepted theory for 
genomic imprinting is the parent-offspring conflict hypothesis (Haig, 2014). 
This predicts that parental interests in the distribution of maternal resources to 
their offspring are different, at least in species where females may reproduce 
with more than one mate during their reproductive lifespan (Patten et al., 2014). 
Therefore, paternally-expressed genes tend to promote the allocation of 
maternal resources to the offspring, leading to the enhancement of fetal and 
placental growth, while maternally-expressed genes restrict it (Fowden et al., 
2011). Arguably, the most compelling examples are the first two identified 
imprinted genes, Insulin growth factor 2 (Igf2), encoding a 
paternally-expressed growth promoting ligand insulin growth factor 2 (IGF2) 
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and Insulin growth factor 2 receptor (Igf2r), which codes for a 
maternally-expressed cell surface receptor Insulin growth factor 2 receptor 
(IGF2R) that inhibits growth by targeting Igf2 for lysosomal degradation 
(Barlow et al., 1991; DeChiara et al., 1991; Nordin et al., 2014). No other 
antagonistic pair of imprinted genes has since been identified. A pair of 
oppositely imprinted genes, Dlk1 and Grb10, may fit the bill since both genes 
code for cell signalling proteins, as paternally expressed Dlk1 promotes while 
the maternally expressed Grb10 restricts embryo growth (Madon-Simon et al., 
2014). It may not be possible to explain the genomic imprinting evolution with 
one single theory, and some non-conflict hypotheses, such as co-adaptive 
gene evolution, were also used to demonstrate the genomic imprinting 
(Spencer and Clark, 2014; Wilkins, 2014). Further functional study of the 
identified imprinted genes will help us to understand the evolutionary basis and 




1.2 Dlk1 in mouse development 
1.2.1 Dlk1 expression in mouse and protein structure 
The paternally-expressed imprinted gene Dlk1 encodes delta-like 1 protein 
(Dlk1), also known as preadipocyte factor 1 (Pref-1) or fetal antigen 1 (FA1), 
which belongs to the epidermal growth factor-like (EGF-like) protein family that 
consists of Notch signalling receptors and ligands (Moon et al., 2002). Dlk1 is 
widely expressed in most embryonic tissues, while its expression is limited to a 
few adult tissues, with the highest expression levels in pituitary and adrenal 
gland (Wang et al., 2006; Falix et al., 2012; Charalambous et al., 2014). This 
indicates a critical role of Dlk1 in mouse early embryonic development. In 
particular, Dlk1 is not expressed in adult adipose and muscle tissues, yet Dlk1 
does influence the adult adipose and muscle mass (Moon et al., 2002; 
Charalambous et al., 2014). Therefore, it can be predicted that Dlk1 controls 
the postnatal body proportions (fat and lean mass ratio) through its actions in 
early embryonic development stage. 
 
EGF-like proteins interact with each other through their EGF-like repeats and 
regulate cells to make fate decisions (Baladrón et al., 2005; Sánchez-Solana 
et al., 2011). However, Dlk1 is recognized as a non-canonical Notch ligand, 
lacking a Delta-Serrate-LAG-2 (DSL) domain which can directly interact with 
Notch receptors. Therefore, Dlk1 may not be the ligand of Notch receptors 
although it regulates Notch1 signalling through a negative feedback 
mechanism (Falix et al., 2012). Hence, identification of Dlk1 receptors and 
interacting proteins is essential to understand Dlk1 functions and mechanisms 
of action. Specifically, Dlk1 is a single transmembrane protein, containing a 
region of six N-terminal EGF-like repeats, a juxtamembrane domain, a 
transmembrane part and a cytoplasmic tail at the C-terminal (Figure 1.2) 
(Smas and Sul, 1993; Wang and Sul, 2006; Hudak and Sul, 2013). Dlk1 can be 
cleaved by TNF-a converting enzyme (TACE) at the juxtamembrane region, 
and the full length extracellular domain of Dlk1 (soluble Dlk1) containing the 
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juxtamembrane region (approximate 50 kDa) alone can account for the 
regulation of several differentiation processes (Smas et al., 1997; Wang and 
Sul, 2006; Andersen et al., 2013). The membrane bounded part of Dlk1 also 
possesses different cellular functions from the soluble Dlk1 (Mortensen et al., 
2012; Traustadóttir et al., 2013; Shin et al., 2014). 
 
Figure 1.2 Modular structure of Dlk1 protein. N, N-terminal; S, signal 
sequence; Green boxes (1-6) indicate the six EGF-like repeats. Jm, 
juxtamembrane domain; Tm, transmembrane domain (phospholipid cell 
membrane illustrated); Cy, cytoplasmic domain; C, C-terminal. 
 
1.2.2 Biological functions of Dlk1 
Dlk1 protein functions have been uncovered using several genetic mouse 
models. The first Dlk1 knockout mice displayed significant embryo growth 
retardation (Moon et al., 2002). And the adult Dlk1 knockout mice developed 
enlarged livers with higher lipid contents and increased adipose tissue mass, 
including white adipose tissue (WAT) and brown adipose tissue (BAT), 
compared to their wild type (WT) littermates (Moon et al., 2002). However, the 
obese phenotype was observed only in mice fed with a high fat diet (Moon et 
al., 2002). In addition, the higher adipose tissue mass was due to enlarged 
adipocyte cell size and not cell number (Moon et al., 2002). A second Dlk1 
knockout mouse model revealed that Dlk1 was related to B cell development 
(Raghunandan et al., 2008). Moreover, our group has shown that the same 
Dlk1 knockout mouse was born about 20% smaller and grew up with a greater 
fat mass content than WT littermates fed with a normal chow diet 
(Madon-Simon et al., 2014). Thirdly, conditional deletions of Dlk1 in pancreas, 
pituitary and placenta did not compensate the phenotype from global knockout 
of Dlk1, suggesting that Dlk1 controlled embryo growth through actions in 




In contrast, transgenic mice with overexpression of the ectodomain of Dlk1 
(soluble Dlk1) in adipose tissue or liver both exhibited reduced adipose tissue 
mass and lower body weight in adults (Lee et al., 2003). Consistent with the 
results from Dlk1 knockout mice, the decreased fat pad mass was related to 
smaller adipocyte cell size and not cell number (Moon et al., 2002; Lee et al., 
2003). In addition, overexpression of soluble Dlk1 reduced the expression 
levels of some transcription factors, such as CCAAT/Enhancer Binding Protein 
Alpha (C/EBPα), associated with the inhibition of adipocyte differentiation (Lee 
et al., 2003). Furthermore, an endogenous Dlk1 overexpression mouse model, 
overexpressing the whole Dlk1 protein, displayed reduced fat mass due to the 
smaller adipocyte cell size (Charalambous et al., 2014). However, endogenous 
Dlk1 overexpression mice presented unchanged adipogenesis as no 
expression changes of adipose differentiation markers or mature adipocyte 
markers were found between the transgenic and WT mice (Charalambous et 
al., 2014). This Dlk1 transgenic mouse model has enhanced insulin sensitivity 
and switches the energy source of muscle mass from glucose to fatty acids, 
potentially explaining the reduced fat mass (Charalambous et al., 2014). 
Hence, the membrane bound regions of Dlk1 may also be essential to the 
balance of adipocyte differentiation. It was reported that the membrane bound 
Dlk1 inhibited preadipocyte proliferation by altering the cell cycle, resulting in 
the inhibition of adipocyte differentiation (Mortensen et al., 2012; Traustadóttir 
et al., 2013). Despite the controversial influences of Dlk1 in adipogenesis. It 
can be concluded that Dlk1 plays critical roles in adipose tissue development 
through embryogenesis.  
 
It is also clear that Dlk1 promotes skeletal muscle development. In Dlk1 
knockout mice, myogenic programming was inhibited along with altered 
expression levels of myogenic transcription factors. As a result, Dlk1 null mice 
exhibited reduced muscle mass at 12 weeks old (Andersen et al., 2013). By 
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contrast, Dlk1 ablation enhanced adult muscle regeneration by regulating the 
expression of myogenic markers (Andersen et al., 2013). Collectively, Dlk1 is a 
key factor in muscle development through embryogenesis and adult muscle 
regeneration (Andersen et al., 2013). So far, most of the Dlk1 studies in 
adipogenesis and myogenesis focus on the investigations at the transcriptional 
level. The upstream cell signalling events involving Dlk1 that control these 
transcriptional changes are not well understood. 
 
A few Dlk1 studies in human have indicated similar functions to those defined 
from mouse models. Dlk1 expression level was reported to be increased in 
serum samples from obese patients, suggesting that Dlk1 might be used as a 
marker of human obesity (Chacón et al., 2008). Dlk1 levels in maternal serum 
collected during pregnancy was correlated with small-for-gestational-age (SGA) 
infants, and Dlk1 levels can be an indicator of healthy or pathological SGA 
infants (Cleaton et al., 2016). Dlk1 is also involved in negative feedback 
inhibition of human skeletal stem cell differentiation (Abdallah et al., 2004). 
 
1.2.3 Potential Dlk1 signalling 
As a member of EGF-like protein family, Dlk1 was considered to be involved in 
Notch signalling especially Notch1 receptor (Traustadóttir et al., 2016). Notch 
signalling pathway was found to be downregulated by Dlk1 in E16.5 embryos 
through comparison of WT and Dlk1 null embryonic tissues by mRNA array. 
This study also provided evidence that Dlk1 can interact with Notch1 receptor 
through EGF repeat 5 and 6 domains of Dlk1, using a mammalian two-hybrid 
system (Traustadóttir et al., 2016). However, more in vitro and in vivo evidence 
is needed to confirm conclusively the direct interaction of Dlk1 and Notch1. 
Hence, Dlk1 may regulate downstream signals through Notch1 receptor 
dependent or independent pathways. Besides, Dlk1 may interact with itself, 
again as uncovered by experiments using a mammalian two-hybrid system, 
although cellular function of Dlk1 self-interaction has not yet been explored 
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(Traustadóttir et al., 2017). Furthermore, it has been found that Dlk1 inhibited 
preadipocyte differentiation via insulin/IGF signalling (Zhang et al., 2003; 
Tseng et al., 2005). Whereas Nueda and co-workers (2007) reported that Dlk1 
promoted adipogenesis in the multi-potential mesenchymal cell line 
C3H10T1/2 through negatively regulating Notch 1 receptor. In mouse 
embryonic fibroblast (MEF) cell lines, Dlk1 was found to activate components 
of the Mitogen-activated protein kinase (MAPK) pathway and sox9 expression, 
leading to the inhibition of adipogenesis (Wang et al., 2010). These results 
suggested that the roles of Dlk1 in adipogenesis were cell type specific. In 
addition, Dlk1 has been shown to prevent chondrogenesis and adipogenesis in 
cell culture by inhibiting the Phosphoinositide 3-kinase/Protein kinase B 
(PI3K/Akt) pathway (Chen et al., 2011). It is not yet possible to identify the 
definitive Dlk1 pathways, in several biological processes, due to the lack in 
knowledges of Dlk1 interacting receptors and other signalling proteins. 
 
Dlk1 is expressed from the paternal Dlk1-Gtl2 locus while the corresponding 
maternal Dlk1 allele is imprinted, and the cis locus expresses several 
non-coding miRNA (Qian et al., 2016; Serrano-Lopez and Cancelas, 2016; 
Schneider et al., 2016). Strikingly, Qian and colleagues recently reported that 
miRNAs expressed from the maternal Dlk1-Gtl2 locus could block multiple 
components of Akt mediated mammalian target of rapamycin (mTOR) pathway, 
maintaining the quiescence of fetal liver hematopoietic stem cells (HSCs) and 
long-term HSCs derived from adult mouse liver (Qian et al., 2016). However, 
the direct interactions between Dlk1 and mTOR signalling on biochemical level 




1.3  Grb10 in mouse development 
1.3.1 Grb10 expression in mouse and protein structure 
Unlike all other imprinted genes, Grb10 has an unusual tissue specific 
expression pattern in mouse. Specifically, Grb10 is paternally-expressed in 
embryonic CNS and adult brain, while maternal Grb10 is broadly expressed in 
the embryo except in CNS tissues (Garfield et al., 2011). In adults, the 
maternal Grb10 expression is restricted to muscle, fat, pancreas, oviduct, 
uterine horn, testis et al, with the highest expression in pancreas and very low 
level in liver (Smith et al., 2007; Wang et al., 2007; Garfield et al., 2011; Cowley 
et al., 2014; Kabir and Kazi, 2014). So far, Grb10 is the first identified imprinted 
gene which has varied imprinted patterns for the paternal and maternal alleles, 
having separate functions in different tissues (Garfield et al., 2011; Plasschaert 
and Bartolomei, 2015).  
 
Grb10 encodes the growth factor receptor–bound protein 10 (Grb10) which 
belongs to an adaptor protein family also including Grb7 and Grb14 (Holt and 
Siddle, 2005). Proteins of this family have similar structures containing an 
N-terminal proline-rich (P) region, a RAS-association-like binding (RA) domain, 
a pleckstrin homology (PH) domain, a between PH and SH2 (BPS) domain, 
and a Src homology 2 region (SH2) domain at the C-terminal end (Figure 1.3) 
(Ceccarelli and Sicheri, 2009). Grb10 had the ability to bind to a variety of 
receptor tyrosine kinases (RTKs) through the SH2 domain, including 
insulin-like growth factor 1 receptor (IGF1R), platelet derived growth factor 
receptor (PDGFR), epidermal growth factor receptor (EGFR) and vascular 
endothelial growth factor receptor 2 (VEGFR2) (Wang et al., 1999; Murdaca et 
al., 2004; Plasschaert and Bartolomei, 2015). Particularly, Grb10 interacted 
with insulin receptor (IR) through the SH2 and BPS domains (Holt and Siddle, 
2005). Based on in vitro studies, Grb10 can form protein complexes with Akt or 
neural precursor cell expressed developmentally down-regulated protein 4 
(Nedd4) through the SH2 domain, and complex formation was associated with 
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phosphorylation, and also ubiquitination and degradation of IR and IGF1R 
(Jahn et al., 2002; Vecchione et al., 2003). Grb10 structural studies revealed 
that the RA-PH regions of Grb10 can physically bind to the Ras proteins, and 
this was supported by the in vitro study using mouse fibroblasts (Deng et al., 
2008; Depetris et al., 2009). 
 
Figure 1.3 Grb10 modular protein structure. P, proline-rich domain; RA, 
RAS-association-like binding domain; PH, pleckstrin homology domain; BPS, 
between PH and SH2 domain; SH2, Src homology 2 domain. Graph is 
modified from Holt and Siddle, 2005. 
 
1.3.2 Biological functions of Grb10 
Biological functions of Grb10 have been discovered by using several Grb10 
knockout and overexpression mouse models developed by different groups. 
Maternal Grb10 obeyed the parent-offspring conflict theory for imprinting 
evolution (Haig, 2014). Maternally expressed Grb10 limited embryo and 
placental growth, since maternal Grb10 knockout mice had a 25-30% larger 
body size than WT mice after birth (Charalambous et al., 2003; Charalambous 
et al., 2010; Madon-Simon et al., 2014). As adults, Grb10 knockout mice had 
increased lean mass and reduced adipose mass, and this was associated with 
improved glucose handling and insulin sensitivity. These findings were 
reported by three groups using different Grb10 knockout mouse lines (Smith et 
al., 2007; Wang et al., 2007; Madon-Simon et al., 2014). Conversely, Grb10 
transgenic mice were heavier than WT with enlarged fat tissues at 5 months 
old, including WAT and BAT (Liu et al., 2014). The combined evidence 
suggests that Grb10 promotes adipose tissue growth and restricts muscle 
development. In addition, Grb10 overexpression mice displayed retarded 
growth during postnatal development and insulin resistance, supporting the 
growth suppressor role of Grb10 (Shiura et al., 2005). A fat tissue specific 
Grb10 knockout mouse model provided further evidence for a role of Grb10 in 
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adipogenesis, except that white adipose depots were significantly enlarged, as 
they were in Grb10 knockout models, perhaps suggesting both direct and 
indirect effects on adipose development or homeostasis. Grb10 deletion in fat 
tissue reduced the expression levels of lipolytic enzymes and fatty acid 
oxidation in BAT, leading to enhanced accumulation of lipid droplets in WAT 
and BAT (Liu et al., 2014). A possible reason for the converse phenotypes of 
global and conditional Grb10 knockout mice might be that Grb10 controls 
postnatal fat tissue formation through multiple tissues. Furthermore, 
conditional deletion or knockdown of Grb10 in mouse pancreas revealed that 
Grb10 inhibited pancreas and pancreatic b-cell development (Doiron et al, 
2012; Zhang et al, 2012). Also, the pancreas-specific Grb10 deletion enhanced 
the insulin sensitivity and glucose handling (Zhang et al., 2012; Ward, 2012). 
Two studies reported that the enlarged muscle tissue in neonatal and postnatal 
Grb10 knockout mice displayed a higher proliferation rate of muscle stem cell 
and myofiber. Grb10 was involved in proliferation and not the differentiation 
process, supporting an inhibitory role of Grb10 in muscle development (Holt et 
al., 2012; Mokbel et al., 2014). 
 
Grb10 alleles in mother and offspring acted in a coordinated manner to 
maximise offspring growth and physiology (Cowley et al., 2014). This was 
achieved by the maternal Grb10 allele regulating nutrient supply to offspring 
through the placenta and mammary gland, while Grb10 in offspring regulates 
demand for nutrients, at least during the postnatal suckling period in mouse 
(Cowley et al., 2014). The dual role for Grb10 in mother and offspring has been 
suggested to be the best example yet identified of co-adaptive gene evolution 
as the driving force for imprinted gene expression (Wolf, 2013; Cowley et al., 
2014; Wilkins, 2014). 
 
All of the above functions are associated with the maternal Grb10 allele. It has 
been shown that Grb10 is expressed in the developing and adult brain, but 
30 
 
exclusively from the paternal allele. Paternal knockout of Grb10 has been 
associated with specific deficits in social dominance behaviour (Garfield et al., 
2011). 
 
1.3.3 Grb10 adaptor signalling 
Grb10, as an adaptor, has the ability to recruit various signalling molecules 
through its multiple function domains (Figure 1.3). In particular, insulin receptor 
substrate 1/2 (IRS1/2) and Akt phosphorylation levels were reduced by Grb10 
overexpression in Chinese hamster ovary (CHO/IR) cells under insulin 
stimulation, suggesting a negative role of Grb10 in insulin signalling (Wick et 
al., 2003). In mouse embryonic fibroblasts, Grb10 can bind to Nedd4 and then 
form a Grb10/Nedd4 protein complex, and the complex was involved in the 
IGF1R degradation and internalization through receptor multi-ubiquitination 
(Vecchione et al., 2003; Monami et al., 2008). These other studies supported 
the evidence that Grb10 negatively regulates IR and IGF1R signalling in vitro 
(Wick et al., 2003; Vecchione et al., 2003; Monami et al., 2008). Besides, a 
siRNA knockdown of endogenous Grb10 in NIH 3T3 cells resulted in 
decreased IRS, Akt and extracellular signal regulated kinase 1/2 (Erk1/2) 
phosphorylation levels induced by insulin growth factor 1 (IGF1), further 
supporting the inhibitory role of Grb10 towards IGF signalling (Dufresne and 
Smith, 2005). By contrast, another study reported that Grb10 promoted 
VEGFR2 phosphorylation by binding to Nedd4 which caused ubiquitination 
and degradation of VEGFR2 in human embryonic kidney cells 293 (HEK293) 
cell line, uncovering a positive feedback to the RTK from Grb10 (Murdaca et al., 
2004). Moreover, it was reported that prolonged insulin stimulation caused the 
IR degradation, and endogenous Grb10 was related to IR proteasome 
degradation following insulin treatment of Hela cells (Ramos et al., 2006). In 
addition, in vivo experiments provided evidence that Grb10 acted as a 
negative regulator of insulin sensitivity in muscle, fat and at the whole body 
level (Wang et al., 2007; Smith et al., 2007; Madon-Simon et al., 2014). 
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Specifically, Grb10 knockout increased the IRS1, Akt and MAPK 
phosphorylation levels in muscle and fat tissues stimulated by insulin (Wang et 
al., 2007; Smith et al., 2007). Additionally, IGF injection activates a lower IRS1 
and Akt phosphorylation level in adult muscle compared to insulin injection 
(Smith et al., 2007). Recently, Grb10 has been identified as the direct 
substrate of mammalian target of rapamycin complex 1 (mTORC1), and Grb10 
phosphorylation by mTORC1 at the S501/503 sites leads to a negative 
feedback on mTORC1 and IR/IGF1R in vitro and in vivo (Hsu et al., 2011; Yu 
et al., 2011; Liu et al., 2014). These studies filled the gap between insulin and 
mTOR signalling in which Grb10 acted as a key negative regulator (Yea and 
Fruman, 2011; Liu and Liu 2014). Furthermore, global loss of Grb10 in mouse 
enhanced the hematopoietic stem cell proliferation through activation of 
Akt/mTORC1 pathway (Yan et al., 2016). Collectively, Grb10 might be an 
essential signal regulator of mTOR pathway. 
 
It was well established that Grb10 negatively regulate Insulin/IGF signalling in 
vitro and in vivo (Desbuquois et al., 2013). Yet it is unlikely that Grb10 is 
involved in the growth through Insulin/IGF signalling. Insulin signalling was 
known to have little effects on growth (Desbuquois et al., 2013; Plasschaert 
and Bartolomei, 2015). By contrast, IGF signalling was the major fetal growth 
regulatory pathway in mouse (Peters, 2014). Especially, the paternally 
expressed Igf2 and maternally expressed Igfr2r established the first 
growth-regulatory axis involved in imprinting in mammals (Baker et al., 1993; 
Lau et al., 1994; Wang et al., 1994). However, Grb10 and Igf2 double knockout 
mice exhibited distinguishable phenotypes from either Grb10 or Igf2 single 
knockout mice, suggesting that Grb10 regulated embryo growth independently 
from Igf2 (Charalambous et al., 2003). Moreover, the epistasis tests of Grb10 
against Igf1r and Insr knockout mice revealed that Grb10 acts primarily on 
growth independently of Igf1r and Insr (Charalambous et al., 2003), although 
Grb10 had high affinity for Igf1r and even higher for Insr (unpublished data). All 
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Grb10 epistasis tests suggest that Grb10 is a growth regulator independent of 
Insulin/IGF signalling. Consequently, little is known about the upstream or 
downstream effectors of Grb10 involved in the regulation of growth. 
 
1.4  Antagonistic roles of Dlk1 and Grb10 in mouse development 
Many of Dlk1 and Grb10 functions are well illustrated in mouse by Dlk1 and 
Grb10 knockout models. The main phenotypes of Dlk1 and Grb10 knockout 
mice are listed and compared below (Figure 1.4). Dlk1 and Grb10 each form a 
link between disrupted growth in early life and physiological changes in later 
life, particularly altered body composition (lean/adipose tissue proportions) and 
glucose-regulated metabolism, suggesting both may be key genetic factors in 
the developmental programming of life-long health (Moon et al., 2002; 
Charalambous et al., 2003; Smith et al., 2007; Wang et al., 2007; 
Charalambous et al., 2014; Madon-Simon et al., 2014). Although this 
programming phenomenon is well established there is essentially no 
understanding of the underlying mechanism. The Dlk1+/p and Grb10m/+ mice 
are proposed to be the first genetic models for developmental programming. 
This project will test that Dlk1 and Grb10 act antagonistically through a 
common pathway on the biochemical level using Dlk1 and Grb10 single and 




Figure 1.4 Antagonistic functions of Dlk1 and Grb10 in embryonic growth 
and adult body composition. Knockout phenotypic features summarised 
from (Moon et al., 2002; Charalambous et al., 2003; Smith et al., 2007; 
Madon-Simon et al., 2014). 
 
Crosses of Dlk1+/p and Grb10m/+ mice indicated that double knockout mice had 
a phenotype very similar to that of Grb10 single knockouts prenatally and 
postnatally. This indicated that Dlk1 and Grb10 play antagonistic roles in 
mouse development in a common genetic pathway (Figure 1.5). Furthermore, 
Dlk1 acted upstream, as an inhibitor of Grb10, which in turn is an inhibitor of 
growth (Madon-Simon et al., 2014). Currently, the biochemical interactions 
between Dlk1 and Grb10 proteins remain undefined. Studies of mTOR 
provided a potential link between the two factors. Two groups using 
phopho-proteomics approaches found that Grb10 was a direct substrate of 
mTORC1 negatively regulating mTOR and IGF/IR signalling in vitro (Hsu et al., 
2011; Yu et al., 2011). Another group uncovered that Grb10 controlled 
adipogenesis and thermogenesis through a negative feedback to mTORC1 
signalling in vivo (Liu et al., 2014). By contrast, miRNAs expressed from the 
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paternal Dlk1-Gtl2 locus negatively regulated the mTOR pathway in HSCs 
(Qian et al., 2016). Paternal Dlk1 expression also can be affected by the 
miRNAs expressed from the maternal Dlk1-Gtl2 locus (Charalambous et al., 
2012). Therefore, Dlk1 may be involved in mTOR signalling activity directly or 
indirectly. Collectively, these studies suggested that Dlk1 and Grb10 possibly 
control growth, metabolism or some other biological processes by regulating 
the mTOR pathway. Do Dlk1 and Grb10 interact via mTOR signalling or any 
other signal pathways during developmental programming? Can further 
signalling changes be detected in Dlk1 and Grb10 knockout mice using an 
unbiased approach? The large-scale quantitative proteomics could be used for 
in-depth study of Dlk1 and Grb10 signalling. The investigation will contribute to 
our understanding of Dlk1 and Grb10 functions, mammalian development as 
well as imprinted gene evolution. 
 
Figure 1.5 Evidence that Dlk1 and Grb10 regulate mouse embryonic 
growth in a common genetic pathway. Figure is modified from 




1.5  TMT quantitative proteomics 
Evidence from our laboratory indicates that the oppositely imprinted Dlk1 and 
Grb10 genes control the mouse fetal growth antagonistically through a 
common genetic pathway (Madon-Simon et al., 2014). Dlk1 and Grb10 protein 
expression levels were reciprocally affected by disruption of each other in 
pMEFs and livers derived from E14.5 (Chapter 3). However, the signalling 
pathways involving Dlk1 and Grb10 in regulation of mouse development are 
still unknown. An in-depth study of the functions and cross talk between Dlk1 
and Grb10 on the embryonic level is needed to understand their roles in 
mouse growth and development, including mechanisms of adipogenesis and 
myogenesis. The new isobaric tandem mass tag (TMT) reagents and 
improvements in quantitative proteomics currently allow the labelling of up to 
ten samples in a single analysis. This allowed comparison of two biological 
replicates each of E14.5 pMEF and liver samples of the four genotypes, WT, 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p. The proteomes and 
phosphoproteomes from WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p E14.5 
pMEFs and livers were analysed and compared. The candidate signal 
pathways and proteins associated with Dlk1 and Grb10 may be revealed by 
bioinformatics analyses, including principle component analysis (PCA), Gene 





In this work, WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p knockout mice 
(Raghunandan et al., 2008; Garfield et al., 2011) were used to provide whole 
liver tissue and to derive embryonic day 14.5 (E14.5) primary mouse 
embryonic fibroblasts (pMEFs) as in vivo and in vitro models, respectively. 
 
The aim was to address the following questions: 
1. What are the phenotypic differences of WT, Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p mice at E14.5 and 6-month of age? 
2. Do Dlk1 and Grb10 proteins affect the expression of each other in E14.5 
embryonic cells and tissues? 
3. How is Dlk1 and Grb10 downstream signal activity, including Akt, Erk1/2 
and mTOR, altered in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p mice? 
4. Can further Dlk1 and Grb10 signalling components be discovered by 
comparing the proteomes and phosphoproteomes of E14.5 WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs and livers? 
5. Can candidate genes or pathways identified using proteomics analyses be 














2.1  Materials 
All chemicals used in this study were purchased from Sigma-Aldrich 




In Dlk1 knockout mice, the promoter and first three exons of paternal Dlk1 
allele were deleted and replaced with a neomycin resistance cassette (neor) 
(Raghunandan et al., 2008). To generate Grb10 knockout mice, a 
LacZ:neomycinr gene-trap cassette was inserted and replaced an 11bp 
fragment of Grb10 exon 8 (Garfield et al., 2011). Those mouse stains were 
maintained on a C57BL/6xCBA mixed inbred genetic background. Only 
Grb10+/p females were used to cross with Dlk1+/p or WT males to produce 
Grb10m/+ and Grb10m/+/Dlk1+/p mice. Dlk1+/p mice used in this study were 
generated by crossing Dlk1+/p males with WT or Grb10+/p females. Note that, 
due to the opposite imprints of the two genes, this heterozygote cross 
produces WT, Dlk1+/p, Grb10m/+ and Grb10m/+/ Dlk1+/p offspring in a 1:1:1:1 
ratio (Figure 2.1). Offspring with the Dlk1+/p and Grb10m/+ heterozygous 
mutations are functionally null for those respective genes.  
 
Figure 2.1 Breeding schema for generation of Dlk1 and Grb10 single and 




Mice were kept with a 13 h of light and 11 h of dark cycle. Temperature and 
humidity were set as 21°C ± 2°C and 55 ± 10%, respectively. Mice were 
maintained with food (CRM formula, Special Diets Services, UK) and water 
available ad libidum. Ventilated cages were used to house the mice. Two to six 
mice were kept in each cage. Mice were weaned and ear clipped at 21 days or 
a few days later. Adult mice were culled by cervical dislocation. E14.5 embryos 
were immersed in ice cold PBS for at least 5 min for the confirmation of death. 





154 mM NaCl, 12.5 mM Na2HPO4.12H2O. 
 
1X TAE buffer 




10 mM Tris.Cl, 154 mM NaCl. 
 
TBST pH7.5 
10 mM Tris.Cl, 154 mM NaCl, 0.1% (v/v) Tween-20. 
 
Lysis buffer 
10 mM Tris.Cl, pH7.6, 5 mM EDTA, 1 mM Ethylene glycol-bis (β-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid (EGTA), 50 mM NaCl, 30 mM sodium 
pyrophosphate, 50 mM NaF, 100 μM sodium orthovanadate, 1% (v/v) Triton 
X-100, 1 mM Diothiothreitol (DTT), and a protease inhibitor tablet (Roche, 




3X Sample buffer 
30 mM Tris.Cl pH6.8, 1% SDS, 5% Glycerol, 100 mM DTT, 0.05% 
Bromophenol blue. 
 
Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
running buffer 
25 mM Tris.Cl, 0.2 M glycine, 0.1% (w/v) Sodium dodecylsulphate (SDS).  
 
 
SDS-PAGE wet transfer buffer 
25 mM Tris.Cl, 0.2 M glycine, 20% (v/v) methanol. 
 
SDS-PAGE blocking buffer 
5% (w/v) dried skimmed milk powder or 5% (w/v) bovine serum albumin (BSA) 
in TBS-Tween. 
 
Antigen retrieval solution pH6.0 





Details of the primary and secondary antibodies used for Western blotting (WB) 
and Immunoprecipitation (IP) in this study, including working dilutions, are 
listed in Table 2.1. Antibodies were diluted in SDS-PAGE blocking buffer. 
A 
Antibody Epitope Species Supplier Code Dilution 
Akt Total Mouse mAb CST 2920 1:2000 
Akt p-Ser473 Rabbit mAb CST 4060 1:2000 
Dlk1 Total Goat pAb R&D AF8277 1:1000 
Erbb2 Total Mouse mAb Thermo MA5-13105 1:200 
Erk1/2 Total Rabbit mAb CST 9102 1:1000 
Erk1/2 p-Thr202 &  
p-Tyr204 
Mouse mAb Sigma M9692 1:4000 
FGFR1 Total Rabbit mAb CST 9740 1:500 
GAPDH Total Mouse mAb Proteintech 60004-1 1:5000 
GAPDH Total Rabbit mAb CST 2118 1:10000 
Grb2 Total Rabbit mAb CST 3972 1:500 
Grb10 Total Rat pAb Monash N/A 1:250 
IRb Total Mouse mAb CST 3020 1:500 
p70 S6K Total Rabbit mAb CST 2708 1:1000 
p70 S6K p-Thr389 Rabbit mAb CST 9234 1:1000 
PI3K p85 Total Rabbit pAb UBI 06-195 1:500 
PDGFRa Total Rabbit mAb CST 3174 1:500 
PDGFRb Total Mouse mAb CST 3175 1:500 






Antibody Supplier Code Dilution 
HRP Goat anti-rabbit Vector PI-1000 1:5000 
HRP Goat anti-mouse Vector PI-2000 1:5000 
HRP Goat anti-rat Vector PI-9401 1:5000 
IRDye 800CW Donkey anti-mouse LI-COR 926-32212 1:10000 
IRDye 800CW Goat anti-rat LI-COR 926-32219 1:10000 
DyLight 680 conjugated goat anti-rabbit CST 5366 1:15000 
 
Table 2.1 Primary and secondary antibodies used for WB and IP. Antibody 
clones, supplier, product information and working dilution are listed in columns 
from left to right. mAb, monoclonal antibody; pAb, polyclonal antibody; HRP, 
Horseradish peroxidase; BL, Bethyl Laboratories,  Montgomery, US; CST, 
Cell Signaling Technology, Hitchin, UK; LI-COR, LI-COR Biosciences, 
Cambridge, UK; Monash, Monash University, Melbourne, Australia; R&D, R&D 
Systems, Abingdon, UK; Sigma, Sigma-Aldrich, Gillingham, UK; Thermo, 
Thermo Fisher Scientific, Gillingham, UK; UBI, Upstate Biotech Incorporated, 
New York, US; Vector, Vector Laboratories, Peterborough, UK. A) Table of 
primary antibodies. B) Table of secondary antibodies. 
 
2.1.4 Growth factors and inhibitors 
All the growth factors and inhibitors used in cell culture are listed in Table 2.2. 
Regulators were diluted in pre-warmed Dulbecco's Modified Eagle's medium 
(DMEM) to the listed concentrations. 
A 
Recombinant cell signal proteins Supplier Code Concentration 
Recombinant Murine PDGF-AA Peprotech 315-17 30 ng/ml 
Recombinant Murine PDGF-BB Peprotech 315-18 30 ng/ml 
Recombinant Murine EGF Peprotech 315-09 100 ng/ml 
Recombinant Murine FGF1 Peprotech 450-33A 10 ng/ml 
Recombinant Mouse IGF1 Sigma I8779 50 ng/ml 





Inhibitors Supplier Code Concentration 
Rapamycin Selleckchem S1039 100 nM 
Torin1 Selleckchem S2827 250 nM 
CHX Sigma C1988 10 ug/ml 
 
Table 2.2 Regulators and inhibitors used in this study. Regulators, product 
supplier, product information and working concentration are listed in columns 
from left to right. Peprotech, London, UK; Sigma, Sigma-Aldrich, Gillingham, 
UK; Selleckchem, Houston, US. A) Regulators used in cell culture experiments. 
B) Inhibitors used in cell culture experiments. 
 
2.2  Methods 
2.2.1 Genotyping 
Ear clips of adult mice and tails of E14.5 embryos were used for genotyping. 
Crude DNA were extracted from each ear clip or tail by adding 600 l fresh 100 
mM NaOH in an 1.5 ml microfuge tube with a pierced lid. NaOH solution was 
heated by immersing the lower part of tubes in boiling water for 10 min. Then 
100 l 1 M Tris-HCl (pH8) was added to each tube after cool down. The 
solution was stored at -20°C, and 1 l was used as the DNA template for 
polymerase chain reaction (PCR). Dlk1 and Grb10 genotyping was carried out 
separately with either Dlk1 primers (Dlk1 5’-CCA AAT TGT CTA TAG TCT CCC 
TC-3’, Neo 5’-CAT CTG CAC GAG ACT AGT G-3’, Screen 5’-CTG TAT GAA 
GAG GAC CAA GG-3’) or Grb10 primers (Grb10F 5’-CCA AGT GGA GAG 
TAC CAT GCC-3’, Grb10R 5’-TCA CCT GAC AGG CAC CTC CCC-3’ and 
βgeoR2 5′-CTT CCG CTT AGT GAC AAC G-3′) (Raghunandan et al., 2008; 
Garfield et al., 2011). Dlk1 primers generated a 414 bp band for WT and a 495 
bp band for mutant alleles (Raghunandan et al., 2008). Grb10 primers yielded 
a 393 bp band for WT and a 177 bp band for mutant alleles. All PCR reactions 
were done with 7.5 l 2X GoTaq Green Maser Mix (Promega, Southampton, 
UK), 0.75 l Dlk1 or Grb10 primers (6 pmol/l), 5.75 l MQ water, and 1 l DNA 
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template using a BioRad T100 PCR machine (BioRad, Hemel Hempstead, 
UK).  
 
Dlk1 genotyping PCR reaction was performed with denaturation at 95°C for 2 
min, 40 annealing cycles (94°C for 30 sec, 57°C for 30 sec, and 72°C for 45 
sec), and elongation at 72°C for 3 min. Grb10 genotyping PCR reaction was 
carried out with denaturation at 95°C for 2 min, 30 annealing cycles (95°C for 
30 sec, 60°C for 30 sec, and 72°C for 45 sec), and elongation at 72°C for 3 min. 
2.5% (w/v) electrophoresis gels were used for Dlk1 and Grb10 genotyping. 
Agarose (Invitrogen, Gillingham, UK) was dissolved in 1X TAE buffer heated 
by a microwave oven for 2 min. 2 l ethidium bromide (Sigma, Gillingham, UK) 
was added to each 100 ml melted gel solution cooled to approximately 60°C. 
The gel was cast with wells at one end such that 15 l PCR product could run 
alongside 6 l of a 1kb DNA ladder (Promega, Southampton, UK) using 1X 
TAE buffer in an Wide Mini-sub Cell GT electrophoresis tank (BioRad, Hemel 
Hempstead, UK). Bands were separated by electrophoresis using a power 
source (BioRad PowerPac 300, Hemel Hempstead, UK) running at 80 V for 35 
min (Dlk1) and 80 V for 45 min (Grb10). Gels were visualized using UV light 
transilluminator and pictures were taken with a ChemiDoc-It2 Imager (UVP, 
Cambridge, UK). 
 
2.2.2 Body composition assay 
Body mass and compositions of mice at 6 months old were measured and 
recorded. Body mass was measured by an electronic scale. Body composition 
assay including fat and lean mass were performed using a Mini-spec body 
composition analyser (Bruker, Coventry, UK) according to the manufacturer's 
instructions. Briefly, the mouse was restrained in a glass tube that was 
inserted into the body composition analyser for a whole body scan, lasting 





2.2.3 Preparation of E14.5 pMEFs and livers 
The whole uterus of a 14.5-day pregnant mouse was dissected out and 
immersed in cold 0.1% PBS for at least 5 min. Then individual embryos were 
separated from their placentae and the yolk sac was peeled from each embryo. 
After being dried and weighted, a portion of the tail from each embryo was 
dissected and stored at -20°C for genotyping, and then each E14.5 embryo 
was kept in 1 ml pre-warmed DMEM medium. Each embryo was decapitated 
and eviscerated, and the liver was collected and stored at -80°C. The rest of 
the embryo was minced using a pair of scissors. 3 ml 0.25% (w/v) 
Trypsin-EDTA solution (Sigma, Gillingham, UK) was added to the mince in a 
15 ml Falcon tube and incubated at 37°C for 20 min. Then another 3 ml 0.25% 
Trypsin-EDTA solution was added to each tube and incubated at 37°C for 
another 20 min. To stop the trypsinization, 6 ml complete medium (DMEM 
medium, 10% (v/v) fetal bovine serum (FBS) (Gibco, Gillingham, UK), 1% (v/v) 
streptomycin (1000 U)/penicillin (10 mg/ml) (Sigma, Gillingham, UK), and 1 
mM L-glutamine (Sigma, Gillingham, UK)) was added to each tube. Tissue and 
medium mixture was mixed well by hand then span down in a ALC PK110 
centrifuge (Thermo Scientific, Gillingham, UK) at 180 g for 5 min. Cell pellets 
were mixed with 12 ml pre-warmed complete medium and cultured in a T75 
tissue culture flask (Fisher Scientific, Loughborough, UK) as passage 0 (P0). 
Flasks were incubated for 24-48 h at 37°C with 5% CO2. This method was 
modified from Takahashi and Yamanaka (2006). 
 
2.2.4 Maintenance of E14.5 pMEFs 
E14.5 pMEFs were cultured with 7 ml or 12 ml complete medium in T25 or T75 
tissue culture flasks, respectively. Cells were washed twice with 0.1% PBS (1 
ml/25 cm2), pre-warmed to 37°C, and replenished with pre-warmed complete 
medium every 48-72 h. Cell splitting was carried out when cells reached about 
80% confluence, as judged by eye. Medium was removed through a glass 
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pipette (Fisher Scientific, Loughborough, UK) by an aspirator (Welch Vacuum, 
Ilmenau, Germany), and then washed with 0.1% PBS (1 ml/25 cm2) twice. 1 
ml/25 cm2 0.25% Trypsin-EDTA solution was added to the flasks and incubated 
at 37°C for 5 min. Flasks were given a slap on the side to dislodge the cells 
from the bottom. Then, twice volume of complete medium was added to the 
flask to stop the trypsin reaction. Cell suspension was separated evenly to 
three flasks.  
 
To freeze the pMEFs, cell suspension was transferred to a 15 ml Falcon tube 
and centrifuged at 120 g for 4 min. Cell pellets were re-suspended in 900 μl 
FBS and transferred to a Cryo-Tube vial (Fisher Scientific, Loughborough, UK). 
Then 100 μl Dimethyl sulphoxide (DMSO) was added to each vial. Vials were 
placed in a tissue-padded polystyrene box, filled with isopropanol, and placed 
at -80°C overnight. The next day vials were moved to liquid nitrogen for long 
term storage. Frozen cells were thawed rapidly by placing Cryo-Tube vials in a 
water bath at 37°C. Once melted, cell suspension was added to 5 ml 
pre-warmed DMEM and then centrifuged at 180 g for 4 min. Cell pellets were 
re-suspended in 12 ml complete medium and transferred to a T75 flask. Flasks 
were placed in the 37°C incubator and cells allowed to attach for 4-6 h prior to 
a change of medium. 
 
2.2.5 Stimulation and inhibition of E14.5 pMEFs 
E14.5 pMEFs were cultured in 6-well cell culture plates, T25 flasks, T75 flasks 
or 10cm cell culture dishes (Fisher Scientific, Loughborough, UK) until the cell 
confluence was higher than 80% for stimulation or inhibition experiments. Cells 
were washed twice with pre-warmed 0.1% PBS and then this was replaced 
with pre-warmed DMEM medium which contained 1% (v/v) streptomycin (1000 
U)/penicillin (10 mg/ml) and 0.1% (w/v) BSA for overnight serum starvation. On 
the following day, cells were treated with 10% pre-warmed FBS or different 
regulators following the concentrations listed in Table 2.2 as described before. 
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Cells were incubated with the regulators for sampling at different time points, 
varying from 5 min to 48 h.  
 
2.2.6 Total protein extractions from E14.5 pMEFs and livers 
To extract total proteins from E14.5 pMEFs, 60 μl or 100 μl lysis buffer was 
added to each well in a 6-well plate or T25 flask. All reactions were stopped 
simultaneously by washing with cold 0.1% PBS twice, and then lysis buffer 
was added. The plate or flask was rotated briefly to ensure all cells had been 
exposed to the buffer. Then a cell scraper (Fisher Scientific, Loughborough, 
UK) was used to remove the cells from the base into the lysis buffer. The 
scraper was washed in PBS between wells or flasks. Cell lysates were 
transferred to ice cold 1.5 ml microfuge tubes and incubated on ice for 20 min 
with vortex mixing every 5 min. Tubes were centrifuged at 14769 g for 10 min 
in a Biofuge Primo R centrifuge pre-chilled to 4°C (Thermo Scientific, 
Gillingham, UK). The supernatants were transferred to a fresh tube and stored 
at -80°C. E14.5 livers were weighted and recorded, and then 5x volumes of 
lysis buffer were added to each liver sample. The mixtures were transferred to 
a Precellys lysing tube (Bertin, Montigny-le-Bretonneux, France) and 
homogenized 3 times for 15 sec using a Minilys personal homogenizer (Bertin, 
Montigny-le-Bretonneux, France). Then cell suspensions were moved to a 1.5 
ml microfuge tube and centrifuged at 14769 g for 10 min in a Biofuge Primo R 
centrifuge pre-chilled to 4°C (Thermo Scientific, Gillingham, UK). 
Supernatants were collected and stored at -80°C. 
 
2.2.7 Protein concentration bicinchoninic acid (BCA) assay 
BSA solutions with known concentrations ranged from 0 to 2 mg/ml were used 
to plot the standard curve. Protein concentrations were measured by mixing 10 
μl lysate or BSA solution with 200 μl BCA protein assay working reagent 
(Fisher Scientific, Loughborough, UK) in a clear bottom 96-well microplate 
(Fisher Scientific, Loughborough, UK) according to the manufacturer's 
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instructions. Plates were incubated at 37°C for 30 min and then cooled to room 
temperature. Absorbance at 560nm was read using a ModulusTM microplate 
multimode reader (Turner Biosystems, Sunnyvale, US). A standard curve 
based on BSA solution with known concentration was plotted in Excel. 
Unknown sample concentration was determined by fitting to the standard 
curve. 
 
2.2.8 Sodium dodecylsulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
To denature proteins, lysate from E14.5 pMEF or liver sample was mixed with 
3X sample buffer or commercial 5X sample buffer (National Diagnostics, 
Nottingham, UK) in a pierced 1.5 ml microfuge tube. Then sample tubes were 
held in boiling water for 10 min. Samples were stored at -80°C and re-boiled 
for 2 min before use each time. 10% SDS-PAGE mini gels were used to run 
the SDS-PAGE WB. Each two resolving gels were made from 2.5 ml 1.5 M 
Tris.Cl (pH8.9), 3.3 ml 30% 37:1 acry:bis (National Diagnostics, Nottingham, 
UK), 4 ml MQ H20, 200 µl 10% SDS, 67 µl Ammonium persulfate (APS), and 4 
µl N,N,N',N-tetramethylethylenediamine (TEMED). Each two stacking gels 
consisted of 1.26 ml 0.5 M Tris.Cl (pH6.8), 0.8 ml 30% 37:1 acry:bis, 2.9 ml 
MQ H20, 100 µl 10% SDS, 50 µl APS, and 5 µl TEMED. Commercial 
mini-PROTEAN TGX precast 10% gels were purchased from BioRad (BioRad, 
Hemel Hempstead, UK). 10-20 μg/well protein extracts were loaded onto gels 
alongside with 2 μl pre-stained DNA markers (NEB, Hitchin, UK). Gel 
eletrophoresis was carried out in SDS-PAGE running buffer using the Mini 
PROTEIN tetra system (BioRad, Hemel Hempstead, UK) at 200 V for 30-50 
min until blue Bromophenol dye had run just off the end of the gel. Proteins 
were transferred from gels to polyvinylidene fluoride (PVDF) membranes 
(Millipore, Watford, UK) in SDS-PAGE transfer buffer using a Criterion Blotter 
wet transfer tank (BioRad, Hemel Hempstead, UK) at 100 V for 90 min. After 
transfer, membranes were washed with MQ water once and then blocked in 
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SDS-PAGE blocking buffer for 1 h with gentle shaking. Primary antibody 
incubation was performed at 4°C overnight. Membranes were incubated with 
secondary antibodies labelled with horseradish peroxidase (HRP) or 
fluorescent dyes for 1 h or 45 min at 4°C, respectively. Membranes were 
washed with 0.1% TBS/tween-20 for 3x 5 min before and after secondary 
antibody incubation. For enhanced chemiluminescence substrate (ECL) 
detection, 1 ml ECL detection reagent (Amersham, Buckinghamshire, UK) was 
poured on each 6x9 cm membrane and incubated at room temperature for 1 
min. Chemiluminescence was detected using a Fusion SL 
Chemiluminescence System (Vilber, Marne-la-Vallée, France). For infrared 
fluorescence detection, membranes were scanned using an Odyssey CLx 
infrared imaging system (LI-COR Biosciences, Cambridge, UK) according to 
the manufacturer’s protocol. Membrane stripping was carried out by serially 
incubating the membrane in MQ water, 200 mM NaOH, and MQ water for 5 
min on a rocking platform at room temperature. Re-probing of the stripped 
membrane started from the blocking step. Quantitative analysis of protein 
bands on the blots was performed using software ImageJ 1.48v or Li-COR 
Image Studio ver 5.0. 
  
2.2.9 Dlk1 sandwich enzyme-linked immunosorbent assay (ELISA) 
WT, Dlk1+/p, and Grb10m/+ pMEFs were cultured in a 6-well plate until reaching 
about 80% confluence, and then cells were replaced with fresh complete 
medium once. Cell medium from each well was collected 24 h or 48 h later and 
kept in individual 2 ml microfuge tubes. A 6-well plate containing the same 
amount of medium and no cells was prepared as a blank control plate. Medium 
from Dlk1+/p pMEFs was used as a negative control. Medium from three wells 
of each sample were collected for Dlk1 ELISA. Dlk1 ELISA was carried out 
using an antibody specific to human Dlk1 (capture) and an antibody specific to 
mouse Dlk1 (detection), following with a HRP-conjugated anti-mouse 
secondary antibody incubation and 3,3′,5,5′-Tetramethylbenzidine (TMB) 
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detection. A Dlk1 standard curve was plotted using recombinant mouse Dlk1 
protein with known concentration. Sample concentrations were determined by 
fitting TMB readings to the Dlk1 standard curve (Cleaton et al., 2016). Medium 
samples were prepared and sent to Dr. Claire L Dent in Queen Mary University 
of London who carried out the Dlk1 sandwich ELISA. 
 
2.2.10 Mouse phospho-receptor tyrosine kinase (RTK) array analysis 
Mouse phospho-RTK array kit (R&D systems, Abingdon, UK) was used to 
perform the analysis according to manufacturer's instructions. 500 µg cell 
lysates from each sample were incubated with an array at 4°C overnight. An 
HRP-conjugated anti-mouse secondary antibody from the kit was used to 
detect the primary antibody on each array. After all the incubation and wash 
steps, 1 ml ECL detection reagent was poured on each array and incubated at 
room temperature for 1 min. Luminescence from secondary antibodies was on 
the array was detected by a Fusion SL Chemiluminescence System (Vilber, 
Marne-la-Vallée, France). Dot pixel intensities from each dot on each array 
were analysed using ImageJ 1.48v software. 
 
2.2.11 Immunoprecipitation (IP) 
MEFs were cultured in T75 flasks or 10cm dishes. After overnight serum 
starvation (see section 2.2.5), cells were treated with PDGF-AA/BB for 5 min 
or 30 min. Then 450 μl complete lysis buffer was added to each flask or dish. 
Cell lysates were vortexed for 2 min and then centrifuged at 12000 x g for 10 
min at 4°C. Supernatants were transferred to a new tube. Protein 
concentrations were measured (see section 2.2.7) and equal amounts of total 
protein from each sample were incubated with an anti-phospho-tyrosine 
antibody conjugated sepharose beads at 4°C with rotation for overnight. Beads 
were washed with 500 μl lysis buffer three times before being incubated with 
protein lysates. The next day, lysate and bead mixtures were centrifuged at 
12000 x g for 30 sec. Supernatants were discarded. And beads were washed 
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with 500 μl lysis buffer twice and 500 μl PBS three times. 20 μl 2X sample 
buffer were added to each sample and then boiled for 5 min. Samples left in 
each tube were loaded on to 10% protein gels for a subsequent Western 
blotting analysis (see section 2.2.8).  
 
2.2.12 Tissue wax sectioning 
E14.5 whole embryos after dissection were fixed in 4% PFA at 4°C overnight. 
Subsequently, embryos were washed with PBS once and stored in 70% 
ethanol at 4°C. In the Leica TP 1020 tissue processor (Leica Biosystems, 
Milton Keynes, UK), tissues were washed twice for 2 h in the following series 
of solutions: 70% ethanol, 90% ethanol, 100% ethanol, Histoclear (National 
Diagnostics, Nottingham, UK) and wax. Then tissues were embedded in 
pre-warmed wax and poured into plastic moulds to form blocks. 
Paraffin-embedded tissue blocks were cut using a Leica RM 2155 microtome 
(Leica Biosystems, Milton Keynes, UK) at 8 m for each section and placed on 
polysine slides (Fisher Scientific, Loughborough, UK). Slides were incubated 
at 40°C overnight and then stored at 4°C. 
 
 
2.2.13 Immunohistochemistry (IHC) of wax sections 
Tissue sections were dewaxed in Histoclear twice for 10 min, rehydrated 
sequentially in 100% ethanol, 70% ethanol and 50% ethanol for 7 min, and 
washed with PBS with shaking for 5 min. Slides were immersed into antigen 
retrieval solution and boiled in a microwave oven for 20 min. After cooling to 
room temperature, sections were washed twice with PBS for 5 min. Before 
serum blocking, sections were separated from each other by drawing wax 
circles around them. Blocking was performed with 95 l diluted normal goat 
serum (55 l serum in 3.3 ml PBS) (CST, Hitchin, UK) on each section for 20 
min at room temperature. Each section was incubated in 95 l primary 
antibody at 4°C for 16-18 h. Following this, sections were washed with 0.25% 
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Triton X-100 (250 l Triton X-100 in 100 ml PBS) and PBS with shaking for 5 
min. Then sections were treated with goat biotinylated secondary antibody 
diluted in normal goat serum blocking solution for 30 min at room temperature 
and washed with 0.5% Triton X-100 (500 l Triton X-100 in 100 ml PBS)  and 
PBS with shaking for 5 min. Next, each section was incubated with 3% 
hydrogen peroxide, streptavidin-horseradish peroxidase complex (ABC kit, 
Vector Laboratories, Peterborough, UK) and diaminobenzidine (DAB kit, 
Vector Laboratories, Peterborough, UK) for 5 min, 30 min and 5 min, 
respectively. Sections were counterstained with Harris Haemotoxylin for 30 
sec and then cleared and dehydrated in 1% HCl in 70% ethanol for 30 sec, 1% 
NH3 in 70% ethanol for 1 min, 70% ethanol for 30 sec and Histoclear twice for 
2 min each. Lastly, sections were mounted with DPX mounting medium and 
imaged under a Nikon E800 microscope and a Nikon digital Sight DS-U1 
camera (Nikon, Kingston Upon Thames Surrey, UK) which were controlled 
using NIS Elements D 2.30 software. 
 
2.2.14 Statistical analysis 
GraphPad Prism 6 software was used to perform all statistical analyses except 
that of proteomics data. Standard error of the mean (SEM) and P values were 
calculated by the software and data was further analysed using either 
One-way ANOVA with Tukey’s post hoc tests or Two-way ANOVA with 
Bonferroni post-tests or Unpaired t-test with two-tailed tests as indicated in the 
results. P<0.05 was considered as significant. 
 
2.2.15 Sample preparation and labelling for tandem mass tag (TMT) 
quantitative proteomic analysis 
TMT tag labelling and TMT proteomics analysis was performed by Dr Kate 
Heesom at the University of Bristol Proteomic Facility who also provided the 




Tissues (pMEFs and livers) were derived from WT, Dlk1+/p, Grb10m/+, and 
Grb10m/+/Dlk1+/p E14.5 embryos (see section 2.2.3). P0 pMEFs were grown in 
T75 flasks with complete medium (see section 2.2.4) until reaching about 90% 
confluence. Total proteins were extracted from the P0 or P1 pMEFs and fresh 
livers (see section 2.2.6). Two biological replicates of each genotype were 
prepared for TMT quantitative proteomic analysis with the duplicates chosen 
from different litters. Protein concentrations were measured by BCA assay as 
described in section 2.2.7. Protein sample qualities were verified by Dlk1, 
Grb10 and GAPDH western blotting. 100 µg of each sample were sent for TMT 
analysis. Two independent TMT analyses were performed on E14.5 pMEF and 
liver samples separately. Aliquots of 100 µg of eight samples per TMT 
experiment were digested with 2.5 µg trypsin at 37°C overnight. Digested 
peptides from each sample were labelled by a unique TMT tag from TMT 
10plex reagents according to the manufacturer’s protocol (Thermo Fisher 
Scientific, Gillingham, UK). Then the labelled samples were pooled. 
 
2.2.16 High pH reversed-phase chromatography 
For the total proteome analysis, an aliquot of 50 µg of the pooled sample was 
evaporated to dryness and resuspended in buffer A (20 mM ammonium 
hydroxide, pH 10) prior to fractionation by high pH reversed-phase 
chromatography using an Ultimate 3000 liquid chromatography system 
(Thermo Fisher Scientific, Gillingham, UK).  In brief, the sample was loaded 
onto an XBridge BEH C18 Column (130Å, 3.5 µm, 2.1 mm X 150 mm, Waters, 
UK) in buffer A and peptides eluted with an increasing gradient of buffer B (20 
mM Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% over 60 minutes.  
The resulting fractions were evaporated to dryness and resuspended in 1% 
formic acid prior to analysis by nano-Liquid chromatography (nano-LC) tandem 
mass spectrometry (MS/MS) using an Orbitrap Fusion Tribrid mass 




For the phosphoproteome analysis, the remainder of the TMT-labelled pooled 
sample was evaporated to dryness and subjected to TiO2-based 
phosphopeptide enrichment according to the manufacturer’s instructions 
(Pierce, Thermo Fisher Scientific, Gillingham, UK). The phospho-enriched 
sample was evaporated to dryness and then resuspended in 1% formic acid 
prior to analysis by nano-LC MS/MS using an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Fisher Scientific, Gillingham, UK).  
 
2.2.17 Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 
nano-High-performance liquid chromatography (nano-HPLC) system in line 
with an Orbitrap Fusion Tribrid mass spectrometer.  In brief, peptides in 1% 
formic acid were injected onto an Acclaim PepMap C18 nano-trap column 
(Thermo Fisher Scientific, Gillingham, UK). After washing with 0.5% (v/v) 
acetonitrile 0.1% formic acid peptides were resolved on a 250 mm × 75 μm 
Acclaim PepMap C18 reverse phase analytical column (Thermo Fisher 
Scientific, Gillingham, UK) over a 150 min organic gradient, using 7 gradient 
segments (1-6% solvent B over 1 min., 6-15% B over 58 min., 15-32% B over 
58 min., 32-40% B over 5 min., 40-90% B over 1 min., held at 90% B for 6 min 
and then reduced to 1% B over 1 min.) with a flow rate of 300 nl/min (Solvent A 
was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% 
formic acid).  Peptides were ionized by nano-electrospray ionization at 2.0 kV 
using a stainless steel emitter with an internal diameter of 30 μm (Thermo 
Fisher Scientific, Gillingham, UK) and a capillary temperature of 275°C. 
 
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer 
combined with Xcalibur 2.0 software (Thermo Fisher Scientific, Gillingham, UK) 
and operated in data-dependent acquisition mode using an SPS-MS3 workflow. 
FTMS1 spectra were collected at a resolution of 120,000, with an automatic 
gain control (AGC) target of 200,000 and a max injection time of 50 ms. The 
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TopN most intense ions were selected for MS/MS. Precursors were filtered 
according to charge state (to include charge states 2-7) and with monoisotopic 
precursor selection. Previously interrogated precursors were excluded using a 
dynamic window (40 s +/-10 ppm). The MS2 precursors were isolated with a 
quadrupole mass filter set to a width of 1.2 m/z. ITMS2 spectra were collected 
with an AGC target of 5000, max injection time of 120 ms and CID collision 
energy of 35%.  
 
For FTMS3 analysis, the Orbitrap was operated at 60, 000 resolution with an 
AGC target of 50 000 and a max injection time of 120ms.  Precursors were 
fragmented by high energy collision dissociation (HCD) at a normalised 
collision energy of 55% to ensure maximal TMT reporter ion yield.  
Synchronous Precursor Selection (SPS) was enabled to include up to 5 MS2 




2.2.18 Proteomics data analysis 
Raw MS data files were analysed by MaxQuant v1.5.3.8 software with an 
Andromeda search engine and searched against Uniprot Mouse database 
downloaded on 170415 (73324 entries). MaxQuant created a reverse of the 
Uniprot Mouse library to get an estimate of false discovery rate (FDR). Default 
MaxQuant FDR was set to >1%. The software also created a library of known 
common contaminants which were excluded from the following bioinformatics 
analyses. MaxQuant analysis was carried out in collaboration with Professor 
Ian Prior from the University of Liverpool. For each protein, ratios of MS 
intensities from Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p were calculated using 
WT as the denominator. Then the ratios were log2 transformed. Average log2 
transformed values were calculated from the biological replicates for each TMT. 
The mean values were used for the following analyses. 4-fold and 1.5-fold 
change was used as the threshold for proteome and phospho-proteome data 
sets, respectively. Uniprot identifiers were converted to Entrez gene (Gene ID) 
by the Uniprot online tool “Retrieve/ID mapping” 
(http://www.uniprot.org/uploadlists/) if necessary.  
 
Gene ontology (GO)-term enrichment analysis was performed using the online 
GO-term analysis tool “Gorilla” (http://cbl-gorilla.cs.technion.ac.il/) (Eden et al., 
2007; Eden et al., 2009). This tool calculated p-values of enriched GO-terms 
from target gene list against background gene list with multiple testing using 
FDR (Eden et al., 2009). Genes out of the fold change threshold were set as 
the target gene list and the whole dataset as the background list. P-value 
threshold was set as 10-5 for E14.5 pMEF and liver proteome and 10-3 for 
E14.5 pMEF and liver phospho-proteome data sets. Biological process, 
molecular function and cellular component enriched terms were all searched. 
P-values of the enriched GO-terms were log10 transformed and expressed as a 




Principle component analysis (PCA) was performed on log2 transformed ratios 
using JMP10 software. All the proteins with missing values from any TMT tags 
were deleted from the PCA analysis. Pearson correlation coefficient (r) was 
calculated using GraphPad Prism 6 software. Hierarchical clustering (HCL) 
analysis using Pearson correlation coefficient (r) was visualized with MeV 
v4.9.0 software. Scatter plots of the whole data sets were generated with 
GraphPad Prism 6 software. 
 
Clustering analysis was carried out using GProX v1.1.16 software (Rigbolt et 
al., 2011). TMT ratios were log2 transformed and unsupervised gene clusters 
were identified using a fuzzy c-means algorithm. The E14.5 pMEF proteome 
dataset was grouped into 4 clusters with settings of regulations threshold=+2, 
fuzzification=2, iterations=200. The E14.5 pMEF phospho-proteome dataset 
was grouped into 6 clusters with settings of regulations threshold=+0.58, 
fuzzification=2, iterations=200. The E14.5 liver proteome dataset was grouped 
into 6 clusters with settings of regulations threshold=+2, fuzzification=2, 
iterations=200. The E14.5 liver phospho-proteome dataset was grouped into 5 
clusters with settings of regulations threshold=+0.58, fuzzification=2, 
iterations=200. Genes grouped into the same cluster from each individual 
dataset were retrieved from GProX v1.1.16 software. Then GO-term 
enrichment analysis was performed for each gene cluster using “GOrilla” 
online tool, as described before. The gene list from each cluster was set as the 
target list and the whole dataset as the background list. P-value threshold was 
set as 10-3. Biological process, molecular function and cellular component 
enriched terms were all searched. P-values of the enriched GO-terms were 
log10 transformed and expressed as a Heatmap using MeV v4.9.0 software 









Biochemical studies of Dlk1 and 




3.1  Background 
Evidence derived from transgenic mouse models indicates that there is a 
genetic interaction between Dlk1 and Grb10 in the regulation of early 
embryonic development and postnatal physiology, with Dlk1 acting as an 
upstream inhibitor of Grb10 (Madon-Simon et al., 2014). However, no studies 
have attempted to establish the biochemical interactions between the protein 
products of these genes and how this governs altered embryo size and adult 
body composition. Dlk1 and Grb10 proteins are both important cell signalling 
factors during mouse development. Dlk1 has been shown to inhibit Notch1 
signalling (Traustadóttir et al., 2016), however, it is a non-canonical ligand from 
the EGF-like protein family lacking a DSL domain which can directly interact 
with Notch receptors (Traustadóttir et al., 2016; Traustadóttir et al., 2017). 
Physiologically relevant receptors of Dlk1 are still unknown. Grb10 is a 
signalling adaptor protein that is identified as a direct substrate of mTORC1 
and can bind to several RTKs, including the IR and IGFR (Yu et al., 2011; Hsu 
et al., 2011; Plasschaert and Bartolomei, 2015). In addition, Grb10 was 
reported to be phosphorylated and stabilized by mTORC1 and mediated a 
negative feedback upon IR/IGFR and mTORC1 signalling in vitro and in vivo 
(Yu et al., 2011; Hsu et al., 2011; Liu et al., 2014). This project will attempt to 
uncover the Dlk1 and Grb10 signalling network, possibly through RTK or 
mTOR signalling pathways, in the mouse fetus at E14.5, using undifferentiated 
pMEFs and livers derived from WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p mice. 
Serum was used to activate RTK downstream signalling pathways in pMEFs 
from the four genotypes, and mTOR inhibitor rapamycin (Yu et al., 2011; Hsu 
et al., 2011) and mTORC1 specific inhibitor Torin1 (Thoreen et al., 2009; Hsu 
et al., 2011) were used to block the downstream signal activities of mTOR. 
This chapter will address the following questions:  
1) Does Dlk1 or Grb10 deletion alter E14.5 embryo size and also adult (6 
months old) body composition, as shown previously? 
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2) Does Dlk1 or Grb10 deletion affect expression level of the other signalling 
protein in knockout tissues and cells, and if so does Dlk1 act at the 
biochemical level as an upstream inhibitor of Grb10? 
3) How do RTK downstream signalling pathways respond to Dlk1 and Grb10 
single and double knockout? 
4) Do signalling changes in knockout tissues or cells support the antagonistic 
functions of Dlk1 and Grb10 based on genetic evidence? 




3.2  Results 
3.2.1 E14.5 fetuses with Grb10m/+ and Grb10m/+/Dlk1+/p genotypes 
exhibited overgrowth in comparison with WT and Dlk1+/p 
To determine the impacts of Dlk1 and Grb10 on fetal growth, wet weights of 
E14.5 embryos from WT, Dlk1 and Grb10 single and double knockout were 
recorded and analysed (Figure 3.1). Compared to WT and Dlk1+/p, Grb10m/+ 
and Grb10m/+/Dlk1+/p embryos were significantly heavier (Figure 3.1B). The 
mean wet weights of WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p embryos were 
0.1992+0.01 g, 0.2034+0.01 g, 0.2872+0.02 g and 0.2575+0.01 g, respectively. 
Grb10m/+ and Grb10m/+/Dlk1+/p embryos were about 44% and 29% heavier than 
WT (Figure 3.1A). No statistical significance was found between E14.5 
Grb10m/+ and Grb10m/+/Dlk1+/p embryos, indicating an indistinguishable 
phenotype between these two genotypes (Figure 3.1B). Dlk1+/p pups were born 
20% smaller than WT as reported (Moon et al., 2003; Madon-Simon et al., 
2014). However, at E14.5 WT and Dlk1+/p embryos had a similar body weight 
with no statistical difference, revealing that Dlk1 may affect fetal growth later in 
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Figure 3.1 Comparisons of fetal weights at E14.5 among the four 
genotypes. A) Grb10m/+ and Grb10m/+/Dlk1+/p fetuses were significantly 
heavier than WT and Dlk1+/p. WT, green scatters; Dlk1+/p, orange scatters; 
Grb10m/+, light blue scatters; Grb10m/+/Dlk1+/p, dark blue scatters. B) Summary 
of statistical analysis among the four genotypes. All values represent means 
plus SEM and have been subject to One-way ANOVA with Tukey’s post hoc 
analysis. WT n=33, Dlk1+/p n=30, Grb10m/+ n=25, Grb10m/+/Dlk1+/p n=21. **** 
P<0.0001. 
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3.2.2 Level of adiposity were increased in Dlk1+/p adult mice, whereas 
Grb10m/+ and Grb10m/+/Dlk1+/p adult mice were leaner compared to 
WT 
For the investigation of Dlk1 and Grb10 influences on postnatal development, 
total body mass and body composition of knockout mice and their WT 
littermates were analysed at 6 months old. Female and male mice were 
compared separately to exclude any sex bias. Although Grb10m/+ and 
Grb10m/+/Dlk1+/p mice were slightly heavier than WT and Dlk1+/p mice (Figure 
3.2A, B), both females and males showed no significant difference in body 
mass according to genotype (Figure 3.2I, J). 
 
Dlk1+/p females were phenotypically fatter as the ratios of fat mass/body weight 
and fat mass/lean mass were both significantly elevated compared to WT 
(Figure 3.2C, G, I). Meanwhile, the content of lean mass in Dlk1+/p females was 
significantly decreased when expressed as the ratio of body weight in 
comparison with WT (Figure 3.2E, I). The ratio of fat mass/lean mass was 
significantly higher in Dlk1+/p males compared to WT (Figure 3.2H, J). The 
ratios of fat mass and lean mass of the body weight in Dlk1+/p males had 
similar trends as the Dlk1+/p females. However, no statistically significant 
differences were found between Dlk1+/p and WT males (Figure 3.2D, F, J). 
 
Grb10m/+ females and males had less fat mass and more lean mass contents 
compared to WT (Figure 3.2C-H). The ratio of fat mass and body weight was 
significantly reduced in female Grb10m/+/Dlk1+/p mice compared to WT (Figure 
3.2C, I). No significance was found between Grb10m/+ and WT females and 
males in consideration of lean mass (Figure 3.2I, J).  
 
Dlk1+/p and Grb10m/+ mice displayed opposite phenotypes. Dlk1+/p mice tended 
to contain more fat mass, while Grb10m/+ mice tended to contain more lean 
mass (Figure 3.2C-H). In comparisons of Dlk1+/p and Grb10m/+ mice, fat mass 
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was significantly increased in Dlk1+/p mice, and lean mass was significantly 
higher in Grb10m/+ mice in both males and females (Figure 3.2I, J). 
 
Grb10m/+ and Grb10m/+/Dlk1+/p mice showed a similar body composition 
phenotype. Both tend to content more lean mass and less fat mass. Moreover, 
no significant differences were found between Grb10m/+ and Grb10m/+/Dlk1+/p 
mice in any comparisons. However, body composition measurements of 
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Figure 3.2 Analysis of body mass and fat/lean body composition in 6 
months old adult mice. A-B) Total body weights of female and male mice 
from all four genotypes. WT, green scatters; Dlk1+/p, orange scatters; Grb10m/+, 
light blue scatters; Grb10m/+/Dlk1+/p, dark blue scatters. C-D) Ratios of fat 
mass/body weight in females and males among the four genotypes. E-F) 
Ratios of lean mass/body weight in female and male mice among the four 
genotypes. G-H) Ratios of fat mass/lean mass in females and males from all 
four genotypes. WT, green bar; Dlk1+/p, orange bar; Grb10m/+, light blue bar; 
Grb10m/+/Dlk1+/p, dark blue bar.  I-J) Summary of statistical analysis about fat 
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and lean mass content in females and males among the four genotypes. All 
values represent means plus SEM and have been subject to One-way ANOVA 
with Tukey’s post hoc analysis. WT n=26 (Female n=13, Male n=13), Dlk1+/p 
n=45 (Female n=29, Male n=16), Grb10m/+ n=16 (Female n=10, Male n=6), 
Grb10m/+/Dlk1+/p n=15 (Female n=4, Male n=11). * P<0.05, ** P<0.01, *** 




3.2.3 Grb10 expression level was elevated in E14.5 Dlk1+/p pMEFs 
To investigate whether Grb10 expression levels were affected by paternal Dlk1 
deletion, total proteins were extracted from E14.5 WT and Dlk1+/p pMEFs. Cells 
were starved overnight, stimulated with 10% FBS and then harvested after 
different time intervals. Western blots were performed using an anti-Grb10 
antibody. In the first two hours of FBS stimulation, Grb10 expression increased 
in both WT and Dlk1+/p pMEFs. Expression dropped to a relatively low level 
from 4-6 h and then increased to peak levels at 16 h before falling again until 
the end of the time-course at 24 h (Figure 3.3). For each blot, the lysates 
harvested from Grb10m/+ pMEFs cultured in complete medium containing 10% 
FBS was used as the control. Grb10 proteins were detected in most samples 
as bands at approximately 60 and 75 kDa, as seen previously (Liu et al., 2014). 
No Grb10 expression was detected in Grb10m/+ pMEFs as expected (Figure 
3.3A), although a protein of around 190 kDa was detected specifically in 
Grb10m/+ lysates which could represent a fusion protein comprised of Grb10 
and β-geo because of the β-geo gene trap insertion in the maternal Grb10 
knockout allele (Garfield et al., 2011) (Figure 3.3A). Grb10 expression levels 
were consistently elevated in Dlk1+/p pMEFs compared with WT at all time 
points, however, no statistically significant differences were found comparing 









Figure 3.3 Grb10 expression levels at different serum stimulation time 
intervals. At all the time points before and after serum stimulation, Grb10 
expression was elevated in Dlk1+/p pMEFs compared to WT. But no statistically 
significant differences were observed. A) A typical Western blot (one of five 
repeats of this experiment). No serum stimulated pMEFs of WT and Dlk1+/p 
were used as the blank controls. Grb10m/+ pMEFs cultured in serum were used 
as the negative controls. GAPDH protein level was used as the loading control. 
B) Western blots from 5 repeats of the experiment were measured and 
quantified for this graph of Grb10 expression, normalised to the GAPDH 
housekeeping protein control. WT, green line; Dlk1+/p, orange line. All values 
represent means plus SEM and have been subject to Two-way ANOVA with 






3.2.4 E14.5 Dlk1+/p pMEFs had a faster Grb10 turnover compared to WT 
To determine the half-lives of Grb10 in WT and Dlk1+/p pMEFs, 10 ug/ml 
cycloheximide (CHX) was applied to block protein synthesis in growing pMEFs. 
Grb10 levels in WT and Dlk1+/p pMEFs were measured on Western blots using 
an anti-Grb10 antibody over a time-course of up to 32 h (Figure 3.4). After 32 h 
of CHX treatment, Grb10 expression was almost undetectable in WT and 
Dlk1+/p pMEFs (Figure 3.4A). Grb10 turnover was faster in Dlk1+/p pMEFs in 
response to CHX inhibition as the calculated Grb10 half-lives in WT and 
Dlk1+/p pMEFs were 2.757 h and 1.984 h, respectively (Figure 3.4B). 
Consistent with the Grb10 expression pattern under serum stimulation, Grb10 
expression levels were higher in Dlk1+/p pMEFs at all time points (Figure 3.4). 
However, no statistical significance was found between WT and Dlk1+/p pMEFs 









Figure 3.4 Analysis of Grb10 expression levels in WT and Dlk1+/p pMEFs 
with CHX treatment. Grb10 protein levels declined gradually after CHX 
addition to WT and Dlk1+/p pMEFs. Grb10 levels dropped more rapidly in 
Dlk1+/p pMEFs during the CHX treatment. A) Western blots representative of 
three independent experiments. WT and Dlk1+/p pMEFs with no CHX treatment 
were used as the negative controls. GAPDH protein level was used as the 
loading control. B) Grb10 expression was normalised to the loading control 
and expressed as a line graph. WT, green line; Dlk1+/p, orange line. All values 
represent means plus SEM and have been subject to Two-way ANOVA with 
Bonferroni post-tests. Half-lives of Grb10 were calculated by one phase decay 




3.2.5 Dlk1 expression was reduced in E14.5 Grb10m/+ pMEFs compared 
to WT 
To compare the Dlk1 expression levels in E14.5 WT and Grb10m/+ pMEFs, Dlk1 
sandwich ELISA was performed using pMEF medium. Dlk1 protein was 
undetectable by western blotting because the extracellular Dlk1 region (soluble 
Dlk1) was cleaved and released to the cell medium by TACE (Hudak and Sul, 
2013). Dlk1 expression level was higher in medium harvested after 48 h than 
24 h (Figure 3.5). Interestingly, lower Dlk1 expression level was detected in 
Grb10m/+ pMEFs compared to WT at both 24 h and 48 h, suggesting Grb10 
promoted Dlk1 expression in pMEFs (Figure 3.5). However, no statistical 
significance was found in Dlk1 levels between WT and Grb10m/+. Low level of 
Dlk1 expression was detected in Dlk1+/p and control (no cell) medium due to 
the background. As described in section 3.3, Grb10 expression was higher in 
E14.5 Dlk1+/p pMEFs compared to WT (Figure 3.3). Collectively, Dlk1 and 







Figure 3.5 ELISA of soluble Dlk1 expression level in medium harvested 
from WT and Grb10m/+ pMEFs. Dlk1 levels were measured and presented as 
a bar graph. Medium collected from plates with no cells were used as the blank 
controls (Control). Dlk1+/p pMEFs were used as the negative controls. WT, 
green bar; Grb10m/+, blue bar; Dlk1+/p, orange bar; Control, brown bar. All 
values represent means plus SEM of three experiments and have been 




3.2.6 Expression of Dlk1 or Grb10 in E14.5 liver was significantly altered 
in Grb10m/+ and Dlk1+/p samples, respectively 
To investigate the expression patterns of Dlk1 and Grb10 in embryonic livers, 
total proteins of E14.5 livers from WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
were extracted. Dlk1 and Grb10 western blotting showed that Dlk1 or Grb10 
deletions altered the expressions of each other in E14.5 livers. Specifically, 
Grb10 expression was significantly decreased in Dlk1+/p livers (Figure 3.6A, C), 
while Dlk1 expression was significantly increased in Grb10m/+ livers (noting that 
Dlk1 was undetectable in E14.5 pMEFs) (Figure 3.6B, D). As shown previously, 
a 190 kDa band, potentially representing a Grb10: β-geo fusion protein was 
detected specifically in Grb10m/+ and Grb10m/+/Dlk1+/p E14.5 livers (Figure 
3.6A). No Dlk1 expression was found in Grb10m/+ and Grb10m/+/Dlk1+/p E14.5 
livers (Figure 3.6B). An opposite expression pattern was found in E14.5 












Figure 3.6 Dlk1 and Grb10 expression patterns in E14.5 WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p livers. Western blots representative of three 
independent experiments for: A) Grb10 (Grb10m/+ and Grb10m/+/Dlk1+/p liver 
lysates were used as the negative controls) and B) Dlk1 (Dlk1+/p and 
Grb10m/+/Dlk1+/p liver lysates were used as the negative controls). GAPDH 
levels were used as the loading controls. Grb10 or Dlk1 expression level was 
normalised to the loading control and expressed as a bar graph for: C) Grb10 
and D) Dlk1. WT, green bar; Grb10m/+, blue bar; Dlk1+/p, orange bar. All values 
represent means plus SEM and have been subject to unpaired T-test with 
two-tailed analysis. WT n=9, Dlk1+/p n=8, Grb10m/+ n=3, Grb10m/+/Dlk1+/p n=3. * 






3.2.7 Similar downstream PI3K-Akt and ERK-MAPK activities were 
found in WT and Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
under serum stimulation 
To evaluate the downstream signal responses to serum stimulation in WT and 
knockout pMEFs, Akt and Erk1/2 phosphorylation status was checked. Cells 
were cultured in DMEM medium without serum for overnight starvation. The 
next day, cells were stimulated by adding 10% FBS then harvested after 
different time intervals from 5 min to 2 h. No phosphorylated Akt and only a low 
level of Erk1/2 phosphorylation were detected in the absence of serum in 
pMEFs of all four genotypes (Figure 3.7A). In WT and Dlk1+/p pMEFs, Akt and 
Erk1/2 exhibited rapid responses to the serum stimulation with phosphorylation 
levels reaching to a maximum at 5 min. Subsequently, levels of 
phosphorylated Erk1/2 started to drop and were lowest at 2 h, whereas higher 
Akt phosphorylation levels were sustained up to 2 h after serum stimulation 
(Figure 3.7). Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs showed similar Akt and 
Erk1/2 phosphorylation patterns with WT and Dlk1+/p, except phosphorylated 
Akt levels were slightly higher and phosphorylated Erk1/2 levels were slightly 
lower. Notably, changes in Akt and Erk1/2 phosphorylation levels under serum 
stimulation were essentially indistinguishable between WT and Dlk1+/p pMEFs 







Figure 3.7 Levels of phosphorylated Akt and Erk1/2 following serum 
stimulation of WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs. Prolonged 
Akt phosphorylation was seen in pMEFs of all four genotype, as was rapid 
Erk1/2 phosphorylation, followed by a gradual decline. A) Western blots 
representative of three independent experiments. E14.5 pMEFs of the four 
genotypes (with no serum stimulation) were used as the negative controls. 
Total Akt and Erk1/2 levels were used as the loading controls for 
phosphorylated Akt and Erk1/2 levels, respectively. p-Akt and pp-Erk1/2 levels 
were normalised to the loading control and visualised in separated line charts 
for: B) p-Akt and C) pp-Erk1/2. WT, green line; Dlk1+/p, orange line; Grb10m/+, 
light blue line; Grb10m/+/Dlk1+/p, dark blue line. All values in graphs B and C 





3.2.8 Akt and Erk1/2 activities in E14.5 WT, Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p livers 
Phosphorylated Akt and Erk1/2 levels were checked in E14.5 livers from mice 
of all four genotypes. In E14.5 WT, Dlk1+/p, Grb10m/+, and Grb10m/+/Dlk1+/p 
livers, strong Akt phosphorylation levels were observed (Figure 3.8A). In 
contrast, p-Erk1/2 levels were relatively low, showing weak bands on Western 
blots (Figure 3.8A). Higher Akt phosphorylation level was observed in Dlk1+/p 
and Grb10m/+/Dlk1+/p livers compared to both WT and Grb10m/+, while p-Akt 
levels were similar between WT and Grb10m/+ livers (Figure 3.8A, B). No 
statistically significant differences were found in Akt phosphorylation levels 
among the four genotypes (Figure 3.8B). Phosphorylation of Erk1/2 was 
upregulated in all three knockout livers compared to WT. Grb10m/+ livers had a 
lower Erk1/2 phosphorylation level than Dlk1+/p and Grb10m/+/Dlk1+/p (Figure 
3.8A, C). Notably, Erk1/2 phosphorylation level was significantly increased in 
Dlk1+/p livers compared to WT with no other significant difference in level of 
phosphorylated Erk1/2 found among WT, Dlk1+/p, Grb10m/+, and 






Figure 3.8 Patterns of phosphorylated Akt and Erk1/2 expression in E14.5 
WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p livers. A) Western blots 
representative of three independent experiments. GAPDH protein levels were 
used as the loading controls. Akt and Erk1/2 phosphorylation levels were 
normalised to the loading control and visualised in separated bar graphs for: B) 
p-Akt and C) p-Erk1/2. WT, dot filled bar; Dlk1+/p, square filled bar; Grb10m/+, 
transverse line filled bar; Grb10m/+/Dlk1+/p, string filled bar. All values represent 
means plus SEM and have been subject to One-way ANOVA with Tukey’s post 





3.2.9 Grb10 expression was reduced following mTORC1 inhibition in 
E14.5 WT and Dlk1+/p pMEFs 
Grb10 was reported to be directly phosphorylated and stabilized by mTORC1 
in pMEFs (Hsu et al., 2011). To discover the impacts of mTORC1 in the 
biochemical link between Dlk1 and Grb10, pMEFs of all four genotypes were 
exposed to the mTORC1 inhibitors, rapamycin and Torin1 for 24 h. Grb10 
expression levels were assessed, along with levels of phosphorylated S6K, by 
Western blotting (Figure 3.9A). No S6K phosphorylation was found in 
rapamycin or Torin1 treated pMEFs, indicating that mTORC1 downstream 
signals were blocked by the inhibitors after 24 h. Grb10 expression was 
reduced by either rapamycin or Torin1 treatment in WT and Dlk1+/p pMEFs 
(Figure 3.9). Furthermore, Grb10 expression levels were lower in pMEFs 
treated with Torin 1 than rapamycin, suggesting Torin1 was a more specific 
and stronger mTORC1 inhibitor (Figure 3.9). In Dlk1+/p pMEFs, Grb10 
expression level was higher than WT without mTORC1 inhibition, as in 
previous experiments. Yet Grb10 protein expression levels were similar in 
rapamycin or Torin1 treated WT and Dlk1+/p pMEFs without statistical 






Figure 3.9 Changes of Grb10 expression in WT and Dlk1+/p pMEFs under 
mTORC1 inhibition. A) Western blots representative of three independent 
experiments. S6K phosphorylation levels were used as the positive controls. 
Cells from WT and Dlk1+/p (no inhibitor treatment) were used as the negative 
controls. GAPDH protein levels were used as the loading controls. B) Grb10 
expression levels were normalised to the loading control. Quantification of 
Grb10 bands was visualised as a bar chart. WT, green bars; Dlk1+/p, orange 
bars. All values represent means SEM and have been subject to Owo-way 
ANOVA with Tukey’s post hoc analysis. WT n=3, Dlk1+/p n=3, Grb10m/+ n=3, 





Paternally-expressed Dlk1 promotes fetal growth while maternally-expressed 
Grb10 inhibits fetal growth (Moon et al., 2002; Charalambous et al., 2003; 
Madon-Simon et al., 2014). The respective growth regulatory roles are 
consistent with the predominant theory for the evolution of imprinted gene 
expression, the parent-offspring conflict hypothesis over fetal growth (Haig, 
2014). The global loss of Dlk1 or Grb10 gene also affects body size, including 
proportions of adipose and lean tissues of adult mice, Dlk1 knockout mice are 
fatter, while Grb10 knockouts are leaner (Moon et al., 2002; Smith et al., 2007; 
Madon-Simon et al., 2014). The opposite effects of Dlk1 and Grb10 on adult 
adipose: lean proportions may result from events started during prenatal 
development. Previous genetic studies of crosses between Dlk1 and Grb10 
knockout mice indicate that Grb10m/+/Dlk1+/p offspring have a phenotype that is 
very similar to that of Grb10m/+ (Madon-Simon et al., 2014). This suggests that 
Dlk1 and Grb10 may act antagonistically through a common pathway to 
regulate the fetal growth. Additionally, Dlk1 acts upstream, as an inhibitor of 
Grb10, which in turn was an inhibitor of embryo growth (Madon-Simon et al., 
2014). Yet, the biochemical interactions between Dlk1 and Grb10 leading to 
the antagonistic phenotypes in the Dlk1+/p and Grb10m/+ pups are still 
unknown. 
 
Here, I found that Grb10m/+ and Grb10m/+/Dlk1+/p embryos at E14.5 were 
significantly larger and heavier than WT and Dlk1+/p embryos, whereas the 
differences between WT and Dlk1+/p embryo weights were indistinguishable 
(Figure 3.1). Madon-Simon and colleagues (2014) reported that Grb10m/+ and 
Grb10m/+/Dlk1+/p pups were significantly larger while Dlk1+/p pups were 
significantly smaller than WT at birth (Madon-Simon et al., 2014). Yet no 
significant difference was found between WT and Dlk1+/p E14.5 embryos 






later gestation stage after E14.5 and before birth. In addition, the wet weights 
of Grb10m/+/Dlk1+/p embryos were slightly lighter than Grb10m/+ (Figure 3.1), 
however, Grb10m/+ and Grb10m/+/Dlk1+/p embryos were not statistically different. 
The failure to detect a statistical difference between these two groups may due 
to the small sample size (Grb10m/+ n=25, Grb10m/+/Dlk1+/p n=21) used in this 
study. A power calculation had been performed on the data of these two 
groups which suggested the required sample size to detect a statistical 
difference should be n=102 (Grb10m/+ n=51, Grb10m/+/Dlk1+/p n=51). More 
samples are need for a compelling conclusion. 
 
At 6 months old, no significant differences in body weights were found in 
females and males among the genotypes studied: WT, Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p (Figure 3.2). Although Grb10 knockout mice were heavier and 
Dlk1 knockout were lighter than WT after birth until weaning at 3 weeks, the 
differences in body weight became smaller after weaning (Moon et al., 2002; 
Wang et al., 2007; Smith et al., 2007; Madon-Simon et al., 2014). The similar 
body weight among mice of all four genotypes at 6-month-old found in this 
study was consistent with previous studies (Figure 3.2). But WT and knockout 
adult mice tended to have different body composition. Adult Dlk1+/p females 
and males tended to have a larger proportion of fat mass and smaller lean 
mass compared to WT and Grb10m/+ mice (Figure 3.2), again as shown 
previously (Moon et al., 2002; Madon-Simon et al., 2014). Dlk1+/p adults 
tended to development more fat mass might result because Dlk1 acts as an 
inhibitor of adipogenesis and an enhancer of myogenic development (Moon et 
al., 2002; Andersen et al., 2013). Notably, the obese phenotype was more 
obvious in Dlk1+/p females than males which might be due to the larger number 
of Dlk1+/p females used in this study or because Dlk1 may have a stronger 
effect on fat development in females. Previous mouse studies have also 
shown that Grb10 knockout mice tend to develop a leaner phenotype (more 
lean mass and less fat mass) in adults using two different mouse lines (Wang 
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et al., 2007; Smith et al., 2007; Madon-Simon et al., 2014), providing genetic 
evidence that Grb10 promoted muscle development (Holt et al., 2012; Mokbel 
et al., 2014). Meanwhile, Grb10m/+ and Grb10m/+/Dlk1+/p adults were 
indistinguishable from each other in body composition (Madon-Simon et al., 
2014). Here, Grb10m/+ females at 6-month-old had a statistically significant 
lower fat mass/body weight ratio compared to WT (Figure 3.2C, I). No other 
statistical significance was found between WT and Grb10m/+ mice. 
Grb10m/+/Dlk1+/p mice were not significantly different from WT when compared 
the fat or lean mass contents (Figure 3.2I, J). But Grb10m/+ and 
Grb10m/+/Dlk1+/p females and males consistently tended to develop more lean 
mass and less fat mass (Figure 3.2C-H). This may be due to the small number 
of Grb10m/+/Dlk1+/p mice used for this study.  
 
The oppositely imprinted genes Igf2r and Igf2 acted antagonistically through 
the same signalling pathway, and the interaction of IGF2R and IGF2 affected 
the expressions and functions of each other as IGF2R inhibits growth by 
targeting IGF2 for lysosomal degradation (Barlow et al., 1991; DeChiara et al., 
1991; Nordin et al., 2014). Also, it has been reported that paternally expressed 
Igf2 can influence expression of maternally expressed CDKN1C (Grandjean et 
al., 2000). Here, E14.5 pMEFs and livers from WT, Dlk1+/p and Grb10m/+ mice 
were used as respective in vitro and in vivo models to investigate whether Dlk1 
deletion could alter the expression of Grb10, or whether Grb10 deletion could 
alter the expression of Dlk1. Specifically, Grb10 protein expression levels in 
E14.5 Dlk1+/p pMEFs were found to be higher than WT cells under serum 
stimulation at all time intervals (Figure 3.3). In addition, when WT and Dlk1+/p 
pMEFs were cultured with CHX to block Grb10 synthesis, the Grb10 half-lives 
of WT and Dlk1+/p pMEFs were 2.757 h and 1.984 h, respectively, indicating a 
more rapid turnover of Grb10 in Dlk1+/p pMEFs than WT (Figure 3.4). Although 
no statistical significance was found between WT and Dlk1+/p pMEFs treated 
with serum or CHX at any time points, Grb10 expression was consistently 
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elevated in Dlk1+/p cells. Dlk1 expression could not be detected in pMEFs by 
Western blotting and instead was detected by ELISA, taking advantage of the 
fact that a proportion of Dlk1 was cleaved and released from the cell surface. 
The soluble form of Dlk1 has been associated with various biological 
processes (Wang and Sul, 2006; Andersen et al., 2013). ELISA may be more 
sensitive than Western blotting and in our experiment which measured soluble 
Dlk1 accumulated in the cell culture medium over 24 h and 48 h. Dlk1 
expression was found to be lower in Grb10m/+ compared to WT pMEFs (Figure 
3.5). Collectively, Grb10 expression level was higher in Dlk1+/p pMEFs while 
soluble Dlk1 protein level was lower in Grb10m/+ pMEFs, suggesting that Dlk1 
and Grb10 affected the expression of each other in E14.5 pMEFs. The higher 
Grb10 expression in Dlk1+/p pMEFs was consistent with the genetic evidence 
that Dlk1 acts as an upstream inhibitor of Grb10 (Madon-Simon et al., 2014). 
 
In E14.5 livers Dlk1 or Grb10 deletion again lead to each altering expression of 
the other signalling protein. However, in contrast to the observations in E14.5 
pMEFs, Grb10 expression level was significantly reduced in Dlk1+/p livers, 
whereas Dlk1 was significantly increased in Grb10m/+ livers (Figure 3.6). This is 
not obviously consistent with the genetic data. One possible reason is that 
different Dlk1 and Grb10 signalling pathways may be involved in pMEF and 
liver development, leading to the completely different effects of Dlk1 and 
Grb10 knockout in E14.5 pMEFs versus livers. Also, different tissues and cells 
might have immediate or delayed response to the global knockout of Dlk1 or 
Grb10. E14.5 livers may respond to the global Dlk1 or Grb10 knockout at later 
stage. In general, Dlk1 and Grb10 displayed opposite expression effects to the 
other in E14.5 pMEF and liver. The dependent Dlk1 and Grb10 expression 
supported the hypothesis that these two genes were involved in the same 
pathway in control of the embryo growth, although the mechanism may be 




Two groups reported that Grb10 could be directly phosphorylated at S501/503 
by mTORC1, and the phosphorylation enhanced the stability of Grb10 which in 
turn inhibited mTORC1 and IR/IGFR signalling in pMEFs (Hsu et al., 2011; Yu 
et al., 2011; Yea and Fruman, 2011). Therefore, Dlk1 knockout may affect the 
mTORC1 regulated Grb10 phosphorylation in pMEFs. I attempted to address 
this using an anti-phospho-Grb10 antibody at S501/503 (Hsu et al., 2011; Yu et 
al., 2011), but this failed to detect specific phospho-Grb10 bands in E14.5 
pMEF samples on Western blots (data not shown). Meanwhile, mTORC1 
inhibition through rapamycin or Torin1 treatment of pMEFs reduced Grb10 
expression in WT and Dlk1+/p pMEFs, indicating that Grb10 accumulation was 
affected by mTORC1 inhibition (Figure 3.9). However, Grb10 phosphorylation 
status in WT and Dlk1+/p pMEFs is currently still unclear. 
 
Grb10 was reported to regulate IR, IGFR and other RTKs (Wick et al., 2003; 
Vecchione et al., 2003; Murdaca et al., 2004; Monami et al., 2008). Therefore I 
investigated whether the signalling downstream of these receptors were 
affected by the knockout of Dlk1 and Grb10. Levels of phosphorylated Akt 
were found to be increased and phosphorylated Erk1/2 decreased in Grb10m/+ 
and Grb10m/+/Dlk1+/p E14.5 pMEFs, compared to Dlk1+/p and WT, when cells 
were starved and then stimulated with serum. Additionally, sustained Akt 
phosphorylation and rapid Erk1/2 phosphorylation responses were observed 
during the 2 h of serum stimulation (Figure 3.7). This was supported by the 
strong Akt and weak Erk1/2 phosphorylation signals detected in E14.5 livers 
among the four genotypes (Figure 3.8). Notably, the Akt and Erk1/2 activities in 
serum stimulated pMEFs were similar between Grb10m/+ and Grb10m/+/Dlk1+/p 
and also between Dlk1+/p and WT. These similarities at the biochemical level 
were consistent with the genetic findings that mice from these two groups had 





In addition, a higher Akt and Erk1/2 phosphorylation level was observed in 
E14.5 Dlk1+/p and Grb10m/+/Dlk1+/p livers compared to WT, however, the 
differences between Grb10m/+ and WT were not significant (Figure 3.8). This 
implied that Dlk1 may be more active during embryonic liver development than 
Grb10. Notably, Akt and Erk1/2 phosphorylation status was not similar 
between Grb10m/+ and Grb10m/+/Dlk1+/p and also between Dlk1+/p and WT 
which was different from the findings in E14.5 pMEFs. Dlk1 and Grb10 
knockout led to different downstream signal phosphorylation responses among 
the four genotypes in E14.5 pMEFs versus livers. This suggests that different 
cell signalling pathways may be involved in pMEF and liver. To further uncover 
the signal pathways involved in Dlk1 and Grb10 on embryo growth, unbiased 
quantitative proteomics approaches will be performed on E14.5 WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs and livers. The findings will be 
discussed in next chapter. 
 
In summary, 1) E14.5 embryo size was not affected by Dlk1 deletion while 
Grb10m/+ and Grb10m/+/Dlk1+/p embryos were significantly enlarged at E14.5. 
At 6 months old, Dlk1+/p adults were fatter while Grb10m/+ and Grb10m/+/Dlk1+/p 
adults were leaner. 
2) At the biochemical level, Dlk1 and Grb10 expression levels were oppositely 
affected by each other in E14.5 pMEFs and livers. Dlk1 acted as the upstream 
inhibitor of Grb10 in pMEFs as the Grb10 expression level was upregulated in 
Dlk1+/p pMEFs. However, the pattern of Dlk1 and Grb10 interactions in E14.5 
livers was different from pMEFs. 
3) RTK downstream Akt activity was slightly elevated and Erk1/2 reduced in 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs stimulated by serum. Meanwhile, WT 
and Dlk1+/p pMEFs displayed similar Akt and Erk1/2 activities. 
4) Downstream Akt and Erk1/2 signalling changes in knockout pMEFs 
supported the antagonistic functions of Dlk1 and Grb10 based on genetic 
evidence (Madon-Simon et al., 2014). 
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5) mTORC1 inhibition reduced Grb10 expression level in both WT and Dlk1+/p 
pMEFs which was in consistent with the evidence that Grb10 was stabilised by 









TMT quantitative proteomics of 
E14.5 Dlk1 and Grb10 knockout 





In this study, unbiased TMT quantitative proteomics analysis was adopted to 
identify potential signal partners and pathways involved in Dlk1 and Grb10 
biochemical interactions. High throughput quantitative proteomics analysis can 
provide in-depth information for further Dlk1 and Grb10 function and potential 
mouse growth-regulatory pathway investigations, while only a few of genes or 
proteins can be studied using the normal targeted experiments. Unbiased 
method can provide more specific and even unknown targets for further Dlk1 
and Grb10 experiments which may increase the targeted experiment efficiency. 
This work focused on proteomics and not transcriptomics study for the reason 
that cellular protein modifications, especially protein phosphorylation, 
manipulate the cell signal interactions during mouse growth regulation 
(Sharma et al., 2014). Transcriptomics analysis cannot provide the protein 
expression or phosphorylation information at the proteomics level. Proteomics 
analysis can better uncover the Dlk1 and Grb10 involved growth-regulatory 
pathways compare to transcriptomics. The new TMT reagents and 
improvements in quantitative proteomics currently allow the labelling of up to 
ten samples in a single analysis. This allowed comparison of two biological 
replicates each of E14.5 pMEF and liver samples of the four genotypes, WT, 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p. The proteomes and 
phosphoproteomes from WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p E14.5 
pMEFs and livers were analysed and compared. Inevitably, the proteomics 
analysis used in this work has limitations. A small sample size (n=2) was 
adopted because one more TMT analysis will be required if we added more 
samples for each genotype. Another independent TMT analysis will increase 
the experimental errors and will be beyond our lab budget. 
 
TMT is an isobaric chemical tag, containing a reporter, a balance and a 
reactive group (Figure 4.1). The reactive region can bind to the N-terminal end 
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of a peptide, labelling the peptide with a TMT tag (Thompson et al., 2003). 
Proteins are digested by trypsin prior to MS analyses, and each protein has a 
unique combination of peptides, or “fingerprint” (Thompson et al., 2003). 
 
Figure 4.1 Basic structure of TMT tag. TMT tag contained a mass reporter, 
mass normalizer and NH2 reactive group. Peptide will be labelled with the tag 
through reacting to the NH2 reactive group. 
 
TMT 10plex reagent was chose for this study which can label a maximum of 
ten samples for a single proteomics analysis. Each TMT tag has the same 
chemical structure (Figure 4.2A), while TMT reporter regions have varied 
molecular weights, through incorporation of heavy carbon or nitrogen isotopes, 
and the balance region normalizes the total molecular weight of each TMT tag 
to be identical (Figure 4.2B) (Thompson et al., 2003). After the first MS 
analysis, peptides from all different samples will generate a single MS peak in 
the spectrum as the TMT labelled peptides have an identical structure and 
molecular mass. TMT reporter ions are then released at higher energy collision 
dissociation (HCD) fragmentation sites prior to second MS analysis (Figure 
4.2A). The intensities of peptide fragment ions based on mass to charge (m/z) 
ratios of the ions are then measured by MS/MS (McAlister et al., 2012). The 
quantification of protein abundance is measured from the peptide intensities, 





Figure 4.2 Chemical structure of TMT 10plex reagent. A) Each TMT tag has 
an identical chemical structure with three regions-a mass reporter, a mass 
normalizer and a NH2 reactive group. HCD site-higher energy collision 
dissociation site. ETD site-electron transfer dissociation site. B) TMT 10plex 
reagent contains ten TMT tags with different molecular weight because of the 
incorporated 13C and 15N heavy isotopes. Red asterisks indicate the 
locations of 13C or 15N heavy isotopes in each structure. The figure was 





To compare the proteome and phosphoproteome among E14.5 WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p embryos, fresh E14.5 pMEF cell lines and pure 
livers were derived from individual embryos. E14.5 pMEF and liver replicates 
of WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p from different litters were 
selected to undertake two independent TMT analyses, one for pMEFs and one 
for livers (Figure 4.3A). Total proteins were extracted and digested to peptides 
from each pMEF and liver sample. Peptides of each sample were labelled with 
8 different TMT isobaric tags from the TMT 10plex reagents prior to 
chromatography and mass spectrometry (MS) analyses (Figure 4.3A). MS 
spectra generated from the spectrometer were analysed by MaxQuant 
software to search against the Uniprot Mouse database downloaded on 
170415 (73324 entries). The MS intensities from each sample acquired using 
MaxQuant were filtered for FDR below 1%. The MS intensity of each protein or 
phosphorylated site was considered as the protein expression or 
phosphorylation level, respectively (Figure 4.3B). Ratios of Dlk1+/p, Grb10m/+ 
and Grb10m/+/Dlk1+/p values from each biological replicate versus WT were 
calculated and log2 transformed. The mean values of the log2 transformed 
ratios, representing the protein expression or phosphorylation fold changes of 









Figure 4.3 Workflow of TMT proteomics analysis. A) Samples from WT, 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p are labelled with green, orange, light 
blue and dark blue rectangles, respectively. E14.5 pMEF and liver TMT 
analyses were performed separately. B) Bioinformatics analysis strategy 
following MS analysis. Protein MS intensity from each TMT tag was extracted 
using MaxQuant v1.5.3.8 software. MS intensity ratio of knockout versus WT 
was calculated and then log2 transformed. Mean ratio of the two biological 
replicates was used for following bioinformatics analyses. Blue arrow indicated 






4.3.1 TMT quantitative proteomics data output 
For E14.5 pMEF and liver total proteome, a list of 6174 proteins were identified, 
including 5499 proteins without missing values from any of the 8 samples in 
each dataset (Figure 4.4A). In parallel, 3208 phosphorylated sites were 
identified in the pMEF phosphoproteome of which 2061 were class I sites 
(localisation probability>0.75), and in the liver phosphoproteome, there were 
4113 phosphorylated sites identified, with 2739 class I sites. However, a 
shorter list of 832 and 1269 “core” phosphorylation sites without missing 
values from all the samples were detected in pMEF and liver 
phosphoproteomes, respectively (Figure 4.4A). Within the 832 “core” pMEF 
phosphoproteins, 1457, 271 and 29 phosphorylated serine, threonine and 
tyrosine sites were identified, respectively (Figure 4.4B). Similarly, in the 1269 
“core” liver phosphoproteins there were 2690, 383 and 53 phosphorylated 
serine, threonine and tyrosine sites, respectively (Figure 4.4B).  
 
 
Figure 4.4 Data output of TMT proteomics. A) Number of the identified 
proteins (Response) and proteins without missing value from any TMT tag 
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(Value) in pMEF and liver total proteomes and phosphoproteomes. B) Number 
of identified phosphorylated sites without missing value from any TMT tag in 
pMEF and liver phosphoproteomes. pS: phospho-Serine; pT: 
phospho-Threonine; pY: phosho-Tyrosine; pSTY: phospho-Serine, 




4.3.2 PCA and HCL analyses for proteomics and phosphoproteomics 
profiles from the four genotypes of E14.5 pMEFs and livers 
Dlk1+/p and Grb10m/+ embryos and adults exhibited opposite growth and 
metabolic health phenotypes (Figure 3.1; 3.2) (Madon-Simon et al., 2014). 
Further, in crosses to generate mice of all four genotypes, Grb10m/+ and 
Grb10m/+/Dlk1+/p embryos were similar to each other and distinct from WT and 
Dlk1+/p embryos. To evaluate the similarity and divergence of Dlk1+/p, Grb10m/+ 
and Grb10m/+/Dlk1+/p E14.5 embryos at a proteomics level, PCA analyses were 
carried out on pMEF and liver proteome and phosphoproteome data sets using 
JMP10 software (Ringnér, 2008), and HCL analyses based on Pearson 
correlation coefficient (r) were performed using GraphPad Prism 6 and MeV 
v4.9.0 software. PCA and HCL analyses were performed on the original MS 
intensities of replicates from all four genotypes and the mean log2
 transformed 
ratios of knockout samples versus WT. PCA analyses of individual samples 
revealed that E14.5 pMEF proteomes and phosphoproteomes possessed 92.2% 
and 75.6% of data variability in component 1, respectively (Figure 4.5A, B). 
Meanwhile, 92.2% and 98.3% of data variability was retained in component 1 
of the liver proteomes and phosphoproteomes, respectively (Figure 4.5C, D). 
However, PCA and HCL analyses of individual samples displayed low 
biological reproducibility as the replicates of each genotype did not share 
similarities in both their proteomes and phosphoproteomes (Figure 4.5A-H). 
 
For the second set of PCA analyses, protein expression or phosphorylation 
changes in the knockout samples versus WT were considered as the 
variances. The protein expression or phosphorylation variations from each 
data set were reduced to a few principle components, and the first two 
components (component 1 and component 2) retained the largest variations 
among all the components. The data variations were expressed as a scatter 
plot projected to component 1 and component 2. The red arrows indicated the 
main direction of the data group projected to these two components (Figure 
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4.5I-L). In E14.5 pMEF and liver proteomes, component 1 possessed 80.7% 
and 61.3% of data variability, respectively. Notably, PCA revealed that 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs and livers were closer at the total 
proteome level, while Dlk1+/p was divergent from Grb10m/+ and Grb10m/+/Dlk1+/p 
(Figure 4.5I, K). In parallel, 78% and 64.7% of data variability was retained in 
component 1 of the pMEF and liver phosphoproteomes, respectively.  
 
HCL analyses showed that Grb10m/+ and Grb10m/+/Dlk1+/p samples, both 
pMEFs and livers, were consistently grouped in the same cluster, using protein 
expression or phosphorylation changes in the knockout samples versus WT 
(Figure 4.5E-H). For pMEF and liver proteomes and phosphoproteomes, 
Pearson correlation coefficient (r) between Grb10m/+ and Grb10m/+/Dlk1+/p 
samples were around 0.75, while Pearson correlation coefficient (r) between 














Figure 4.5 PCA and HCL analyses of E14.5 pMEF and liver proteomes 
and phosphoproteomes. Protein expression or phosphorylation levels from 
all eight samples were projected to the first two components, and the variance 
projections on component 1 and component 2 were expressed as a 
two-dimensional scatter plot. A) pMEF proteome. B) pMEF phosphoproteome. 
C) Liver proteome. D) Liver phosphoproteome. HCL results of all eight 
samples were visualized as Heatmaps using Pearson correlation coefficient (r). 
Each square represented Pearson correlation coefficient (r) between any two 
samples. Green and red scale above the Heatmap indicated the Pearson 
correlation coefficient (r) values. E) pMEF proteome. F) pMEF 
phosphoproteome. G) Liver proteome. H) Liver phosphoproteome. Protein 
expression or phosphorylation ratios of knockout versus WT were projected to 
the first two components, and the variances were expressed as a 
two-dimensional scatter plot. Red arrow in each data set indicated the main 
direction of each knockout sample projected on component 1 and component 
2. I) pMEF proteome. J) pMEF phosphoproteome. K) Liver proteome. L) Liver 
phosphoproteome. HCL analyses based on Pearson correlation coefficient (r) 
were visualized as Heatmaps among Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
samples using WT as the denominator. Each square represented Pearson 
correlation coefficient (r) between any two knockout samples. Green and red 
scale above the Heatmap indicated the Pearson correlation coefficient (r) 
values. M) pMEF proteome. N) pMEF phosphoproteome. O) Liver proteome. P) 
Liver phosphoproteome.   
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4.3.3 Distinct patterns of reduced expression were found in E14.5 pMEF 
and liver proteomes and phosphoproteomes 
To look at the overall distribution of protein expression or phosphorylation 
detected by TMT proteomics analyses in vitro and in vivo, four scatter plots 
were presented for each individual pMEF and liver data set, using mean value 
of log2 Grb10
m/+/Dlk1+/p/WT as the X-axis value and mean log2 Dlk1
+/p/WT or 
log2 Grb10
m/+/WT as the Y-axis values (Figure 4.6). A stringent 4-fold change 
was set as the threshold (faint dotted lines) for pMEF and liver proteomes 
because of the large data size, while a 1.5-fold change was set for pMEF and 
liver phosphoproteomes (Figure 4.6). As can be seen in the E14.5 pMEF 
proteome and phosphoproteome plots, a large amount of proteins displayed 
4-fold down regulation in Grb10m/+/Dlk1+/p compared to WT pMEFs. Most of 
those proteins had a reduction trend in Dlk1+/p and Grb10m/+ pMEFs as well 
(Figure 4.6A, B). The liver proteome also showed a pattern of reduction in 
protein expression, similar to the pMEF proteome (Figure 4.6C), but it was less 
marked and there was a greater difference between expression profiles in 
response to single and double knockout of Dlk1 and Grb10 in E14.5 livers. In 
particular, a group of proteins were 4-fold down in Dlk1+/p compared to WT 
livers, and a relatively smaller amount of proteins were 4-fold downregulated in 
Grb10m/+ and Grb10m/+/Dlk1+/p livers (Figure 4.6C). In the E14.5 liver 
phosphoproteome plot, most of the scatter was located inside the 1.5-fold 
change threshold. A few phosphorylated proteins were more than 1.5-fold 
down in Grb10m/+/Dlk1+/p livers (Figure 4.6D). Notably, E14.5 Grb10m/+ and 


















Figure 4.6 Scatter plots of E14.5 pMEF and liver proteomes and 
phosphoproteomes. Each dot represented a logarithmically transformed 
protein or phosphorylated protein expression value, expressed as a ratio of 
knockout versus WT. Yellow dots were the proteins plotted for the expression 
or phosphorylation levels of Dlk1+/p/WT against Grb10m/+/Dlk1+/p/WT. Blue dots 
were the proteins plotted for the expression or phosphorylation levels of 
Grb10m/+/WT against Grb10m/+/Dlk1+/p/WT. Bold dotted lines were the X and Y 
axes. Faint dotted lines indicated 4-fold and 1.5-fold change thresholds for 
total proteomes and phosphoproteomes, respectively. A) pMEF proteome. B) 




4.3.4 Transmembrane receptor signalling related GO-terms were 
enriched in Dlk1+/p, Grb10m/+, and Grb10m/+/Dlk1+/p pMEF and liver 
proteome 
To evaluate the biological functions of proteins and phosphorylated proteins 
with changes in levels outside of the respective 4- and 1.5-fold thresholds 
(Figure 4.6), GO-term enrichment analysis was carried out using these 
proteins as the target list and the complete data set as the background using 
online GO-term analysis tool “Gorilla” (http://cbl-gorilla.cs.technion.ac.il/). The 
enriched GO-terms from pMEF and liver proteomes and phosphoproteomes 
were combined and visualized as a Heatmap, in which green boxes indicated 
the significantly enriched terms (Figure 4.7). The detailed results of GO-term 
enrichment analysis were listed in tables in Appendix (Table 7.2). Notably, a 
number of GO-terms relating to membrane associated proteins were enriched 
in both pMEF and liver proteomes, indicating that a subset of proteins with 
differential expression in knockout pMEF and liver were involved in 
transmembrane receptor signaling at a total proteomics level. Relevant 
enriched GO-terms included: “membrane part”, “extracellular region”, “integral 
component of membrane”, “transmembrane receptor activity”, 
“transmembrane signaling receptor activity” and “transmembrane receptor 
protein kinase activity”. Additionally, the GO-terms “cytoplasmic part”, “vesicle”, 
“lysosome” and “lipid metabolic process” were enriched, but only in the pMEF 
proteome. The GO-terms “intrinsic/integral component of plasma membrane”, 
“elastic fiber”, “phagocytic vesicle”, “receptor activity”, “signaling receptor 
activity”, “signal transducer activity”, “molecular transducer activity”, “calcium 
ion binding” and “negative regulation of cell proliferation” were specifically 
enriched in the liver proteome. The GO-terms “hydrolase activity” and “ATPase 
activity” were enriched only in the pMEF phosphoproteome, while “negative 
regulation of immune system process”, “regulation of myeloid cell 
differentiation” and “negative regulation of hemopoiesis” GO-terms were 





Figure 4.7 Heatmap summary of GO-term enrichment analyses of E14.5 
pMEF and liver proteomes and phosphoproteomes. Four columns 
summarise GO-terms enriched in one or more of the E14.5 proteome data sets, 
from left to right: pMEF proteome, pMEF phosphoproteome, liver proteome 
and liver phosphoproteome. Enriched GO-terms discovered from the four data 
sets are listed to the right of the heat map. Enriched GO-terms are shown as 
green, while non-enriched GO-terms are red. Brightness of the green boxes 




4.3.5 Proteomics analysis revealed expression of several RTKs was 
decreased in E14.5 Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
and livers 
A protein list was retrieved from the enriched molecular function GO-terms of 
“transmembrane receptor activity”, “transmembrane signaling receptor activity” 
and “transmembrane receptor protein kinase activity”, as these GO-terms were 
enriched in E14.5 pMEF and liver proteomes. The expression ratios of these 
proteins in knockout pMEF and liver versus WT were log2 transformed and 
expressed as a Heatmap with upregulated proteins in red and downregulated 
proteins in green boxes (Figure 4.8), and as two individual scatter plots using 
log2 Grb10
m/+/Dlk1+/p values as the X-axis (Figure 4.8). Interestingly, most of 
these proteins were downregulated in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
compared to WT at the proteomic level. In particular, protein expression levels 
of several RTKs including PDGFRa, FGFR1, Tgfbr3, Ephb3, Lpar1, Npr3, Itpr1 
and Ryr3 were reduced in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEF and 
liver compared to WT (Figure 4.8). In addition, Kcnk1 was the only protein with 
increase expression in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEF and liver. 
Ddr2, Erbb2 and Vmn1r30 expression were only increased in Grb10m/+ pMEF 
and decreased in all the other knockout data sets. Ptpn6, Itgb2 and Abca1 
expression levels were found to be specifically elevated in Grb10m/+ and 
Grb10m/+/Dlk1+/p livers. Sfrp1 and Fcgrt expression were slightly increased in 
Grb10m/+ liver and decreased in other knockout data sets. Cd40 had a varied 
expression pattern in different data sets, showing an increase in Dlk1+/p pMEF, 
Grb10m/+ and Grb10m/+/Dlk1+/p livers and a decrease in Dlk1+/p liver and 














Figure 4.8 Expression patterns of proteins from the enriched molecular 
function GO-terms found in pMEF and liver proteomes. A) Logarithmically 
transformed protein expression ratios of knockout against WT were expressed 
as a Heatmap. Columns represented E14.5 pMEF and liver proteome data 
sets. Proteins were listed on the right. Green, black and red boxes indicated 
upregulated, unchanged and downregulated proteins in knockout samples 
compared to WT, respectively. Scale above the Heatmap indicated protein fold 
change level. B) Scatter plot of protein expression in E14.5 pMEFs. C) Scatter 
plot of protein expression in E14.5 livers. Yellow dots indicated protein 
expression ratios of Dlk1+/p/WT (Y-axis) against Grb10m/+/Dlk1+/p/WT (X-axis). 
Blue dots were the proteins plotted for the expression ratios of Grb10m/+/WT 




4.3.6 Unsupervised clustering analysis identified distinct protein 
clusters with special expression or phosphorylation profiles in 
E14.5 pMEFs 
To dissect out the protein or phosphorylated protein groups with similar 
expression or phosphorylation patterns in E14.5 pMEFs among the four 
genotypes, unsupervised clustering analysis utilizing a Fuzzy-c means 
algorithm was performed using GProX v1.1.16 software. 4- and 1.5-fold 
changes of knockout versus WT were set as the thresholds for pMEF 
proteome and phosphoproteome, respectively. Proteins or phosphorylated 
proteins outside of the fold change cut off were partitioned to different clusters. 
In each cluster, each protein or phosphorylated protein presented an individual 
curve with different colours. The colours represented the distance of each 
protein to the cluster centre calculated by the Fuzzy-c means algorithm. 
 
In the pMEF proteome, four distinct protein expression patterns were identified 
(Figure 4.9A). Only 19 proteins were identified in cluster 1 which exhibited a 
special expression profile, with downregulation in Dlk1+/p and upregulation in 
Grb10m/+ and Grb10m/+/Dlk1+/p compared to WT. The 137 proteins in cluster 2 
displayed upregulated expression levels in Dlk1+/p and downregulated in 
Grb10m/+ and Grb10m/+/Dlk1+/p compared to WT, while the 267 proteins in 
cluster 3 had increased expression levels in Dlk1+/p and decreased in Grb10m/+ 
and Grb10m/+/Dlk1+/p compared to WT (Figure 4.9A). In cluster 4, 449 protein 
expression levels were elevated in Dlk1+/p, slightly elevated in Grb10m/+ and 
reduced in Grb10m/+/Dlk1+/p compared to WT (Figure 4.9A). 
 
Next, the protein list from each cluster was extracted and GO-term enrichment 
analysis carried out against the whole data set of the pMEF proteome. The 
enriched GO-terms were expressed as a Heatmap with enriched GO-terms in 
green (Figure 4.9B). The detailed results of GO-term enrichment analysis were 
listed in tables (Table 7.3). In cluster 1, “brown fat cell differentiation” was the 
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only enriched GO-term (Figure 4.9B). “Extracellular region”, “extracellular 
space”, “extracellular region part” and “calcium ion binding” were the enriched 
GO-terms associated with proteins in cluster 2 (Figure 4.9B). GO-terms 
“transmembrane signalling receptor activity”, “transmembrane receptor 
activity”, “signalling receptor activity” and “signal transducer activity” were 
enriched in cluster 3 (Figure 4.9B). In cluster 4, mitochondrion function 
associated GO-terms of “mitochondrion”, “cytoplasmic part”, “mitochondrial 
part”, “membrane part” and small molecule catabolic and metabolic associated 
GO-terms of “organic acid catabolic process”, “carboxylic acid catabolic 
process”, “organic acid metabolic process”, “alpha-amino acid catabolic 
process”, “small molecule catabolic process”, “oxoacid metabolic process”, 
“cellular amino acid catabolic process”, “carboxylic acid metabolic process”, 
“cellular amino acid metabolic process” were enriched (Figure 4.9B). 
 
In parallel, 6 clusters of phosphorylated proteins were identified according to 
expression profiles between the different genotypes. Numbered 1-6, these 
clusters comprised 453, 301, 99, 152, 87 and 91 phosphorylated proteins, 
respectively (Figure 4.9C). Expression relative to WT of phosphorylated 
proteins in cluster 1 decreased in Grb10m/+/Dlk1+/p and increased in Dlk1+/p and 
Grb10m/+, while in contrast those in cluster 5 increased in Grb10m/+/Dlk1+/p and 
decreased in Dlk1+/p and Grb10m/+ (Figure 4.9C). The phosphorylated proteins 
in cluster 2 showed relatively high levels of phosphorylation in Dlk1+/p and a 
dramatic reduction in Grb10m/+ and Grb10m/+/Dlk1+/p compared to WT (Figure 
4.9C). Cluster 3 had a pattern of downregulation in Dlk1+/p, upregulation in 
Grb10m/+ and a lower upregulation level in Grb10m/+/Dlk1+/p (Figure 4.9C). 
Expression of phosphoproteins versus WT in clusters 4 was upregulated in 
Grb10m/+ and downregulated in Dlk1+/p and Grb10m/+/Dlk1+/p, while in contrast 
those in cluster 6 downregulated in Grb10m/+ and upregulated in Dlk1+/p and 




GO-term enrichment analysis revealed that GO-term of “response to radiation” 
was enriched in Cluster 1 (Figure 4.9D). In cluster 4, associated GO-terms 
were “regulation of secretion”, “regulation of peptide transport”, “regulation of 
secretion by cell”, “regulation of sequence-specific DNA binding transcription 
factor activity” and “positive regulation of sequence-specific DNA binding 
transcription factor activity”. No enriched GO-terms were identified in the other 
















Figure 4.9 Hierarchy clustering and GO-term enrichment analyses of 
E14.5 pMEF total proteome and phosphoproteome. A) Four protein 
clusters were identified with distinct expression patterns among the Dlk1+/p, 
Grb10m/+, and Grb10m/+/Dlk1+/p pMEF proteomes, each expressed relative to 
their expression in WT. Curve colour indicates the distance of the protein from 
the cluster centre according to the indicated scale (membership). A bar graph 
shows the number of proteins in each cluster and the background (cluster 0). 
Dlk1KO, Dlk1+/p; Grb10KO, Grb10m/+; DKO, Grb10m/+/Dlk1+/p. B) GO-terms 





and expressed as a Heatmap. Columns labelled with numbers represent the 
corresponding cluster in A, with enriched GO-terms from all clusters listed on 
the right. Green and red boxes indicate the enriched and non-enriched 
GO-terms for each protein cluster. C) Six clusters of phosphorylated proteins 
were identified with special phosphorylation profiles among the Dlk1+/p, 
Grb10m/+, and Grb10m/+/Dlk1+/p versus WT. D) Enriched GO-terms from each 
cluster were expressed as a Heatmap. Columns labelled with numbers 




4.3.7 Proteins were clustered according to expression patterns in E14.5 
liver Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p livers 
Unsupervised clustering analysis was carried out on E14.5 liver proteome and 
phosphoproteome using the same strategy as pMEF as described for pMEF 
samples (see section 4.3.6). Among proteins expressed at levels beyond the 
4-fold change thresholds, 6 subsets of proteins with special expression profiles 
were acquired by clustering analysis. The 92 proteins in cluster 1 had an 
expression pattern of decrease in Dlk1+/p and elevation in Grb10m/+ and 
Grb10m/+/Dlk1+/p compared to WT proteome. Meanwhile the 176 and 108 
proteins in cluster 2 and 3 showed decreased expression level in Dlk1+/p and 
increased in Grb10m/+ compared to WT, while Grb10m/+/Dlk1+/p levels 
intermediate between those of Dlk1+/p and Grb10m/+ (Figure 4.10A). The 85 
proteins in cluster 4 had similar expression levels between WT and Dlk1+/p, 
while they were increased in Grb10m/+ and reduced in Grb10m/+/Dlk1+/p 
compared to WT. In cluster 5, the 45 proteins had an expression profile of 
elevation in Dlk1+/p and reduction in Grb10m/+ and Grb10m/+/Dlk1+/p compared 
to WT. A small group of 21 proteins in cluster 6 had increased expression 
levels in Dlk1+/p and Grb10m/+/Dlk1+/p and decreased in Grb10m/+ compared to 
WT (Figure 4.10A).  
 
The subsequent GO-term enrichment analysis uncovered that B cell and 
immune system associated GO-terms of “regulation of B cell activation”, 
“immune response-regulating signalling pathway”, “immune effector process”, 
“regulation of B cell proliferation”, “regulation of mononuclear cell proliferation”, 
“regulation of lymphocyte proliferation”, “immune system process”, “regulation 
of leukocyte proliferation”, “immune response-regulating cell surface receptor 
signaling pathway”, “positive regulation of B cell activation”, “positive regulation 
of interleukin-12 production” were enriched in cluster 1 (Figure 4.10B). 
Additionally, GO-terms of “transmembrane signaling receptor activity”, 
“transmembrane receptor activity”, “receptor activity”, “molecular transducer 
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activity” and “signalling receptor activity” were enriched in both cluster 1 and 4 
(Figure 4.10B). Besides, “extracellular region”, “extracellular space”, “G-protein 
coupled receptor activity”, “secretion”, “cell migration” and “cell motility” 
GO-terms were also found to be enriched in cluster 4 (Figure 4.10B). 
GO-terms of “negative regulation of cell proliferation”, “multicellular organismal 
process”, “negative regulation of epithelial cell proliferation” and “osteoblast 
differentiation” were enriched in cluster 5 and “cell differentiation” and “identical 
protein binding” in cluster 6 (Figure 4.10B). No enriched GO-terms were found 
in cluster 2 and 3 (Figure 4.10B). 
 
In liver phosphoproteome, 5 clusters with distinct phosphorylation patterns 
were discovered. Protein phosphorylation levels in were lower in Dlk1+/p and 
the lowest in Grb10m/+/Dlk1+/p cluster 1 and higher in Dlk1+/p and the highest in 
Grb10m/+/Dlk1+/p in cluster 3, while the changes in Grb10m/+ were opposite to 
Dlk1+/p and Grb10m/+/Dlk1+/p in these two clusters (Figure 4.10C). Notably, 
phosphorylated proteins in cluster 4 and 5 illustrated opposite phosphorylation 
levels in Dlk1+/p and Grb10m/+ proteomes, either increase or decrease, and the 
changes in Grb10m/+/Dlk1+/p proteome was similar as WT (Figure 4.10C). 
Phosphorylation level of proteins in cluster 2 had a gradual down regulation 
pattern in Grb10m/+ and Grb10m/+/Dlk1+/p and were upregulated in Dlk1+/p 
compare to WT (Figure 4.10C). 
 
The following GO-term enrichment analysis indicated that “positive regulation 
of cellular metabolic process”, “regulation of cellular metabolic process”, 
“positive regulation of metabolic process”, “positive regulation of 
nucleobase-containing compound metabolic process” and “positive regulation 
of macromolecule metabolic process” GO-terms were enriched in cluster 2 
containing 112 phosphoproteins, while “translational elongation”, “large 
ribosomal subunit”, “ribosomal subunit” and “ribonucleoprotein complex” were 
enriched in 43 phosphoproteins from cluster 3 (Figure 4.10D). And 84 
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phosphoproteins in cluster 5 possessed biological function annotations of 
“integral component of plasma membrane” and “intrinsic component of plasma 
membrane” (Figure 4.10D). No enriched GO-terms were found in cluster 1 and 















Figure 4.10 Hierarchy clustering and GO-term enrichment analyses of 
E14.5 liver total proteome and phosphoproteome. A) Six protein clusters 
were grouped with different expression patterns among the Dlk1+/p, Grb10m/+ 





expression ratio of knockout versus WT. Curve colour indicates the distance of 
the protein from the cluster centre according to the indicated scale 
(membership). A bar graph shows the number of proteins numbers in each 
cluster and the background (cluster 0). Dlk1KO, Dlk1+/p; Grb10KO, Grb10m/+; 
DKO, Grb10m/+/Dlk1+/p. B) GO-terms enriched (based on p-Values) within each 
cluster (1, 2, 3, 4, 5 and 6) were extracted and visualized as a Heatmap. 
Columns labelled with numbers represent the corresponding cluster in A, with 
enriched GO-terms from all clusters listed on the right. Green and red boxes 
indicate the enriched and non-enriched GO-terms for each protein cluster. C) 
Five clusters of phosphorylated proteins were identified with distinct 
expression patterns among the Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p liver 
phosphoproteomes. Each curve represents levels of a phosphorylated protein, 
relative to WT expression. D) Enriched GO-terms from cluster were expressed 
as a Heatmap. Columns labelled with numbers represented the corresponding 





Two independent TMT quantitative proteomics analyses generated four data 
sets for the proteomes and phosphoproteomes of E14.5 pMEFs and livers 
from four genotypes, WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p. The analyses 
provided a wealth of information, including expression levels of thousands of 
proteins and phosphorylated proteins, for Dlk1 and Grb10 function and 
signalling studies (Figure 4.4). PCA and HCL analyses on the mean ratios of 
knockout versus WT revealed that Grb10m/+ and Grb10m/+/Dlk1+/p had higher 
Pearson correlation coefficient value and was grouped in the same cluster at 
the proteomics level, while Dlk1+/p was divergent in both pMEFs and livers. 
Interestingly, Grb10m/+ and Grb10m/+/Dlk1+/p had even higher Pearson 
correlation coefficient value in E14.5 pMEF and liver phosphoproteomes, 
suggesting the overall signal transduction through phosphorylation was similar 
in these two samples (Figure 4.5I-P). The PCA and HCL analyses of proteomic 
and phosphoproteomic data supported the published genetic evidence that 
while Dlk1+/p and Grb10m/+ single mutants had opposite phenotypes, including 
growth and metabolic health characteristics, Grb10m/+/Dlk1+/p double mutants 
were indistinguishable from Grb10m/+ (Moon et al., 2002; Smith et al., 2007; 
Wang et al., 2007; Madon-Simon et al., 2014). However, PCA and HCL 
analyses for the individual samples failed to group the replicates of each 
genotype in the same cluster, and these results were relatively noisy which 
were difficult to tell the similarities and divergence among the four genotypes 
(Figure 4.5A-H). All samples from E14.5 pMEFs or livers were pulled and 
analysed in the same TMT proteomics process. The low correlation between 
the biological replicates of each genotype suggested that the experimental 
noise and error were relatively high. This study only chose two biological 





Strikingly, the scatter plots of the four data sets presented a consistent pattern 
of reduced expression in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p proteomes and 
phosphoproteomes compared to WT, indicating that Dlk1 and Grb10 may 
promote wide-scale protein stabilisation or phosphorylation at E14.5 in vitro 
and in vivo (Figure 4.6). This could be a product of immediate and downstream 
effects of signalling defects in the knockouts. It is known that Dlk1 and Grb10 
are widely expressed in the embryo, and both have a significant impact on fetal 
growth (Moon et al., 2002; Charalambous et al., 2003; Charalambous et al., 
2010; Charalambous et al., 2014; Madon-Simon et al., 2014). This may explain 
the emergence of the large scale of protein expression or phosphorylation 
reduction in E14.5 embryos caused by Dlk1 and Grb10 single and double 
knockout. Notably, more proteins were 4-fold down regulated in the Dlk1+/p 
liver proteome, whereas larger numbers of proteins were down regulated in 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEF proteomes (Figure 4.6). This suggests 
that Dlk1 and Grb10 may have different effects in E14.5 pMEF and liver 
development and function, respectively. 
 
GO-term enrichment analysis was performed to uncover the biological 
functional properties of the proteins with greatest fold changes in Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p proteomes and phosphoproteomes. Proteins or 
phosphorylated proteins were not separated based on upregulation or 
downregulation levels in the three knockout for GO-term enrichment analyses, 
as protein expression or phosphorylation levels were largely decreased 
according to the scatter plot for each data set (Figure 4.6). Notably, a few 
different GO-terms were associated with RTK signalling activity, 
“transmembrane receptor activity”, “transmembrane signaling receptor activity” 
and “transmembrane receptor protein kinase activity”, were enriched in both 
E14.5 pMEF and liver proteomes (Figure 4.7), suggesting that Dlk1 and Grb10 
may be involved in RTK signal transduction in E14.5 embryo. It is well 
established that Grb10 can interact with and regulate several RTKs in vitro and 
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in vivo (Wick et al., 2003; Vecchione et al., 2003; Murdaca et al., 2004; 
Monami et al., 2008; Wang et al., 2007; Smith et al., 2007; Plasschaert and 
Bartolomei, 2015). The role of Dlk1 in RTK signalling is not well demonstrated 
so far. The GO-term enrichment results were consistent with the previous 
studies demonstrating roles for Grb10 in RTK signalling and also indicated a 
role for Dlk1 in regulating RTK signalling pathways. Similarities in proteomic 
changes in both single and double mutants for Dlk1 and Grb10 are consistent 
with the genetic evidence that both factors may influence one or more common 
signalling pathways during fetal development (Madon-Simon et al., 2014). 
 
In Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p liver proteomes, enriched GO-term of 
“negative regulation of cell proliferation” indicated that Dlk1 and Grb10 may 
affect proliferation of one or more cell types in liver. In addition, GO-terms of 
“intrinsic/integral component of plasma membrane”, “elastic fiber”, “receptor 
activity”, “signaling receptor activity”, “signal transducer activity”, “molecular 
transducer activity” and “calcium ion binding” were specifically enriched in liver 
proteome (Figure 4.7), suggesting that Dlk1 and Grb10 may be active factors 
involved in these biological processes in E14.5 livers. 
 
The GO-terms “lytic vacuole” and “lysosome” were specifically enriched in 
pMEF knockout proteomes (Figure 4.7), suggesting that Dlk1 and Grb10 may 
participate in membrane receptor-mediated endocytosis in E14.5 pMEFs. It 
has been reported that Grb10 regulates the IGF1R lysosomal degradation 
process in collaboration with Nedd4 in pMEFs which overexpressed IGF1R or 
Grb10 (Monami et al., 2008). A role for Dlk1 in lysosomal function in pMEFs is 
not yet known, however, the GO-term enrichment analysis suggested that Dlk1 
may also play a role in receptor-mediated endocytosis of E14.5 pMEFs. 
Further, GO-term related to phagocytosis (“phagocyte vesicle”) was 
specifically enriched in the E14.5 liver proteome (Figure 4.7), suggesting that 





Dlk1 and Grb10 knockout mice as adults displayed increased and reduced 
adiposity, respectively, as demonstrated in Chapter 3 (Figure 3.2) and several 
previous studies (Moon et al., 2002; Lee et al., 2003; Charalambous et al., 
2003; Smith et al., 2007; Wang et al., 2007; Charalambous et al., 2010; 
Charalambous et al., 2014; Madon-Simon et al., 2014). Here, the GO-term 
“lipid metabolic process” was enriched in Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEF proteomes (Figure 4.7), further supporting roles for 
Dlk1 and Grb10 in lipid development or metabolism at the proteomic level. The 
adult adipose development and lipid metabolism affected by Dlk1 and Grb10 
may be consequences of earlier altered development happened at the 
embryonic stage. Meanwhile, “hydrolase activity” and “ATPase activity” 
GO-terms were enriched in the pMEF knockout phosphoproteomes while 
“negative regulation of hemopoiesis” was enriched in the liver knockout 
phosphoproteome (Figure 4.7). This demonstrated that Dlk1 and Grb10 may 
affect the signal transductions of these biological processes in E14.5 pMEFs 
and livers. 
 
Interestingly, the only overlap in enriched GO-terms between samples was in 
several membrane protein GO-terms, as discussed above. No overlap in 
GO-terms was found between pMEF proteome and phosphoproteme, liver 
proteome and phosphoproteome. This suggests that Dlk1 and Grb10 knockout 
may have different long-term (protein expression) and short-term 
(phosphorylation) effects on cells or tissues in E14.5 embryo. Similarly, there 
was no overlap in enriched GO-terms from the pMEF and liver 
phosphoproteome (Figure 4.7), suggesting that the direct downstream 
signalling effects are tissue specifically different in the embryo. 
 
Since molecular function GO-terms of “transmembrane receptor activity”, 
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“transmembrane signalling receptor activity”, “transmembrane receptor protein 
kinase activity” were enriched in E14.5 pMEF and liver proteomes, the 29 
proteins belonging to these GO-terms were evaluated by generating a 
Heatmap and scatter plots to compare their expression levels (Figure 4.8). 
Strikingly, most of these proteins displayed 4-fold down regulation in the 
knockout pMEF and liver proteomes versus WT on the Heatmap (Figure 4.8A). 
However, the corresponding phosphorylation levels of these proteins were not 
significantly changed in the phosphoproteomes. This could mean that the 
phosphorylation levels of these proteins were actually upregulated in the 
knockout pMEFs and livers as the corresponding total protein expression 
levels were reduced. Phosphoproteomics analysis can detect only a few 
phosphorylated tyrosine sites (Figure 4.2B), consisting of less than 2% of all 
the pSTY sites because of the technique limitation (Sharma et al., 2014). 
Therefore, it is possible that the RTK tyrosine phosphorylation information was 
missing or inaccurate, for some reason, in the phosphoproteomics analysis. 
For these reasons, changes in phosphorylation status of multiple RTKs in cells 
of all four genotypes were later evaluated using a mouse phospho-RTK array 
among (Chapter 5). 
 
GO-term enrichment analysis showed that a broad range of biological 
functions were significantly enriched in pMEF and liver knockout proteomes 
and phosphoproteomes. This suggested that Dlk1 and Grb10 were involved in 
a variety of developmental processes in the E14.5 embryo. Clustering analysis 
was performed to further separate the proteins falling out of the expression or 
phosphorylation change thresholds which grouped several protein clusters 
with differential expression or phosphorylation responses to Dlk1+/p, Grb10m/+ 
and Grb10m/+/Dlk1+/p knockout in cells and tissues from E14.5 embryos. 
Notably, several clusters in the four data sets exhibited a special pattern that 
Dlk1+/p and Grb10m/+ displayed opposite protein expression or phosphorylation 
changes compared to WT, while Grb10m/+/Dlk1+/p was consistently similar to 
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Grb10m/+ but with slightly smaller changes (Figure 4.9A, C; Figure 4.10A, C). 
This was in agreement with the Grb10m/+/Dlk1+/p phenotype discovered in the 
mice in Chapter 3 and a previous genetic study (Madon-Simon et al., 2014) 
and also added evidence to the hypothesis that Dlk1 and Grb10 play 
antagonistic functions potentially on the common pathway. 
 
The clustering analysis provided valuable information for future Dlk1 and 
Grb10 studies on specific areas. For instance, proteins in cluster 1 from the 
pMEF proteome were enriched in the GO-term “brown fat differentiation” in 
E14.5 Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs (Figure 4.9B). Evidence 
exists from previous studies demonstrated the involvement of both Dlk1 and 
Grb10 in BAT development and thermogenesis (Charalambous et al., 2014; 
Liu et al., 2014). Proteins in this cluster might interact with Dlk1 and Grb10 in 
regulating brown fat differentiation. Transmembrane receptor activity 
associated GO-terms were enriched in cluster 3 of pMEF proteome (Figure 
4.9B) while RTK activity correlated GO-terms were specifically enriched in 
cluster 1 and 4 of liver proteome (Figure 4.10B) which was consistent with the 
GO-enrichment analysis for the whole pMEF or liver proteome (Figure 4.7). 
This further suggests that Dlk1 and Grb10 can be important cell signalling 
regulators in RTK signalling. It is known that Dlk1 and Grb10 are correlated 
with adipogenesis and myogenesis at the transcriptional level (Mortensen et 
al., 2012; Holt et al., 2012; Traustadóttir et al., 2013; Charalambous et al., 
2014; Andersen et al., 2013; Mokbel et al., 2014), while biological function of 
sequence-specific DNA binding transcription factor activity was 
overrepresented in pMEF phosphoproteome (Figure 4.9D). Proteins in this 
cluster can be candidates for further Dlk1 and Grb10 involved transcription 
process studies. In liver proteome, proteins in cluster 1 were found to be 
related to B cell development and immune system response (Figure 4.10B). 
Dlk1 was reported to be associated with B cell development derived from adult 
bone marrow and spleen using Dlk1 knockout mice (Raghunandan et al., 
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2008). The role of Grb10 in B cell development is currently not well studied. 
Here, GO-term enrichment analysis showed that Dlk1 and Grb10 associated B 
cell or immune system development events may also exist in the embryonic 
livers. A relatively small number of enriched GO-terms were identified in pMEF 
and liver phosphoproteome, while more information was found in the total 
proteomes. This may because protein expression was broadly affected by the 
global deletion of Dlk1 or Grb10, while dynamic signal response was more 
sensitive to short-term stimulation. Clustering and the following GO-term 
enrichment analysis also indicate some GO-terms that relate to functions 
where there is no evidence for Dlk1/Grb10 involvement. The information needs 
some initial validation similar as the signalling studies I did following with the 









Evidence that Dlk1 and Grb10 
interact through a common 





In the previous chapter, RTK signal activity related GO-terms were found to be 
significantly enriched in E14.5 pMEF and liver proteomes by GO-term 
enrichment analysis (Figure 4.7). Most of the proteins belonging to the 
identified enriched GO-terms, for instance PDGFRa, were found to have 
reduced expression levels in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
and livers compared to WT (Figure 4.8). One of a few proteins, for instance 
Erb-B2 receptor tyrosine kinase 2 (Erbb2), had different expression levels 
among the four genotypes (Figure 4.8). Initial experiments focused on 
PDGFRa and Erbb2 as two targets to evaluate the accuracy of the TMT 
proteomics analysis utilizing Western blotting. It is known that PDGFRa and 
PDGFRb can form functional heterodimers in the cell membrane 
(Borkham-Kamphorst and Weiskirchen, 2016). However, PDGFRb did not 
show significant expression changes among the four genotypes in the pMEF 
and liver proteomes. Therefore, PDGFRb was selected as a negative control 
for TMT validation experiments.  
 
Further, several RTKs and their signalling partners in those enriched RTK 
activity related GO-terms exhibited changed protein expression levels among 
the four genotypes in the pMEF and liver proteomes (Figure 4.7; Figure 4.8). 
However, the corresponding phosphorylation changes of these RTKs and 
downstream signal partners were not detected in the pMEF and liver 
phosphoproteomes. Hence, a mouse phospho-RTK array was used to 
evaluate RTK phosphorylation levels comparing E14.5 pMEFs of all four 
genotypes. This indicated altered phosphorylation in a small number of RTKs 
in E14.5 pMEFs, notably PDGFRa, but also EGFR. 
 
For the RTK signalling studies in E14.5 pMEFs, candidate pathways through 
PDGFRa and FGF1R were of interest as they both exhibited decreased 
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expression levels in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEF and liver 
proteomes (Figure 4.8). EGFR signalling was selected based on the 
phospho-RTK array results. Furthermore, previous mouse genetic studies in 
our laboratory have indicated that Grb10 may control growth independently of 
either IGF or IR signalling (Charalambous et al., 2003 and unpublished data). 
However, published biochemical data provides compelling evidence for a 
functional interaction between Grb10 and IGF1R or IR. Hence, involvement of 
Dlk1 and Grb10 in IGF/insulin signalling was also considered in parallel with 
PDGFR, FGF1R and EGFR. The corresponding ligands: PDGF-AA/BB, FGF1, 
EGF, IGF1 and insulin were used to stimulate pMEFs of all four genotypes 
prior to analyses of downstream signalling events. 
 
The experiments in this chapter were aimed at validating the proteomics data 
and identifying signalling mechanisms influenced by either or both, Dlk1 and 
Grb10. Western blotting of several RTKs and mouse phospho-RTK array were 
used to validating the proteomic data. Candidate RTK signalling studies were 
selected based on the proteomics data (Chapter 4), mouse phospho-RTK 





5.2.1 PDGFRa, Erbb2 and PDGFRb expression patterns found by 
Western blotting were similar those from TMT analysis 
To evaluate the expression patterns of several RTKs, independently of the 
TMT analysis (Chapter 4), the same portion of E14.5 pMEF cell lysates which 
were prepared for TMT analysis were used as the technical replications for 
Western blotting validation. Three other biological replications of E14.5 pMEFs 
from the four genotypes were also prepared for Western blotting validation.  
PDGFRa expression was reduced in Dlk1+/p and significantly reduced in 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs compared to WT, with the lowest levels 
being in Grb10m/+/Dlk1+/p pMEFs (Figure 5.1A, B). Erbb2 expression was 
decreased in Dlk1+/p and Grb10m/+/Dlk1+/p pMEFs and increased in Grb10m/+ 
pMEFs compared to WT. However, no statistical significance was found by 
One-way ANOVA analysis for Erbb2 expression among the four genotypes 
(Figure 5.1 A, C). No significant PDGFRb expression differences were found 
among WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs (Figure 5.1 A, D). 
These results were similar as the TMT data from E14.5 pMEF total proteome 











Figure 5.1 PDGFRa, Erbb2 and PDGFRb expression levels in E14.5 
pMEFs of four different genotypes, evaluated by Western blotting. A) 
Representative Western blots probed with antibodies specific for PDGFRa, 
Erbb2 and PDGFRb proteins in E14.5 pMEFs of the four indicated genotypes. 
An anti-GAPDH antibody was used to provide the loading control. PDGFRa, 
Erbb2 or PDGFRb expression levels were normalised to the GAPDH loading 
control and expressed as bar charts (B-D). B) PDGFRa (number of biological 
replicates n= 5) C) Erbb2 (n = 3) D) PDGFRb (n = 2). WT, green bars; Dlk1+/p, 
orange bars; Grb10m/+, light blue bars; Grb10m/+/Dlk1+/p, dark blue bars. All 
values represent means plus SEM and have been subject to One-way ANOVA 







5.2.2 Mouse phospho-RTK array analysis indicated similar RTK 
phosphorylation levels in WT, Dlk1+/p, Grb10m/+ and Grb10m/+/ 
Dlk1+/p pMEFs 
To compare the RTK phosphorylation profiles in WT, Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs, mouse phospho-RTK array was carried out. Cell 
lysates of the four genotypes were collected from confluence pMEFs cultured 
in complete medium and then incubated with the phopho-RTK array. Each 
array contained 39 phosphorylated RTK capture antibodies with duplicated 
dots (Figure 5.2A; Table 7.1). In E14.5 pMEFs, only a few of these RTKs 
displayed strong phosphorylation levels including PDGFRa, EGFR, HGFR and 
VEGFR3 (labelled with 1-4 numbers) (Figure 5.2A). Several RTKs had 
moderate phosphorylation levels, such as MuSK (labelled with 5) (Figure 5.2A). 
And some RTKs exhibited low phosphorylation levels, for instance EphR B6 
(labelled with 6) (Figure 5.2A). PDGFRa phosphorylation level was the highest 
among 39 mouse RTKs (Figure 5.2). Interestingly, PDGFRb phosphorylation 
level was very low in E14.5 pMEFs (indicated by red arrow). The mean pixel 
densities of phosphorylated PDGFRa, EGFR, HGFR, VEGFR3, MuSK and 
EphR B6 dots on each array were measured and presented as a bar chart 
(Figure 5.2B). In all cases, RTK phosphorylation levels were essentially 
indistinguishable when arrays were compared following exposure to protein 






1 p-EGFR, 2 p-HGFR, 3 p-PDGFRa,  
4 p-VEGFR3, 5 p-MuSK, 6 p-EphR B6, 





Figure 5.2 Mouse phospho-RTK array analysis of E14.5 pMEFs of four 
different genotypes. Each array had duplicated dots for 39 phosphorylated 
RTK antibodies. Three pairs of reference spots, containing phospho-Tyrosine 
antibodies, were located at three corners of each array. Reference spots, used 
for aligning the target spots, were not considered as the loading control. A) 
EGFR, HGFR, PDGFRa, VEGFR3, MuSK and EphR B6 displayed relatively 
strong phosphorylation levels in E14.5 pMEFs among all four genotypes which 
were labelled with numbers (1-6) on the graph. The position of phosphorylated 
PDGFRb antibody was indicated with a red arrow. B) Mean pixel intensities for 
each RTK duplicated dots were measured, and mean intensities of EGFR, 
HGFR, PDGFRa, VEGFR3, MuSK and EphR B6 were expressed as a bar 
graph (WT, green bar; Dlk1+/p, orange bar; Grb10m/+, light blue bar; 
Grb10m/+/Dlk1+/p, dark blue bar). All values are from a single experiment using 




5.2.3 PDGF-AA triggered rapid downstream Akt and Erk1/2 signal 
responses in WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
PDGF-AA is a specific ligand of PDGFRa which does not cross react with other 
PDGF receptors, notably PDGFRb (Borkham-Kamphorst and Weiskirchen, 
2016). Hence PDGF-AA was used to specifically activate PDGFRa in E14.5 
pMEFs. Cells were starved for overnight (12-14 h) in DMEM medium 
containing 1% BSA and no FBS. The next day, cells were stimulated with 30 
ng/ml murine PDGF-AA for 5 min, 30 min and 60 min. PDGFRa and PDGFRb 
expression and downstream Akt and Erk1/2 phosphorylation levels were 
measured. 
 
PDGFRa expression in Dlk1+/p and Grb10m/+ pMEFs was both slightly 
downregulated when cells were stimulated with PDGF-AA, while PDGFRa 
expression in WT and Grb10m/+/Dlk1+/p pMEFs remained essentially 
unchanged during the 1 h stimulation time. PDGFRa expression was elevated 
in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p compared to WT when cells were 
starved overnight (“0” time point) (Figure 5.3A, B). Particularly, PDGFRa 
expression was significantly increased in Grb10m/+ pMEFs compared to WT at 
“0” time point (Figure 5.3A, B). Meanwhile PDGFRb expression was relatively 
stable in WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs under PDGF-AA 
treatment (Figure 5.3A, C). This indicated that exposure to 30 ng/ml PDGF-AA 
did not cause degradation of either PDGFRa or PDGFRb in E14.5 pMEFs. 
These compared to a reduction of PDGFRa expression and no changes in 
PDGFRb expression in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
compared to WT, when cells were cultured with complete medium containing 
10% FBS (Figure 5.1).  
 
Downstream Akt and Erk1/2 phosphorylation levels were relatively low after 
overnight starvation. However, both were activated by PDGF-AA and showed 
the highest phosphorylation level at 5 min. At later time points, 30 and 60 mins, 
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phosphorylation of Akt and Erk1/2 was reduced, but not fully in comparison 
with levels following overnight serum starvation (Figure 5.3A, D, E). No 
significant differences of Akt phosphorylation levels were found in pMEFs 
when compared among four genotypes, although Akt phosphorylation was 
consistently slightly higher in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
compared to WT (Figure 5.3A, D). Erk1/2 phosphorylation displayed a similar 
response pattern to PDGF-AA stimulation among cells of the four genotypes 
















Figure 5.3 PDGF receptor expression levels and downstream signal 
protein phosphorylation status in PDGF-AA stimulated E14.5 pMEFs of 
the four genotypes. A) Western blots representative of six independent 
experiments. Overnight serum starved E14.5 pMEFs of each genotype (no 
PDGF-AA stimulation) were used as negative controls. GAPDH protein level 
was used as the loading control for PDGFRa and PDGFRb, while total Akt and 
Erk1/2 were controls for phosphorylated Akt and Erk1/2 levels, respectively. 
Western blots were scanned and values normalised to loading controls were 
plotted in separated line charts for: B) PDGFRa, C) PDGFRb, D) p-Akt and E) 
pp-Erk1/2. WT, green line; Dlk1+/p, orange line; Grb10m/+, light blue line; 
Grb10m/+/Dlk1+/p, dark blue line. All values represent means plus SEM and 
have been subject to Two-way ANOVA with Bonferroni post-tests. WT n=4, 







5.2.4 PDGF-BB induced sustained Akt phosphorylation in pMEFs of all 
genotypes and a stronger Erk1/2 response in Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs 
PDGF-BB is the only ligand that can activate all three PDGF receptor dimers, 
PDGFRaa, bb and ab (Borkham-Kamphorst and Weiskirchen, 2016). To 
investigate the responses of PDGF receptors and downstream Akt and Erk1/2 
signals to PDGF-BB stimulation, cells were treated with 30 ng/ml murine 
PDGF-BB after overnight starvation.  
 
PDGF-BB caused modest but significant reductions in PDGFRa and PDGFRb 
expression levels during the PDGF-BB stimulation period in WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs (Figure 5.4A-C). PDGFRa expression 
was elevated in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs when cells were 
cultured without 10% FBS, and a significant elevation of PDGFRa was 
observed in Dlk1+/p pMEF compared to WT at “0” time point (Figure 5.3A, B). In 
general, PDGFRa expression was higher in Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs compared to WT during the PDGF-BB stimulation 
period (Figure 5.4A, B). No distinct or significant PDGFRb expression 
differences were found among WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
pMEFs treated with PDGF-BB (Figure 5.4 A, C). 
 
PDGF-BB stimulation led to prolonged Akt signalling as the Akt 
phosphorylation level went up rapidly after 5 min and was sustained for the full 
60 min duration of the experiment in pMEFs of all four genotypes (Figure 5.4A, 
D). Akt phosphorylation level was consistently lower in Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs compared to WT, but no significant difference was 
found among pMEFs of the four genotypes (Figure 5.4 A, D). 
 
In parallel, the highest Erk1/2 phosphorylation level was found at 5 min in WT, 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs under PDGF-BB treatment, and 
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then Erk1/2 activities quickly dropped to lower level at 30 min and to the lowest 
level at 60 min (Figure 5.4A, E). Notably, Erk1/2 phosphorylation level was 
increased in Dlk1+/p and Grb10m/+/Dlk1+/p pMEFs and significantly increased in 
Grb10m/+ pMEFs compared to WT, showing Erk1/2 signal activity was more 
sensitive to PDGF-BB stimulation in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
















Figure 5.4 PDGF receptor expression and downstream signal 
phosphorylation levels measured in PDGF-BB stimulated E14.5 pMEFs 
of the four different genotypes. A) Western blots representative of seven 
independent experiments. Overnight serum starved E14.5 pMEFs of the 
indicated genotypes, without PDGF-BB stimulation, were used as the negative 
controls. GAPDH protein level was used as the loading control for PDGFRa 
and PDGFRb while total Akt and Erk1/2 were the controls for phosphorylated 
Akt and Erk1/2 levels, respectively. PDGFRa, PDGFRb, p-Akt and pp-Erk1/2 
levels were normalised to the loading control and visualised in separated line 
charts for: B) PDGFRa, C) PDGFRb, D) p-Akt and E) pp-Erk1/2. WT, green 
line; Dlk1+/p, orange line; Grb10m/+, light blue line; Grb10m/+/Dlk1+/p, dark blue 
line. All values represent means plus SEM and have been subject to Two-way 
ANOVA with Bonferroni post-tests. WT n=4, Dlk1+/p n=4, Grb10m/+ n=4, 







5.2.5 Higher phosphorylation levels of PI3K and Grb2 were stimulated 
by PDGF-AA and PDGF-BB, respectively, in Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs 
Autophosphorylation and dimerization of PDGFRa and PDGFRb result in 
autophosphorylation of tyrosine residues, followed by activation of 
downstream signals including PI3K and growth factor receptor bound protein 2 
(Grb2) (Ostman and Heldin, 2001). To determine the phosphorylation levels of 
PDGFRa and PDGFRb under PDGF-AA and PDGF-BB stimulation, pMEF 
lysates were extracted from PDGF-AA or PDGF-BB stimulated cells. The 
lysates were immunoprecipitated (IP) using a mouse anti-p-Tyr antibody, and 
then specific phosphorylated proteins were identified on IP Western blots using 
antibodies specific to total PDGFRa, PDGFRb, PI3K p85 subunit and Grb2 
(Figure 5.5A). Aliquot of cell lysates were used to run a standard WB along 
with the IP as a control (Figure 5.5A).  
 
Very low level of p-PDGFRa and p-PDGFRb were detected in WT, Dlk1+/p, and 
Grb10m/+/Dlk1+/p pMEFs during 30 min of PDGF-AA stimulation (Figure 5.5A, 
B). Interestingly, PDGFRa phosphorylation level at 5 min and PDGFRb 
phosphorylation levels at 0 and 5 min were significantly higher in Grb10m/+ 
pMEFs in comparison with WT (Figure 5.5A, B). PDGFRa and PDGFRb 
phosphorylation dropped to low levels at 30 min (Figure 5.5A, B). Meanwhile, 
total PDGFRa and PDGFRb expression levels were stable and similar among 
WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs during PDGF-AA 
stimulation, suggesting PDGFRa signalling in Grb10m/+ pMEFs was more 
sensitive to PDGF-AA stimulation (Figure 5.3A-C; Figure 5.5A).  
 
PI3K activation levels were upregulated in Grb10m/+ and Grb10m/+/Dlk1+/p 
compared to WT and Dlk1+/p pMEFs treated with PDGF-AA, and WT and 
Dlk1+/p pMEFs exhibited a comparatively low level of PI3K activation (Figure 
5.5A, B). Particularly, PI3K activation was significantly higher at 5 min and 30 
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min in Grb10m/+ compared to WT pMEFs, which was consistent with the higher 
PDGFRa phosphorylation level found in Grb10m/+ pMEFs (Figure 5.5B). As 
described before (Figure 5.3A, D), Akt phosphorylation levels peaked at 5 min 
and went down afterwards when pMEFs were stimulated by PDGF-AA, while 
PI3K activation responded to PDGF-AA stimulation in a similar pattern (Figure 
5.5A, B). Grb2 phosphorylation levels were slightly higher in Grb10m/+ and 
Grb10m/+/Dlk1+/p compared to WT and Dlk1+/p pMEFs. However, a low 
phosphorylation level of Grb2 was discovered in PDGF-AA sitmulated pMEFs 
of all four genotyopes (Figure 5.5A). 
 
In parallel, PDGFRa and PDGFRb signalling were activated by PDGF-BB, as 
pMEFs of all four genotypes displayed high PDGFRa and PDGFRb 
phosphorylation levels which peaked at 5 min and then went down to a low 
level at 30 min (Figure 5.5 A, B). PDGFRa phosphorylation levels were similar 
among the four genotypes during the 30 min of PDGF-BB stimulation (Figure 
5.5A, C). PDGFRb phosphorylation level was slightly higher in Grb10m/+ pMEF 
at 5 min in comparison with the other three genotypes (Figure 5.5A, C). Total 
PDGFRb levels were reduced by PDGF-BB stimulation and no distinguishable 
differences were found among all four genotypes (Figure 5.3A-C; Figure 5.5A). 
Collectively, these results suggested that PDGFRb signalling was more 
sensitive to PDGF-BB stimulation in Grb10m/+ pMEFs.  
 
PI3K phosphorylation was stimulated by PDGF-BB in pMEFs to activate both 
PDGFRa and PDGFRb (Figure 5.5A). PI3K phosphorylation level was similar 
among WT, Dlk1+/p and Grb10m/+/Dlk1+/p pMEFs but higher in Grb10m/+ pMEFs 
(Figure 5.5A, C). PDGFRa and PDGFRb phosphorylation levels dropped 
rapidly after 5 min, while p-PI3K levels reduced gradually from 5 min to 30 min 
(Figure 5.5A, C). PI3K displayed prolonged signalling under PDGF-BB 
stimulation, supporting the sustained p-Akt activity observed in PDGF-BB 
treated pMEFs as mentioned before (Figure 5.4A, D; Figure 5.5A, C). 
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Additionally, Grb2 phosphorylation level was lowest in WT. Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs showed higher p-Grb2 level than WT and Dlk1+/p 
(Figure 5.5A, C). Erk1/2 phosphorylation levels were higher in Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs stimulated by PDGF-BB as mentioned 
before (Figure 5.4A, E; Figure 5.5A). These results indicated a more active 
















Figure 5.5 PDGFRa and PDGFRb IP from E14.5 pMEFs under PDGF-AA 
and BB stimulation. A) Representative immunoprecipitation (IP p-Tyr; top) 
and Western blots (WB; bottom) of three independent experiments in each 
case except Grb2 immunoprecipitation which was repeated once. Overnight 
serum starved E14.5 pMEFs of the indicated genotypes, without PDGF-AA/BB 
stimulation, were used as the negative controls. Light chain of p-Tyr antibody 
level was used as the loading control. PDGFRa, PDGFRb and PI3K activation 
levels, under PDGF-AA/BB stimulation, were normalised to the loading control 
and visualised in separated line charts for: B) PDGF-AA stimulation and C) 
PDGF-BB stimulation. WT, green line; Dlk1+/p, orange line; Grb10m/+, light blue 
line; Grb10m/+/Dlk1+/p, dark blue line.  All values represent means plus SEM 
and have been subject to Two-way ANOVA with Bonferroni post-tests. * 




5.2.6 Lower Erk1/2 activity was discovered in Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs during EGF stimulation 
To determine the EGFR signalling activities in pMEFs among four genotypes, 
cells were stimulated with 100 ng/ml EGF for 5 min, 30 min and 60 min. In 
response to EGF stimulation, Akt phosphorylation level peaked at 5 min and 
then dropped down rapidly in WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
pMEFs. No significant difference in Akt phosphorylation levels were found 
among the four genotypes (Figure 5.6A, B). Meanwhile, Erk1/2 activities were 
downregulated in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs compared to 
WT (Figure 5.6A, C). In particular, pp-Erk1/2 level was reduced in Dlk1+/p 
pMEFs at 5 min and in Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs at 30 min, when 








Figure 5.6 Akt and Erk1/2 phosphorylation activities in response to EGF 
stimulation of E14.5 pMEFs of different genotypes. A) Western blots 
representative of two independent experiments. Overnight serum starved 
pMEFs of each genotype (no EGF stimulation) were used as the negative 
controls. GAPDH protein level was used as the loading control for EGFR, while 
total Akt and Erk1/2 were controls for phosphorylated Akt and Erk1/2 levels, 
respectively. Western blots were scanned and values normalised to loading 
controls were plotted in separated line graphs for: B) EGFR and C) pp-Erk1/2. 
WT, green line; Dlk1+/p, orange line; Grb10m/+, light blue line; Grb10m/+/Dlk1+/p, 






5.2.7 FGFR1 signalling was indistinguishable in E14.5 pMEFs of the four 
genotypes 
FGFR1 was one of the downregulated RTKs discovered by the GO-term 
enrichment analysis in E14.5 pMEF total proteome (see section 4.5). To 
evaluate the FGFR1 signalling response, pMEFs of the four genotypes were 
treated with 10 ng/ml FGF1 for different time intervals within 1 h (Figure 5.7A). 
Total FGFR1 expression did not change much in WT and Dlk1+/p pMEFs, while 
it was found to be slightly reduced in Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
during the 60 min stimulation time (Figure 5.7A, B). Moreover, FGFR1 
expression was found to be lower in Grb10m/+ and lowest in Grb10m/+/Dlk1+/p 
pMEFs by proteomics analysis (Figure 4.5A). In parallel, a higher and transient 
Erk1/2 phosphorylation was found in Grb10m/+/Dlk1+/p pMEFs which peaked at 
5 min (Figure 5.7A, C). Erk1/2 signal activity was similar and weak among WT, 
Dlk1+/p and Grb10m/+ pMEFs (Figure 5.7A, C). No statistically significant 
difference of Erk1/2 phosphorylation level was found among the four 
genotypes. Downstream Akt signalling was not active during the 1 hour of 





Figure 5.7 FGFR1 expression and downstream signal phosphorylation 
levels were measured in FGF1 stimulated E14.5 pMEFs of all four 
genotypes. A) Western blots representative of two independent experiments. 
Overnight serum starved E14.5 pMEFs of each genotype (no FGF1 stimulation) 
were used as the negative controls. GAPDH protein level was used as the 
loading control for FGFR1, while total Akt and Erk1/2 were controls for 
phosphorylated Akt and Erk1/2 levels, respectively. Western blots were 
scanned and values normalised to loading controls were plotted in separated 
line charts for:  B) FGFR1 and C) pp-Erk1/2. WT, green line; Dlk1+/p, orange 
line; Grb10m/+, light blue line; Grb10m/+/Dlk1+/p, dark blue line. All values 
represent means plus SEM and have been subject to Two-way ANOVA with 
Bonferroni post-tests.  
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5.2.8 Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs displayed strong insulin 
stimulated Akt signalling 
Grb10 was reported to negatively regulate insulin receptor signalling in pMEFs 
(Yu et al., 2011). To investigate if Dlk1 and Grb10 were involved in embryonic 
growth through insulin signalling, pMEFs were stimulated with 20 nM insulin. 
Insulin receptor beta (IRb) expression was not affected by insulin treatment in 
WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs as the IRb expression 
stayed stable thoughout the stimulation time-course (Figure 5.8A, B). No 
significant differences in IRb expression were found among WT, Dlk1+/p and 
Grb10m/+/Dlk1+/p pMEFs, while Grb10m/+ pMEFs showed a slightly higher IRb 
expression among all four genotypes (Figure 5.8A, B). Interestingly, an 
elevation of Akt phosphorylation was found in Grb10m/+ and Grb10m/+/Dlk1+/p 
pMEFs compared to WT and Dlk1+/p under all the time points, and the Akt 
phosphorylation sustained in Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs during the 
stimulation period (Figure 5.8A, C). A rapid Erk1/2 phosphorylation response 








Figure 5.8 IRb expression and downstream Akt and Erk1/2 
phosphorylation levels were measured in insulin stimulated E14.5 
pMEFs of the four different genotypes. A) Western blots representative of 
two independent experiments. Overnight serum starved E14.5 pMEFs of each 
genotype (no insulin stimulation) were used as the negative controls. GAPDH 
protein level was used as the loading control for IRb, while total Akt and Erk1/2 
were controls for phosphorylated Akt and Erk1/2 levels, respectively. Western 
blots were scanned and values normalised to loading controls were plotted in 
separated line charts for: B) IRb, C) p-Akt and D) pp-Erk1/2. WT, green line; 




5.2.9 IGF1R signalling was independent from Dlk1 and Grb10 in E14.5 
pMEFs 
IGF signalling is a major fetal growth regulatory pathway (Barlow et al., 1991; 
DeChiara et al., 1991; Nordin et al., 2014). Yet genetic evidence derived from 
Grb10m/+ and IGF1R+/p crossed mice suggested that Grb10 acted primarily on 
growth independently of Insulin/IGF signalling (Charalambous et al., 2003; 
unpublished data). To evaluate if IGF1 signalling was modified by Dlk1 or 
Grb10 knockout at a biochemical level, pMEFs of the four different genotypes 
were treated with 50 ng/ml IGF1 for 5 min, 30 min and 60 min (Figure 5.9). A 
very weak signal response was detected from IRb and downstream Akt and 
Erk1/2 during the stimulation time-course, indicating that IGF1 signalling was 




Figure 5.9 IRb expression, downstream Akt and Erk1/2 phosphorylation 
levels in IGF1 stimulated E14.5 pMEFs among the four genotypes. 
Western blots representative of one experiment. Overnight serum starved 
E14.5 pMEFs of each genotype (no IGF1 stimulation) were used as the 
negative controls. GAPDH protein level was used as the loading control for IRb, 






This chapter focused on evaluating dynamic RTK downstream signalling in 
E14.5 WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs and was guided by 
the previous described TMT proteomics results (Chapter 4). Firstly, I chose 
three RTK targets to check the accuracy of the proteomics analysis. The 
PDGFRa, PDGFRb and Erbb2 Western blottings in E14.5 pMEFs showed 
results consistent with the proteomics data (Figure 4.8; Figure 5.1). PDGFRa 
expression was down-regulated in the three knockout pMEFs. Erbb2 
expression was reduced in Dlk1+/p and Grb10m/+/Dlk1+/p pMEFs and elevated 
in Grb10m/+ pMEFs. PDGFRb expression was similar among the four 
genotypes (Figure 5.1). Unfortunately, none of the PDGFRa, PDGFRb and 
Erbb2 antibodies worked well on WB of E14.5 liver lysates, so their expression 
status in liver using this technique remains unknown (data not shown).  
 
Secondly, a mouse phospho-RTK array displayed an equivalent tyrosine 
phosphorylation level among four genotypes, whereas most of the total RTK 
expression levels were reduced in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
pMEFs according to the TMT proteomics data (Figure 4.8). In particular, 
PDGFRa showed the highest phosphorylation level among the 39 RTKs on the 
array, suggesting a relatively strong PDGFRa signalling activity in E14.5 
pMEFs (Figure 5.2). Since total PDGFRa expression levels were reduced in 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs compared to WT, according to 
both proteomics and Western blot analyses, this means that PDGFRa may 
have higher phosphorylation activity in the knockout pMEFs. 
 
A third set of experiments aimed to evaluate signalling responses through 
some of the identified receptors by stimulating pMEFs of different genotypes 
with the cognate ligands, PDGF-AA/BB, EGF, FGF1, IGF1 and insulin. 
PDGF-AA and PDGF-BB were used to stimulate the PDGF receptors to 
evaluate the phosphorylation levels of the receptors and downstream signals 
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in E14.5 pMEFs. 
 
PDGF-AA induced a significantly higher PDGFRa phosphorylation level in 
Grb10m/+ pMEFs compared to WT. Meanwhile the PDGFRa phosphorylation 
level stimulated by PDGF-AA was relatively low in WT, Dlk1+/p and 
Grb10m/+/Dlk1+/p pMEFs. In addition, two direct downstream signal partners of 
PDGF receptors, PI3K and Grb2, had higher phosphorylation levels in 
Grb10m/+ and Grb10m/+/Dlk1+/p compared to WT and Dlk1+/p pMEFs under 
PDGF-AA treatment (Figure 5.5A, B). However, the downstream Akt and 
Erk1/2 phosphorylation activities stimulated by PDGF-AA were similar and 
transient in pMEFs of the four genotypes (Figure 5.3; Figure 5.5). Collectively, 
these results indicated that the downstream PDGFRa signalling was more 
sensitive in Grb10m/+ and Grb10m/+/Dlk1+/p than WT and Dlk1+/p pMEFs, 
especially in Grb10m/+, and the downstream Akt and Erk1/2 responses 
activated by PDGF-AA were rapid and similar among pMEFs of the four 
genotypes. These results indicated that Grb10 normally negatively regulated 
the downstream PDGFRa signalling (as judged by PDGFRa phosphorylation 
and downstream PI3K and Grb2 activation) in E14.5 pMEFs treated with 
PDGF-AA. 
 
By contrast, PDGF-BB promoted sustained PI3K and Akt phosphorylation in 
WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs, suggesting a more active 
downstream PI3K/Akt signalling under PDGF-BB treatment than PDGF-AA. 
Furthermore, PDGF-BB treatment led to higher Grb2 and Erk1/2 
phosphorylation levels in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs than 
WT. PDGFRa and PDGFRb phosphorylation levels induced by PDGF-BB were 
stronger than PDGF-AA. However, no distinct difference of p-PDGFRa or 
p-PDGFRb was found in pMEFs among the four genotypes. In addition, 
PDGF-BB induced the reduced PDGFRa and PDGFRb expression in pMEFs 
(Figure 5.4; Figure 5.5). Overall, PDGF-BB simultaneously activated the 
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PDGFRa and PDGFRb and caused the PDGF receptor degradation. 
Activation of the PDGF receptors was associated with higher levels of 
phosphorylated PI3K and Grb2, as well as their respective downstream targets 
Akt and Erk1/2. Both Dlk1 and Grb10 appeared to act as inhibitors of the 
PDGF-BB/PDGF receptors/Grb2/Erk1/2 pathway, as the Erk1/2 
phosphorylation level was elevated in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p 
pMEFs in comparison with WT. This is consistent with studies showing that 
Grb10 acts as an inhibitor of several RTKs (Wick et al., 2003; Vecchione et al., 
2003; Dufresne and Smith, 2005; Monami et al., 2008; Hsu et al., 2011; Yu et 
al., 2011; Liu et al., 2014). 
 
Strikingly, PDGF-AA and PDGF-BB raised differential signal responses in 
E14.5 pMEFs. This was presumably due to the different targets of these two 
ligands. PDGF-AA specifically activates PDGFRa homodimers, while 
PDGF-BB can simultaneously stimulate heterodimers and homodimers of 
PDGFRa and PDGFRb (Borkham-Kamphorst and Weiskirchen, 2016). Hence, 
a sustained activation of PI3K-Akt pathway and more active Grb2-Erk1/2 
signalling were detected in E14.5 pMEFs induced by PDGF-BB (Figure 5.3; 
Figure 5.4; Figure 5.5). Notably, mouse phospho-RTK array and PDGF-BB 
stimulation both showed strong PDGFRa phosphorylation levels in E14.5 
pMEFs among the four genotypes. Yet the PDGFRa phosphorylation was 
relatively low in pMEFs incubated with PDGF-AA. The phospho-RTK array 
was performed using protein lysates from pMEFs cultured with 10% FBS. The 
numerous growth factors in the serum, possibly including PDGF-BB, induced 
and maintained the high PDGFRa phosphorylation level in pMEFs. Also, the 
serum may cause the PDGFRa degradation in Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs, as PDGFRa expression levels were lower in the three 
knockout pMEFs compared to WT, when cells were cultured with medium 
containing serum. And PDGFRa expression levels were higher in knockout 
pMEFs compared to WT when cells were serum starved overnight (Figure 
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5.3A-C). This suggests that Dlk1 and Grb10 might play an important role in 
regulating the PDGFRa turnover and activity in pMEFs. Besides, the very low 
phosphorylation level of PDGFRb appeared in the PDGF-AA treated pMEFs 
was unexpected. This might be the cross talks between the PDGFRa and 
PDGFRb, or the PDGFRb antibody was not completely specific. Altogether, 
PDGF-AA and PDGF-BB stimulation studies uncovered that Dlk1 and Grb10 
may interact with each other via PDGFR signalling in E14.5 pMEFs. 
 
In similar experiments, EGF induced transient Akt phosphorylation and FGF1 
essentially no p-Akt activation, with similar responses seen in E14.5 WT, 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs. Furthermore, Erk1/2 
phosphorylation levels stimulated by FGF1 were similar in pMEFs among the 
four genotypes, while reduced Erk1/2 phosphorylation was found in Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs treated with EGF (Figure 5.6; Figure 
5.7).  The unaltered response to EGF and FGF1 stimulation in pMEFs of all 
four genotypes demonstrates the specificity of the effect of Dlk1 and Grb10 
through PDGF receptors.  
 
The downstream Akt and Erk1/2 activities were very low in E14.5 WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs stimulated with 50 ng/ml IGF1 (Figure 
5.9). This suggests that Dlk1 and Grb10 may not be involved in IGF1R 
signalling, supporting the genetic evidence that Grb10 acted independently 
from IGF1R signalling to promote fetal growth (Charalambous et al., 2003). 
However, the low Akt and Erk1/2 activities could due to the relatively low 
concentration of IGF1 used in this study.IGF1 concentration was chose based 
on previous studies (Belletti et al., 2002; You et al., 2002; Wu et al., 2005), but 
some groups used 100 ng/ml IGF1 to stimulate MEF cells (Rui et al., 2001; 
Akundi et al., 2012). Different IGF1 concentrations (possibly 50 ng/ml, 100 




Meanwhile, under insulin treatment, a significantly higher Akt phosphorylation 
level was detected in Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs than WT and 
Dlk1+/p (Figure 5.8). Grb10m/+ mice were large and lean (greater muscle mass) 
as adults (Figure 3.2) and could clear a glucose load more efficiently and 
exhibit enhanced insulin signalling in peripheral tissues (Smith et al., 2007; 
Wang et al., 2007). Collectively, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
illustrated a more sensitive insulin and Akt signalling. It is known that insulin 
signalling plays essential roles in metabolism and has a modest effect on fetal 
growth (Guo 2014). Insr knockout mice were born about 10% smaller than WT 
(Accilli et al., 1996; Joshi et al., 1996; Kitamura et al., 2003). Numerous 
biochemical studies have demonstrated that Grb10 negatively regulates 
insulin signalling through IR in vitro and in vivo (Wick et al., 2003; Wang et al., 
2007; Smith et al., 2007; Zhang et al., 2012; Andrew, 2012). Indistinguishable 
changes of Akt and Erk1/2 phosphorylation levels were found between WT 
and Dlk1+/p pMEFs treated with insulin. Ruiz-Hidalgo and co-workers reported 
that Dlk1 inhibited adipogenesis in insulin stimulated 3T3-L1 cells through 
ERK/MAPK pathway, and the mRNA levels of IGF1R and IRS1 were not 
affected by Dlk1 (Ruiz-Hidalgo et al., 2002). In this work, Erk1/2 
phosphorylation level was similar in undifferentiated WT and Dlk1+/p pMEFs 
when stimulated with insulin, demonstrating that Dlk1 may be specifically 
involved in adipogenic differentiation of pMEFs. The role of Dlk1 in other 
insulin signalling, such as glucose metabolism, is less well studied. The higher 
insulin signalling found in Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs could 
contribute to the higher proliferation rate of these cells (Madon-Simon et al., 
2014). Genetic evidence from our laboratory from crosses between Insr 
knockout and Grb10 knockout mice indicate that Grb10 influences growth 
largely independently of insulin receptor (unpublished data). Nevertheless, this 
could be investigated further using pMEF cell cultures. The involvement of 




In conclusion, PDGFRa and PDGFRb signalling was identified as the potential 
cell signal pathways involved in Dlk1 and Grb10 interactions in E14.5 pMEFs. 
The candidate RTK signal pathways were selected based on TMT proteomics 
and phopho-RTK array results as well as the literatures (Figure 5.10). 
Downstream signal activities of PDGFRa and PDGFRb were found to be more 
sensitive in Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs compared to WT 
However, the downstream signal activities of other candidate RTKs, including 
FGFR1, EGFR, IGF1R and InsR, were not significantly changed in the 
knockout pMEFs. 
 
Figure 5.10 Summary of candidate RTK signal pathways studied in this 
work. PDGFRa and PDGFRb were found to be the best candidate RTKs 














6.1 Conclusions of major findings 
How imprinted genes regulate embryonic growth which subsequently affects 
adult physiology is not well studied. This is hampered by the lack of knowledge 
of the imprinted gene interactions and cellular signal pathways involved in 
growth control. Oppositely imprinted genes, Dlk1 and Grb10, form a 
mammalian growth-regulatory axis, potentially independent from the IGF 
signalling pathway (Moon et al., 2002; Charalambous et al., 2003; 
Madon-Simon et al., 2014). In this study, I looked for evidence of signalling 
between Dlk1 and Grb10 in pMEFs and livers derived from E14.5 WT, Dlk1+/p, 
Grb10m/+ and Grb10m/+/Dlk1+/p embryos that might explain their opposing 
phenotypic roles in fetal growth and energy homeostasis. My focus was on 
biochemical methods, including unbiased TMT quantitative proteomics 
analyses. 
 
In chapter 3, I found that Dlk1+/p embryos had a body size indistinguishable 
from WT at E14.5, while Grb10m/+ and Grb10m/+/Dlk1+/p embryos were 
significantly enlarged compared to WT and Dlk1+/p. In parallel, Dlk1+/p adults 
were fatter whereas Grb10m/+ and Grb10m/+/Dlk1+/p were leaner than WT at 
6-month-old. This was in keeping with previously published studies on Dlk1 
and Grb10 knockout mice (Moon et al., 2002; Charalambous et al., 2003; 
Smith et al., 2007; Wang et al., 2007; Charalambous et al., 2014; 
Madon-Simon et al., 2014). At a biochemical level, Dlk1 and Grb10 proteins 
each affected expression of the other in E14.5 pMEFs and livers. However, the 
Dlk1 and Grb10 expression patterns were opposite between E14.5 pMEFs and 
livers. The Grb10 expression level was higher in Dlk1+/p pMEFs and 
significantly lower in Dlk1+/p livers compared to WT, while soluble Dlk1 protein 
level was lower in Grb10m/+ pMEFs and significantly higher in Grb10m/+ livers. 
Genetic evidence supports the hypothesis that Dlk1 acts as an upstream 
inhibitor of Grb10 in regulating mouse fetal growth (Madon-Simon et al., 2014). 
Only the Dlk1/Grb10 expression profiles in E14.5 pMEFs fit this hypothesis. 
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This may due to the possibility of a more prominent role in cell proliferation in 
pMEFs versus insulin-regulated lipid metabolism in liver. Furthermore, WT and 
Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p exhibited similar Akt and Erk1/2 
phosphorylation levels in serum-induced E14.5 pMEFs, suggesting a similar 
downstream signal activation responses between these two groups. This 
further supports the genetic evidence that Grb10m/+ and Grb10m/+/Dlk1+/p are 
similar while Dlk1+/p is divergent at the biochemical level (Madon-Simon et al., 
2014). Lastly, mTOR inhibition reduced Grb10 expression level in WT and 
Dlk1+/p pMEFs which is consistent with previous phosphoproteome and 
biochemical studies of mTOR, showing that Grb10 was stabilized and directly 
phosphorylated by mTORC1 (Hsu et al., 2011; Yu et al., 2011; Liu et al., 2014). 
 
In chapter 4, I compared the proteomes and phosphoproteomes from E14.5 
pMEFs and livers among the four genotypes using TMT proteomics analyses. I 
found that Grb10m/+ and Grb10m/+/Dlk1+/p were similar while Dlk1+/p was 
divergent in E14.5 pMEFs and livers at a proteomics level using PCA and HCL 
analyses in consideration of the biological replicates from each genotype. This 
is consistent with the genetic evidence derived from Dlk1+/p and Grb10m/+ 
crossed mice (Madon-Simon et al., 2014). Global knockout of Dlk1 or Grb10 
broadly affected the protein expression and phosphorylation in E14.5 pMEFs 
and livers at a proteomics level. Dlk1 and Grb10 act as a cell ligand and 
cytoplasmic adaptor, respectively (Smas and Sul, 1993; Wang and Sul, 2006; 
Hudak and Sul, 2013; Holt and Siddle, 2005; Ceccarelli and Sicheri, 2009), 
and both are important cell signalling proteins which regulate mouse fetal 
growth and many cellular processes, such as adipogenesis and myogenesis 
(Moon et al., 2003; Charalambous et al., 2003; Charalambous et al., 2014; 
Andersen et al., 2013; Holt et al., 2012; Mokbel et al., 2014; Liu et al., 2014). 
This can explain why either Dlk1 or Grb10 deletion causes largely a reduction 
of protein expression or phosphorylation in proteomes and phosphoproteomes 
of pMEF and liver. RTK activity associated GO-terms were significantly 
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enriched in pMEF and liver total proteomes of Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p when compared to WT. Particularly striking, given the 
signalling roles predicted for Dlk1 and Grb10, the expression levels of several 
RTKs and signal partners, such as PDGFRa, FGF1R and protein tyrosine 
phosphatase receptor type F (PTPRF), were reduced in Dlk1+/p, Grb10m/+, 
Grb10m/+/Dlk1+/p pMEF and liver proteomes. This suggests that Dlk1 and 
Grb10 may interact with one or more RTK signalling pathways in E14.5 pMEFs 
and livers. Clustering followed by GO-term enrichment analyses uncovered 
groups of proteins linked with known Dlk1 and Grb10 functions according to 
the literature, and further supported the notion that Dlk1 and Grb10 both are 
involved in RTK signal networks. The identification, in parallel, of proteins not 
previously associated with Dlk1 or Grb10 suggests potential novel functions for 
both signalling molecules. RTKs are key developmental regulators involved in 
a wide range of cellular processes in mammals, and aberrant RTK signalling 
can result in cancer and other developmental disorders (Casaletto and 
McClatchey, 2012). Furthermore, Grb10 is known as a binding partner of a 
variety of RTKs through its multiple domains (Wang et al., 1999; Jahn et al., 
2002; Vecchione et al., 2003; Murdaca et al., 2004; Holt and Siddle, 2005; 
Ceccarelli and Sicheri, 2009). Dlk1 is a putative ligand for which the 
physiological receptor is still unknown. It is possible that Dlk1 can also bind 
and activate some RTKs (Falix et al., 2012). 
 
In chapter 5, I examined several candidate RTKs and activated these with their 
specific ligands in E14.5 WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs to 
verify the major findings of proteomics analyses. In knockout cells, changes in 
signalling through PDGFRa and PDGFRb were consistent with a role for these 
receptors as targets for Dlk1 and Grb10 action. In the case of Grb10 these 
RTKs could be direct targets as Grb10 has been shown to interact with 
PDGFR in vitro (Wang et al., 1999), while the interaction of Dlk1 might be 
direct or indirect as no published data has provided evidence for direct 
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interaction between Dlk1 and PDGFR. Firstly, total PDGFRa expression was 
reduced in E14.5 Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs compared to 
WT by Western blotting which confirmed the proteomics data. PDGFRa 
displayed strong phosphorylation level in E14.5 pMEFs using mouse 
phospho-RTK array analysis, and PDGFRa phosphorylation level was similar 
among the four genotypes. Furthermore, the specific activation of PDGFRa 
signalling by PDGF-AA induced significantly higher PDGFRa, Grb2 and PI3K 
phosphorylation levels in Grb10m/+ pMEFs. In parallel, simultaneous 
stimulation of PDGFRa and PDGFRb by PDGF-BB caused a prolonged Akt 
phosphorylation among all four genotypes and a stronger Erk1/2 
phosphorylation in the three knockout pMEFs compared to WT. These results 
suggest that Grb10 inhibits PDGFRa signalling activity, while Dlk1 and Grb10 
both reduce the PDGFR downstream Erk1/2 activation in pMEFs. Meanwhile, 
EGF stimulation caused phosphorylation of Erk1/2 to a lower level in knockout 
pMEFs. A previous study reported that Grb10 interacts with EGFR through its 
SH2 domain (Ooi et al., 1995). However, the role of Grb10 in EGFR signalling 
is not well demonstrated. FGF1 stimulated low level of Akt and similar Erk1/2 
phosphorylation levels among the four genotypes, suggesting that Dlk1 and 
Grb10 might be independent from FGF1R signalling in E14.5 pMEFs. 
Additionally, there was little response to IGF through Akt or Erk1/2, consistent 
with growth regulation by Dlk1 and Grb10 being independent of IGF signalling 
on pMEFs. This is consistent with the genetic evidence that Grb10 regulates 
mouse fetal growth independently from IGF pathway (Charalambous et al., 
2003). Insulin stimulated pMEFs displayed strong Akt phosphorylation level 
specifically in Grb10m/+ and Grb10m/+/Dlk1+/p cells and indistinguishable Erk1/2 
activation among the four genotypes, suggesting an inhibition role of Grb10 
insulin signalling through Akt-mTOR pathway, consistent with the role for 
Grb10 in insulin signalling widely reported in the literature (e.g. Smith et al., 




6.2 Is PDGFR the major growth receptor in the Dlk1/Grb10 growth 
regulatory pathway? 
Among all the RTKs investigated in this study, PDGFR signalling was identified 
as the best candidate pathway for Dlk1/Grb10-mediated growth regulation 
based on the proteomics, mouse phospho-RTK array and cell signalling 
analyses on E14.5 WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs. 
PDGFRa and PDGFRb both are essential factors in mouse embryonic 
development as either PDGFRa or PDGFRb null embryos usually die before 
birth (Soriano 1994; Soriano 1997; French et al., 2008). PDGFRa knockout 
embryos were slightly smaller than WT with abnormal neural crest and somite 
development (Soriano 1997). PDGFRb null embryos had similar body size as 
WT, but the PDGFRb knockout significantly affected the embryonic kidney 
development (Soriano 1994). The signalling studies in Chapter 5 showed that 
Dlk1 and Grb10 were involved in the PDGF receptor signalling in E14.5 
pMEFs, and that signal transduction through PDGFRa and PDGFRb was not 
identical (Figure 6.1). It has been reported that E14.5 Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs had a higher proliferation rate and Dlk1+/p lower than 
WT, and no difference was found in the cell size of E14.5 pMEFs among the 
four genotypes (Madon-Simon et al., 2014). Madon-Simon and colleagues 
hypothesised that a higher cell proliferation rate may lead to the enlarged 
embryo size of Grb10m/+ and Grb10m/+/Dlk1+/p at E14.5 (Madon-Simon et al., 
2014). PI3K-Akt and MAPK-Erk1/2 are known as the PDGF receptor 
downstream signalling pathways which mediate cell differentiation and 
proliferation, respectively (reviewed in Andrae et al., 2008; 
Borkham-Kamphorst and Weiskirchen, 2016). According to the biochemical 
results found in this study, Dlk1 and Grb10 may regulate the differentiation and 
proliferation of E14.5 pMEFs via PDGF receptors through PI3K-Akt and 










Figure 6.1 Proposed Dlk1 and Grb10 signal interactions through PDGFRa 
and PDGFRb in E14.5 pMEFs. A) PDGF-AA stimulated significantly higher 
PDGFRa and PI3K phosphorylation levels in Grb10m/+ pMEFs. Grb10 inhibits 
the phosphorylation of PDGFRa and PI3K in PDGF-AA treated E14.5 pMEFs. 
B) PDGF-BB induced significantly higher Erk1/2 and slightly lower Akt 
phosphorylation levels in E14.5 Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
than WT. Dlk1 inhibits Grb10 which consequently facilitates downstream Akt 
phosphorylation and suppresses Erk1/2 phosphorylation in PDGF-BB treated 
E14.5 pMEFs. 
 
6.3 Future works 
This study left the following questions: Is the stronger Erk1/2 phosphorylation 
induced by PDGF-BB in E14.5 Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p pMEFs 
related to cell proliferation rate? How do the downstream signals change the 
cell behaviours of knockout E14.5 pMEFs?  
 
This can be addressed by checking the cell cycle characteristics, 
measurements of the expression levels of proliferation markers and correlated 
downstream transcription factors (e.g. Cyclin dependent kinase 1 (Cdk1) and 
cAMP response element binding protein (CREB)) among WT, Dlk1+/p, Grb10m/+ 
and Grb10m/+/Dlk1+/p pMEFs (Santamaria et al., 2007; Mayr and Montminy, 
2001). The complete signal transduction through Dlk1, Grb10 and PDGFRs to 
the downstream signalling and cellular output (cell proliferation or cell cycle) 
will need to be fully demonstrated in the future. 
 
Can the phenotype and PDGFR signalling alterations be mimicked by 
short-term deletion of Dlk1 and Grb10 in E14.5 pMEFs? Also, can the changes 
be rescued?  
 
E14.5 Dlk1 and Grb10 single and double knockdown pMEF cell lines can be 
generated using Dlk1 and Grb10 siRNAs cloned into Lentivirus. Immortal 
pMEF (p53-/-) cell lines need to be generated before introducing the Dlk1 and 
Grb10 siRNAs (Carnero et al., 2000). The rescue experiments can be 
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performed by introducing Dlk1 or Grb10 proteins to Dlk1+/p, Grb10m/+ and 
Grb10m/+/Dlk1+/p pMEFs. The cellular output and signal changes from the 
knockdown and transgenic cell lines may be measured and compared with the 
knockout cells. 
 
Which domains of Grb10 are required for its correct sub-cellular localisation, 
phosphorylation and activity when interacting with RTKs, mTOR or other 
cellular functional kinases? 
 
This can be addressed by making GFP-fusions to both full-length and mutant 
Grb10 proteins, including those lacking the five recognised signalling motifs 
(Proline-rich domain, SH2, PH, BPS and RAS), as well as specific 
phosphorylation sites. These Grb10-GFP fusion proteins will be introduced into 
WT and Grb10m/+ pMEFs in order to evaluate the effects on sub-cellular 
localisation, cell behaviour (cell proliferation and cell cycle characteristics) and 
downstream signalling events. Again immortal pMEF cell lines will be used for 
these experiments (Carnero et al., 2000). 
 
Can the expression and phosphorylation variations of RTKs, especially 
PDGFRs, uncovered by quantitative proteomics be verified in E14.5 livers?  
 
The Dlk1, Grb10 and RTK signalling studies carried out in E14.5 pMEF 
cultures could in principle be carried out in E14.5 hepatocytes derived from 
E14.5 livers (Gouon-Evans et al., 2006). Specific antibodies are required for 
the WB and immunostaining experiments for hepatocytes and embryonic liver 
tissue sections. 
 
How might the expression and phosphorylation status of PDGFRs change in 




The PDGFRa and PDGFRb expression and phosphorylation patterns in 
embryonic tissues of WT, Dlk1+/p, Grb10m/+ and Grb10m/+/Dlk1+/p are still 
unknown. This can be measured by staining whole embryos or separate tissue 
sections from the four genotypes. These two receptors may be widely 
expressed in the embryo as both are important embryonic growth factors 
(Soriano 1994; Soriano 1997; French et al., 2008). PDGF receptors may have 
overlap expression with Dlk1 and Grb10 which are both reported to be broadly 
expressed in the embryo (Moon et al., 2002; Wang et al., 2006; Garfield et al., 
2011; Charalambous et al., 2014). Whole E14.5 embryo sections from WT 
were stained with PDGFRa and Grb10 antibodies (Figure 6.2). PDGFRa and 
Grb10 were both widely expressed in E14.5 mouse embryos. Specifically, 
PDGFRa showed relatively strong expression levels in the embryonic nose, 
maxilla, lips, tongue, teeth, lung, stomach and limb, while Grb10 was relatively 
highly expressed in the embryonic liver and inner surface of stomach lumen. 
Additionally, PDGFRa and Grb10 were both expressed in muscle and dermis. 
Figure 6.2 PDGFRa and Grb10 expression in WT E14.5 embryos. 
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Representative WT E14.5 embryo section stained with PDGFRa or Grb10 
antibody. 
 
How will the early developmental signalling affect the postnatal physiology, 
especially the regulation of adult body composition? Can the Dlk1, Grb10 and 
PDGFR signalling variations be traced from early embryonic stages to adults? 
 
Dlk1 and Grb10 are both essential programming factors during embryogenesis 
(Moon et al., 2002; Charalambous et al., 2003; Charalambous et al., 2010; 
Madon-Simon et al., 2014). They also regulate the adult fat and muscle 
formation through early embryonic development (Moon et al., 2002; Andersen 
et al., 2009; Andersen et al., 2013; Charalambous et al., 2014; Madon-Simon 
et al., 2014). PDGFRa was expressed in adipocyte precursor cells based on 
the cell lineage study (Berry and Rodeheffer, 2013), and PDGFRa activation 
reduced the ratio of adipocyte/fibroblast in Day 1 mouse embryos (Sun et al., 
2017). Transgenic mice with higher PDGFRa activity developed smaller WAT 
mass at 18 days old (Sun et al., 2017). PDGFRa was also a marker of 
adipogenic cell populations in skeletal muscle progenitors (Pannérec et al., 
2013) and was highly activated in those cells during adult skeletal muscle 
regeneration (Mueller et al., 2016). It can be predicted that PDGFR signalling 
may be the key signal pathway between Dlk1 and Grb10 in regulation of adult 
body composition and physiology. However, this needs to be verified by 
checking the expression and phosphorylation levels of PDGFRs and the 
downstream signals in developing and adult fat and muscle tissues from the 
four genotypes. Also, Dlk1, Grb10 and PDGFR signals may affect the 
development or functions of other adult tissues such as liver, pancreas and 
lung as Dlk1 and Grb10 both have been shown to be involved in the 
development or metabolism of these tissues (Raghunandan et al., 2008; 







Coordinate  RTK/Control  Coordinate  RTK/Control  
A1, A2  ___  C17, C18  Tie-1  
A23, A24  ___  C19, C20  Tie-2  
B1, B2  EGF R  C21, C22  TrkA  
B3, B4  ErbB2  C23, C24  TrkB  
B5, B6  ErbB3  D1, D2  TrkC  
B7, B8  ErbB4  D3, D4  VEGF R1  
B9, B10  FGF R2 (IIIc)  D5, D6  VEGF R2  
B11, B12  FGF R3  D7, D8  VEGF R3  
B13, B14  FGF R4  D9, D10  MuSK  
B15, B16  Insulin R  D11, D12  EphA1  
B17, B18  IGF-I R  D13, D14  EphA2  
B19, B20  Axl  D15, D16  EphA3  
B21, B22  Dtk  D17, D18  EphA6  
B23, B24  Mer  D19, D20  EphA7  
C1, C2  HGF R  D21, D22  EphA8  
C3, C4  MSP R  D23, D24  EphB1  
C5, C6  PDGF Rα  E1, E2  EphB2  
C7, C8  PDGF Rβ  E3, E4  EphB4  
C9, C10  SCF R  E5, E6  EphB6  
C11, C12  Flt-3  E7, E8  PBS  
C13, C14  M-CSF R  F1, F2  ___  
C15, C16 c-Ret 
 
Table 7.1 Full list of RTK targets on mouse phospho-RTK array. Table is 




GO Term P-value FDR q-value Enrichment N B n b 
membrane part 2.29E-08 2.87E-05 1.4 3445 881 503 180 
cytoplasmic part 4.95E-08 3.10E-05 1.21 3445 1813 503 320 
vesicle 2.61E-07 1.09E-04 1.34 3445 989 503 193 
membrane-bounded vesicle 7.37E-07 2.31E-04 1.34 3445 926 503 181 
lytic vacuole 3.05E-06 7.63E-04 2.36 3445 84 503 29 
lysosome 3.05E-06 6.36E-04 2.36 3445 84 503 29 
extracellular region 3.06E-06 5.48E-04 1.9 3445 173 503 48 
extracellular region part 3.65E-06 5.72E-04 1.31 3445 946 503 181 
integral component of membrane 7.78E-06 1.08E-03 1.44 3445 533 503 112 
transmembrane receptor activity 1.10E-06 3.20E-03 2.68 3445 64 503 25 
transmembrane signaling receptor activity 2.20E-06 3.20E-03 2.65 3445 62 503 24 
transmembrane receptor protein kinase 
activity 
2.34E-06 2.26E-03 4.89 3445 14 503 10 
lipid metabolic process 1.52E-06 1.37E-02 1.9 3445 184 503 51 
 
B 
GO Term P-value FDR q-value Enrichment N B n b 
hydrolase activity 3.49E-04 3.68E-01 1.32 478 60 295 49 






GO Term P-value FDR q-value Enrichment N B n b 
integral component of membrane 6.87E-05 8.61E-02 1.54 3445 533 290 69 
extracellular region 7.59E-05 4.75E-02 2.06 3445 173 290 30 
intrinsic component of membrane 8.27E-05 3.45E-02 1.52 3445 546 290 70 
membrane part 1.57E-04 4.92E-02 1.36 3445 881 290 101 
elastic fiber 5.91E-04 1.48E-01 11.88 3445 3 290 3 
integral component of plasma membrane 8.56E-04 1.79E-01 2.44 3445 73 290 15 
phagocytic vesicle 8.80E-04 1.58E-01 4.75 3445 15 290 6 
intrinsic component of plasma membrane 9.12E-04 1.43E-01 2.35 3445 81 290 16 
transmembrane receptor activity 5.64E-07 1.64E-03 3.53 3445 64 290 19 
transmembrane signaling receptor activity 1.63E-06 2.37E-03 3.45 3445 62 290 18 
signaling receptor activity 5.58E-06 5.40E-03 3.19 3445 67 290 18 
receptor activity 1.51E-05 1.10E-02 2.71 3445 92 290 21 
molecular transducer activity 1.51E-05 8.80E-03 2.71 3445 92 290 21 
signal transducer activity 1.34E-04 6.47E-02 2.17 3445 137 290 25 
transmembrane receptor protein kinase 
activity 
5.68E-04 2.36E-01 5.09 3445 14 290 6 
calcium ion binding 8.46E-04 3.07E-01 2.12 3445 112 290 20 






GO Term P-value FDR q-value Enrichment N B n b 
negative regulation of immune system 
process 
6.43E-05 2.71E-01 3.65 598 12 123 9 
negative regulation of myeloid cell 
differentiation 
6.86E-05 1.45E-01 4.86 598 6 123 6 
regulation of myeloid cell differentiation 3.99E-04 5.61E-01 4.17 598 7 123 6 
negative regulation of hemopoiesis 3.99E-04 4.21E-01 4.17 598 7 123 6 
 
Table 7.2 GO-term enrichment analysis results of E14.5 pMEF and liver proteomes and phosphoproteomes. A) E14.5 pMEF 
proteome. B) E14.5 pMEF phosphoproteome. C) E14.5 liver proteome. D) E14.5 liver phosphoproteome. N: total number of genes; 
B: total number of genes in the corresponding GO term; n: total gene numbers outside of the fold change threshold; b: obtained 





GO Term P-value FDR q-value Enrichment N B n b 
Cluster 1 
brown fat cell differentiation 0.000158 1 98.31 3441 7 10 2 
Cluster 2 
extracellular region 1.76E-10 2.36E-07 5.4 3441 177 72 20 
extracellular space 4.30E-09 2.88E-06 4.29 3441 234 72 21 
extracellular region part 5.27E-05 2.35E-02 1.79 3441 963 72 36 
calcium ion binding 1.95E-05 4.90E-02 4.57 3441 115 72 11 
biological adhesion 5.89E-05 5.66E-01 3.75 3441 153 72 12 
Cluster 3 
transmembrane signaling receptor activity 3.11E-06 7.84E-03 5.45 3441 53 131 11 
transmembrane receptor activity 4.58E-06 5.77E-03 5.25 3441 55 131 11 
signaling receptor activity 1.11E-05 9.35E-03 4.82 3441 60 131 11 
signal transducer activity 2.35E-05 1.48E-02 3.23 3441 130 131 16 
Cluster 4 
mitochondrion 1.69E-11 2.26E-08 1.96 3441 577 265 87 
cytoplasmic part 7.35E-11 4.91E-08 1.29 3441 2111 265 210 
mitochondrial part 0.00000289 0.00129 2 3441 285 265 44 
membrane part 0.00000404 0.00135 1.46 3441 905 265 102 
organic acid catabolic process 2.84E-08 0.000273 4.41 3441 53 265 18 
carboxylic acid catabolic process 2.84E-08 0.000137 4.41 3441 53 265 18 
organic acid metabolic process 0.000000152 0.000485 2.27 3441 240 265 42 
alpha-amino acid catabolic process 0.000000157 0.000376 7.21 3441 18 265 10 
small molecule catabolic process 0.000000275 0.000528 3.56 3441 73 265 20 
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oxoacid metabolic process 0.000000385 0.000616 2.23 3441 239 265 41 
cellular amino acid catabolic process 0.000000466 0.00064 5.95 3441 24 265 11 
carboxylic acid metabolic process 0.000000741 0.00089 2.23 3441 227 265 39 
cellular amino acid metabolic process 0.00000164 0.00175 3.01 3441 95 265 22 
 
B 
GO Term P-value FDR q-value Enrichment N B n b 
Cluster 1 
response to radiation 0.000911 1 2.64 344 9 116 8 
Cluster 4 
regulation of secretion 0.000592 1 4.58 344 11 41 6 
regulation of peptide transport 0.000648 1 3.92 344 15 41 7 
regulation of secretion by cell 0.000815 0.977 5.24 344 8 41 5 
regulation of sequence-specific DNA 

















GO Term P-value FDR q-value Enrichment N B n b 
Cluster 1 
regulation of B cell activation 1.55E-04 1.00E+00 14.04 3441 28 35 4 
immune response-regulating signaling 
pathway 
2.04E-04 9.79E-01 13.11 3441 30 35 4 
immune effector process 3.46E-04 5.53E-01 7.93 3441 62 35 5 
regulation of B cell proliferation 4.04E-04 5.54E-01 19.66 3441 15 35 3 
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regulation of mononuclear cell 
proliferation 
4.67E-04 5.61E-01 10.63 3441 37 35 4 
regulation of lymphocyte proliferation 4.67E-04 4.98E-01 10.63 3441 37 35 4 
immune system process 5.01E-04 4.81E-01 4.12 3441 191 35 8 
regulation of leukocyte proliferation 5.73E-04 5.01E-01 10.08 3441 39 35 4 
immune response-regulating cell surface 
receptor signaling pathway 
7.09E-04 5.24E-01 16.39 3441 18 35 3 
positive regulation of B cell activation 7.09E-04 4.86E-01 16.39 3441 18 35 3 
positive regulation of interleukin-12 
production 
9.86E-04 6.31E-01 39.33 3441 5 35 2 
transmembrane signaling receptor activity 1.64E-04 4.12E-01 9.27 3441 53 35 5 
transmembrane receptor activity 1.95E-04 2.46E-01 8.94 3441 55 35 5 
receptor activity 1.98E-04 1.66E-01 6.78 3441 87 35 6 
molecular transducer activity 1.98E-04 1.25E-01 6.78 3441 87 35 6 
signaling receptor activity 2.96E-04 1.49E-01 8.19 3441 60 35 5 
Cluster 4 
transmembrane signaling receptor activity 5.48E-04 6.90E-01 7.21 3441 53 45 5 
transmembrane receptor activity 6.52E-04 5.47E-01 6.95 3441 55 45 5 
receptor activity 8.11E-04 5.10E-01 5.27 3441 87 45 6 
molecular transducer activity 8.11E-04 4.08E-01 5.27 3441 87 45 6 
signaling receptor activity 9.74E-04 4.09E-01 6.37 3441 60 45 5 
extracellular region 1.96E-07 2.62E-04 5.62 3441 177 45 13 
extracellular space 2.83E-05 1.89E-02 3.92 3441 234 45 12 
G-protein coupled receptor activity 4.24E-04 1.00E+00 19.12 3441 12 45 3 
secretion 2.33E-05 2.24E-01 6.44 3441 95 45 8 
cell migration 5.35E-05 2.57E-01 4.99 3441 138 45 9 
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cell motility 9.28E-05 2.97E-01 4.65 3441 148 45 9 
Cluster 5 
negative regulation of cell proliferation 2.84E-04 1.00E+00 7.91 3441 128 17 5 
multicellular organismal process 2.91E-04 1.00E+00 3.52 3441 518 17 9 
negative regulation of epithelial cell 
proliferation 
3.75E-04 1.00E+00 20.24 3441 30 17 3 
osteoblast differentiation 5.95E-04 1.00E+00 17.35 3441 35 17 3 
Cluster 6 
cell differentiation 1.85E-04 1.00E+00 7.04 3441 349 7 5 
identical protein binding 3.27E-04 8.25E-01 6.25 3441 393 7 5 
 
D 
GO Term P-value FDR q-value Enrichment N B n b 
Cluster 2 
positive regulation of cellular metabolic 
process 
5.91E-04 1.00E+00 2.01 597 131 43 19 
regulation of cellular metabolic process 6.16E-04 1.00E+00 1.58 597 255 43 29 
positive regulation of metabolic process 7.17E-04 1.00E+00 1.93 597 144 43 20 
positive regulation of 
nucleobase-containing compound 
metabolic process 
9.38E-04 1.00E+00 2.24 597 93 43 15 
positive regulation of macromolecule 
metabolic process 
9.96E-04 9.03E-01 1.94 597 136 43 19 
Cluster 3 
large ribosomal subunit 3.02E-04 2.04E-01 18.66 597 6 16 3 
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ribosomal subunit 3.02E-04 1.02E-01 18.66 597 6 16 3 
ribonucleoprotein complex 6.20E-04 1.40E-01 4.08 597 64 16 7 
translational elongation 6.75E-04 1.00E+00 37.31 597 2 16 2 
Cluster 5 
integral component of plasma membrane 5.53E-04 3.74E-01 9.05 597 11 24 4 
intrinsic component of plasma membrane 5.53E-04 1.87E-01 9.05 597 11 24 4 
 
Table 7.3 GO-term enrichment analysis results of protein clusters identified from E14.5 pMEF and liver proteomes and 
phosphoproteomes. A) E14.5 pMEF proteome. B) E14.5 pMEF phosphoproteome. C) E14.5 liver proteome. D) E14.5 liver 
phosphoproteome. N: total number of genes; B: total number of genes in the corresponding GO term; n: total gene numbers outside 
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